

SNC S/N search

July 2006  
ML  
4/4/07

=&gt; d his ful

(FILE 'REGISTRY' ENTERED AT 12:35:54 ON 13 JUL 2006)

```

DEL HIS Y
L1      STR 84057-84-1
L2      26 SEA FAM FUL L1
        D SCAN
        E C9H7C12N5
        E C9H7C12N5/MF
        E C9H7CL2N5/MF
L3      69 SEA ABB=ON PLU=ON C9H7CL2N5.XCLH/MF OR C9H7CL2N5.CLH/MF OR
        C9H7CL2N5.BRH/MF OR C9H7CL2N5/MF
L4      3 SEA ABB=ON PLU=ON L3 AND L2
        D SCAN

```

FILE 'CAPLUS' ENTERED AT 12:41:14 ON 13 JUL 2006

```

L5      1114 SEA ABB=ON PLU=ON L2
L6      39538 SEA ABB=ON PLU=ON EPILEPSY/OBI OR ANTIEPILEP?/OBI OR
        CONVULS?/OBI OR ANTICONVUL?/OBI
L7      41971 SEA ABB=ON PLU=ON L6 OR SEIZURE?/OBI
L8      699 SEA ABB=ON PLU=ON L7 AND L5

```

FILE 'CAPLUS' ENTERED AT 12:47:28 ON 13 JUL 2006

```

L9      211210 SEA ABB=ON PLU=ON MORPHOL?/OBI
L10     504660 SEA ABB=ON PLU=ON PARTICLE?/OBI
L11     145393 SEA ABB=ON PLU=ON (SURFACE (3A) AREA)/BI
L12     6 SEA ABB=ON PLU=ON L8 AND L9
L13     4 SEA ABB=ON PLU=ON L8 AND L10
L14     3 SEA ABB=ON PLU=ON L8 AND L11
L15     159110 SEA ABB=ON PLU=ON DRUG DELIVE?/OBI
L16     63 SEA ABB=ON PLU=ON L8 AND L15
L17     3486 SEA ABB=ON PLU=ON EXCIPIENT?/OBI
L18     2 SEA ABB=ON PLU=ON L17 AND L8
L19     12564 SEA ABB=ON PLU=ON EXCIPIENT?/BI
L20     5 SEA ABB=ON PLU=ON L8 AND L19
L21     450154 SEA ABB=ON PLU=ON MORPHOL?/BI
L22     1177796 SEA ABB=ON PLU=ON PARTICLE?/BI
L23     15 SEA ABB=ON PLU=ON L8 AND (L22 OR L21 )
L24     1347 SEA ABB=ON PLU=ON TONICITY?/BI

```

FILE 'REGISTRY' ENTERED AT 12:50:35 ON 13 JUL 2006

```

E DEXTROSE
E DEXTROSE/CN
L25    1 SEA ABB=ON PLU=ON DEXTROSE/CN

```

FILE 'CAPLUS' ENTERED AT 12:50:46 ON 13 JUL 2006

```

L26    191485 SEA ABB=ON PLU=ON L25 OR DEXTROSE/OBI
L27    9 SEA ABB=ON PLU=ON L8 AND L26
L28    0 SEA ABB=ON PLU=ON L8 AND L24
L29    24 SEA ABB=ON PLU=ON (L12 OR L13 OR L14) OR L18 OR L20 OR L23
        OR L27
L30    10 SEA ABB=ON PLU=ON CARRIER/OBI AND L8
L31    31 SEA ABB=ON PLU=ON L30 OR L29
L32    74 SEA ABB=ON PLU=ON ARONHIME J?/AU
L33    6 SEA ABB=ON PLU=ON SAMBURSKI G?/AU
L34    78 SEA ABB=ON PLU=ON (L32 OR L33)
L35    2 SEA ABB=ON PLU=ON L34 AND L5
L36    0 SEA ABB=ON PLU=ON L35 NOT L31
L37    12 SEA ABB=ON PLU=ON L5 AND L21

```

Maria Louisa Lao 10/511, 987

L38	4 SEA ABB=ON D SCAN TI	PLU=ON	L37 NOT L31
L39	341291 SEA ABB=ON	PLU=ON	((XRAY OR X RAY) (L) DIFFRACT?)/BI
L40	2 SEA ABB=ON	PLU=ON	L39 AND L5
L41	1286897 SEA ABB=ON	PLU=ON	CRYST?/OBI
L42	11 SEA ABB=ON	PLU=ON	L5 AND L41
L43	11 SEA ABB=ON	PLU=ON	L40 OR L42
L44	10 SEA ABB=ON	PLU=ON	L43 NOT L31
L45	75 SEA ABB=ON	PLU=ON	ARONHIME J?/AU
L46	6 SEA ABB=ON	PLU=ON	SAMBURSKI G?/AU
L47	79 SEA ABB=ON	PLU=ON	L45 OR L46
L48	2 SEA ABB=ON	PLU=ON	L5 AND L47

=> fil reg

FILE 'REGISTRY' ENTERED AT 12:58:32 ON 13 JUL 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2006 HIGHEST RN 892389-74-1  
DICTIONARY FILE UPDATES: 12 JUL 2006 HIGHEST RN 892389-74-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que stat 12

L1 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE  
L2 26 SEA FILE=REGISTRY FAM FUL L1

100.0% PROCESSED 51 ITERATIONS  
SEARCH TIME: 00.00.01

26 ANSWERS

=> fil caplus  
FILE 'CAPLUS' ENTERED AT 12:58:48 ON 13 JUL 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2006 VOL 145 ISS 3  
FILE LAST UPDATED: 12 Jul 2006 (20060712/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos 131  
L1 STR  
L2 26 SEA FILE=REGISTRY FAM FUL L1  
L5 1114 SEA FILE=CAPLUS ABB=ON PLU=ON L2  
L6 39538 SEA FILE=CAPLUS ABB=ON PLU=ON EPILEPSY/OBI OR ANTIEPILEP?/OBI  
OR CONVULS?/OBI OR ANTICONVUL?/OBI  
L7 41971 SEA FILE=CAPLUS ABB=ON PLU=ON L6 OR SEIZURE?/OBI  
L8 699 SEA FILE=CAPLUS ABB=ON PLU=ON L7 AND L5  
L9 211210 SEA FILE=CAPLUS ABB=ON PLU=ON MORPHOL?/OBI  
L10 504660 SEA FILE=CAPLUS ABB=ON PLU=ON PARTICLE?/OBI  
L11 145393 SEA FILE=CAPLUS ABB=ON PLU=ON (SURFACE (3A) AREA) /BI  
L12 6 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L9  
L13 4 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L10  
L14 3 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L11  
L17 3486 SEA FILE=CAPLUS ABB=ON PLU=ON EXCIPIENT?/OBI  
L18 2 SEA FILE=CAPLUS ABB=ON PLU=ON L17 AND L8  
L19 12564 SEA FILE=CAPLUS ABB=ON PLU=ON EXCIPIENT?/BI  
L20 5 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L19  
L21 450154 SEA FILE=CAPLUS ABB=ON PLU=ON MORPHOL?/BI  
L22 1177796 SEA FILE=CAPLUS ABB=ON PLU=ON PARTICLE?/BI  
L23 15 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND (L22 OR L21 )  
L25 1 SEA FILE=REGISTRY ABB=ON PLU=ON DEXTROSE/CN  
L26 191485 SEA FILE=CAPLUS ABB=ON PLU=ON L25 OR DEXTROSE/OBI  
L27 9 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L26  
L29 24 SEA FILE=CAPLUS ABB=ON PLU=ON (L12 OR L13 OR L14) OR L18 OR  
L20 OR L23 OR L27

L30 10 SEA FILE=CAPLUS ABB=ON PLU=ON CARRIER/OBI AND L8  
 L31 31 SEA FILE=CAPLUS ABB=ON PLU=ON L30 OR L29

=> d que nos 138

L1 STR  
 L2 26 SEA FILE=REGISTRY FAM FUL L1  
 L5 1114 SEA FILE=CAPLUS ABB=ON PLU=ON L2  
 L6 39538 SEA FILE=CAPLUS ABB=ON PLU=ON EPILEPSY/OBI OR ANTIEPILEP?/OBI  
     OR CONVULS?/OBI OR ANTICONVUL?/OBI  
 L7 41971 SEA FILE=CAPLUS ABB=ON PLU=ON L6 OR SEIZURE?/OBI  
 L8 699 SEA FILE=CAPLUS ABB=ON PLU=ON L7 AND L5  
 L9 211210 SEA FILE=CAPLUS ABB=ON PLU=ON MORPHOL?/OBI  
 L10 504660 SEA FILE=CAPLUS ABB=ON PLU=ON PARTICLE?/OBI  
 L11 145393 SEA FILE=CAPLUS ABB=ON PLU=ON (SURFACE (3A) AREA) /BI  
 L12 6 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L9  
 L13 4 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L10  
 L14 3 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L11  
 L17 3486 SEA FILE=CAPLUS ABB=ON PLU=ON EXCIPIENT?/OBI  
 L18 2 SEA FILE=CAPLUS ABB=ON PLU=ON L17 AND L8  
 L19 12564 SEA FILE=CAPLUS ABB=ON PLU=ON EXCIPIENT?/BI  
 L20 5 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L19  
 L21 450154 SEA FILE=CAPLUS ABB=ON PLU=ON MORPHOL?/BI  
 L22 1177796 SEA FILE=CAPLUS ABB=ON PLU=ON PARTICLE?/BI  
 L23 15 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND (L22 OR L21 )  
 L25 1 SEA FILE=REGISTRY ABB=ON PLU=ON DEXTROSE/CN  
 L26 191485 SEA FILE=CAPLUS ABB=ON PLU=ON L25 OR DEXTROSE/OBI  
 L27 9 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L26  
 L29 24 SEA FILE=CAPLUS ABB=ON PLU=ON (L12 OR L13 OR L14) OR L18 OR  
     L20 OR L23 OR L27  
 L30 10 SEA FILE=CAPLUS ABB=ON PLU=ON CARRIER/OBI AND L8  
 L31 31 SEA FILE=CAPLUS ABB=ON PLU=ON L30 OR L29  
 L37 12 SEA FILE=CAPLUS ABB=ON PLU=ON L5 AND L21  
 L38 4 SEA FILE=CAPLUS ABB=ON PLU=ON L37 NOT L31

=> d que nos 144

L1 STR  
 L2 26 SEA FILE=REGISTRY FAM FUL L1  
 L5 1114 SEA FILE=CAPLUS ABB=ON PLU=ON L2  
 L6 39538 SEA FILE=CAPLUS ABB=ON PLU=ON EPILEPSY/OBI OR ANTIEPILEP?/OBI  
     OR CONVULS?/OBI OR ANTICONVUL?/OBI  
 L7 41971 SEA FILE=CAPLUS ABB=ON PLU=ON L6 OR SEIZURE?/OBI  
 L8 699 SEA FILE=CAPLUS ABB=ON PLU=ON L7 AND L5  
 L9 211210 SEA FILE=CAPLUS ABB=ON PLU=ON MORPHOL?/OBI  
 L10 504660 SEA FILE=CAPLUS ABB=ON PLU=ON PARTICLE?/OBI  
 L11 145393 SEA FILE=CAPLUS ABB=ON PLU=ON (SURFACE (3A) AREA) /BI  
 L12 6 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L9  
 L13 4 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L10  
 L14 3 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L11  
 L17 3486 SEA FILE=CAPLUS ABB=ON PLU=ON EXCIPIENT?/OBI  
 L18 2 SEA FILE=CAPLUS ABB=ON PLU=ON L17 AND L8  
 L19 12564 SEA FILE=CAPLUS ABB=ON PLU=ON EXCIPIENT?/BI  
 L20 5 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L19  
 L21 450154 SEA FILE=CAPLUS ABB=ON PLU=ON MORPHOL?/BI  
 L22 1177796 SEA FILE=CAPLUS ABB=ON PLU=ON PARTICLE?/BI  
 L23 15 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND (L22 OR L21 )  
 L25 1 SEA FILE=REGISTRY ABB=ON PLU=ON DEXTROSE/CN  
 L26 191485 SEA FILE=CAPLUS ABB=ON PLU=ON L25 OR DEXTROSE/OBI  
 L27 9 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L26

L29            24 SEA FILE=CAPLUS ABB=ON PLU=ON (L12 OR L13 OR L14) OR L18 OR  
L20 OR L23 OR L27  
L30            10 SEA FILE=CAPLUS ABB=ON PLU=ON CARRIER/OBI AND L8  
L31            31 SEA FILE=CAPLUS ABB=ON PLU=ON L30 OR L29  
L39            341291 SEA FILE=CAPLUS ABB=ON PLU=ON ((XRAY OR X RAY) (L) DIFFRACT?)/  
BI  
L40            2 SEA FILE=CAPLUS ABB=ON PLU=ON L39 AND L5  
L41            1286897 SEA FILE=CAPLUS ABB=ON PLU=ON CRYST?/OBI  
L42            11 SEA FILE=CAPLUS ABB=ON PLU=ON L5 AND L41  
L43            11 SEA FILE=CAPLUS ABB=ON PLU=ON L40 OR L42  
L44            10 SEA FILE=CAPLUS ABB=ON PLU=ON L43 NOT L31

=> d que nos 148



*Inventor search*

L45            75 SEA FILE=CAPLUS ABB=ON PLU=ON ARONHIME J?/AU  
L46            6 SEA FILE=CAPLUS ABB=ON PLU=ON SAMBURSKI G?/AU  
L47            79 SEA FILE=CAPLUS ABB=ON PLU=ON L45 OR L46  
L1            STR  
L2            26 SEA FILE=REGISTRY FAM FUL L1  
L5            1114 SEA FILE=CAPLUS ABB=ON PLU=ON L2  
L7            2 SEA FILE=CAPLUS ABB=ON PLU=ON L5 AND L47

=> d .ca l31 1-31;d .ca l38 1-4; d .ca l44 1-10; d ibib 148 1-2

L31 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:340351 CAPLUS  
DOCUMENT NUMBER: 144:390947  
TITLE: Preparation of sulfamoylbenzamides as agonists of cannabinoid receptors  
INVENTOR(S): Dolle, Roland E.; Worm, Karin; Zhou, Q. Jean  
PATENT ASSIGNEE(S): Adolor Corporation, USA  
SOURCE: U.S. Pat. Appl. Publ., 130 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006079557	A1	20060413	US 2005-251160	20051013
WO 2006044645	A2	20060427	WO 2005-US36997	20051012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2004-618387P	P 20041013
ED Entered STN: 13 Apr 2006				
GI				



**AB** The title sulfamoylbenzamides I [wherein n = 0-3; R1 = H, F, Cl, Br, (cyclo)alkyl, (hetero)aryl, (hetero)aralkyl, etc.; R2 and R3 = independently H, (cyclo)alkyl, (hetero)aryl, (hetero)aralkyl, etc.; or R2 and R3 form a ring; R4 = H or alkyl; R6-R8 = independently H, F, Cl, Br, or alkyl; R9-R11 = independently H or alkyl; R12 and R13 form a ring; with provisos], or pharmaceutically acceptable salts thereof were prepared as agonists of cannabinoid (CB) receptors. For example, II was prepared in a multi-step synthesis. II showed agonistic activity with EC50 = 2003 and 7.8 nM against human cloned CB1 and CB2 receptors, resp. The compds. are useful for treating and/or preventing pain, gastrointestinal disorders, inflammation, immune diseases, ischemic conditions, etc. (no data).

**INCL** 514317000; 514602000; 514319000; 546205000; 564086000

**CC** 28-18 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 25, 63

**ST** prepn sulfamoylbenzamide **morpholine** agonist cannabinoid receptor human; treatment pain inflammation immune ischemia asthma disease

**IT** Allergy

Allergy inhibitors

Alzheimer's disease

Analgesics

Anti-Alzheimer's agents

Anti-inflammatory agents

Anti-ischemic agents

Antiarrhythmics

Antiasthmatics

**Anticonvulsants**

Antidiabetic agents

Antidiarrheals

Antiemetics

Antihypertensives

Antimigraine agents

Antiosteoporotic agents

Antiparkinsonian agents

Antirheumatic agents

Apoptosis

Asthma

Autoimmune disease

Cachexia

Celiac disease

Diarrhea

Digestive tract, disease

Eating disorders  
 Emphysema  
 Gastrointestinal agents  
 Human  
 Hypertension  
 Immune disease  
 Immunosuppressants  
 Inflammation  
 Ischemia  
 Mental and behavioral disorders  
 Multiple sclerosis  
 Myasthenia gravis  
 Nausea  
 Nervous system, disease  
 Nervous system agents  
 Nervous system depressants  
 Osteoporosis  
 Pain  
 Parkinson's disease  
 Psoriasis  
 Reperfusion  
 Rheumatoid arthritis  
**Seizures**  
 Sjogren syndrome  
 Transplant rejection  
 Vomiting

(preparation of sulfamoylbenzamides as agonists of cannabinoid receptors)

IT 50-48-6 50-78-2 57-27-2, biological studies 57-41-0 57-42-1  
 59-92-7, biological studies 76-41-5 76-42-6 76-57-3 76-99-3  
 77-07-6 103-90-2 125-28-0 125-29-1 298-46-4, 5H-Dibenz[b,f]azepine-  
 5-carboxamide 359-83-1 437-38-7 466-99-9 469-62-5 768-94-5,  
 Tricyclo[3.3.1.13,7]decan-1-amine 2323-36-6 13956-29-1 15686-91-6  
 20594-83-6 22204-53-1 27203-92-5, Tramadol 28860-95-9 42408-82-2  
 51146-56-6 52485-79-7 53179-11-6 53648-55-8 56030-54-7  
 60142-96-3 71195-58-9 84057-84-1 107447-28-9  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (drug candidate; preparation of sulfamoylbenzamides as agonists of cannabinoid receptors)



IT 62-53-3, Phenylamine, reactions 74-11-3, 4-Chloro benzoic acid  
 74-89-5, Methylamine, reactions 96-32-2, Bromoacetic acid methyl ester  
 98-80-6, Phenyl boronic acid 99-94-5, 4-Methyl benzoic acid 100-46-9D,  
 Benzylamine, resin bound 103-67-3, N-Methylbenzylamine 103-67-3D,  
 N-Methyl-N-benzylamine, resin bound 108-18-9 109-90-0, Ethyl  
 isocyanate 110-89-4, Piperidine, reactions 110-91-8,  
 Morpholine, reactions 123-75-1, Pyrrolidine, reactions  
 124-40-3, N,N-Dimethylamine, reactions 141-91-3, 2,6-Dimethylmorpholine  
 496-12-8, 1,3-DihydroIsoindole 503-29-7, Azetidine 586-76-5,  
 4-Bromobenzoic acid 627-41-8 635-46-1 2051-28-7 2548-29-0  
 2799-21-5 3367-95-1, N,N-Diethylpiperidine-3-carboxamide 3731-52-0D,  
 3-Pyridinemethylamine, resin bound 3850-30-4 4025-64-3 5006-62-2,  
 Ethyl piperidine-3-carboxylate 5071-96-5D, 3-Methoxybenzylamine, resin  
 bound 5382-16-1, 4-Hydroxypiperidine 5813-64-9 5813-64-9D, resin  
 bound 13074-39-0, Adamantan-2-amine 13293-47-5 13392-28-4  
 13889-98-0, N-Acetylpirperazine 15901-42-5 17768-41-1,  
 Tricyclo[3.3.1.13,7]decane-1-methanamine 35794-11-7,  
 3,5-Dimethylpiperidine 38256-93-8, N-Methyl-2-methoxyethylamine  
 51942-56-4 57260-71-6, N-tert-Butoxycarbonylpiperazine 59815-29-1  
 69460-11-3 73522-42-6 90812-24-1 100243-39-8, (S)-3-  
 Hydroxypyrrolidine 116574-75-5, 3-Fluoropiperidine 131348-01-1  
 151104-64-2 165883-10-3D, resin bound 191483-49-5 264927-50-6

313346-23-5 500596-03-2 591781-14-5 847798-58-7 883145-58-2  
883145-59-3 883145-60-6  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of sulfamoylbenzamides as agonists of cannabinoid receptors)

L31 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:269581 CAPLUS  
DOCUMENT NUMBER: 144:312071  
TITLE: Preparation of tricyclic anilide spirolactam CGRP receptor antagonists  
INVENTOR(S): Bell, Ian M.; Gallicchio, Steven N.; Stump, Craig A.; Theberge, Cory R.; Vacca, Joseph P.; Zartman, C. Blair; Zhang, Xufang  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 121 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006031491	A2	20060323	WO 2005-US31617	20050906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-608294P P 20040909  
OTHER SOURCE(S): MARPAT 144:312071  
ED Entered STN: 23 Mar 2006  
GI



**AB** Title compds. I [A1 and A2 independently = bond or CR13R14, where one of A1 and A2 is optionally absent; B1 and B4 independently = C when double bond present, CR1 or N; B2 and B3 independently = bond, CR1R2, CO, CS, O, S, etc., where one of B2 and B3 is optionally absent; D1 and D2 independently = O, S, SO<sub>2</sub>, CR1R2, CO, etc.; J = =C(R6a)-; CR13R14, and CO; K = =C(R6b), CR13R14, CO, etc.; T, U and V independently = =C(R1)- and =N-, wherein at least one of T, U, and V = =C(R1)-; W, X, Y, and Z = bond, CR1R2, CS, O, etc.; R1 and R2 = H, (un)substituted alkyl, cycloalkyl, alkynyl, etc.; R4 = H, (un)substituted alkyl, benzyl, etc.; R5a, R5b, and R5c = H, alkyl, alkoxy, halo, etc.; R6a = H, OH, halo, CN, (un)substituted alkyl, etc.; R13 and R14 = H, OH, halo, and (un)substituted alkyl; m = 1 or 2; n = 1 or 2], and their pharmaceutically acceptable salts, useful as antagonists of calcitonin gene-related peptide (CGRP) receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. Thus, e.g., II was prepared by reaction of (-)-5-amino-1,3-dihydrospiro[indene-2,3'-pyrrololo[2,3-b]pyridin]-2' (1'H)-one (preparation given) with lithium (4-oxo-2a,3,4,5-tetrahydropyrrolo[4,3,2-de]quinolin-1(2H)-yl)acetate (preparation given). I demonstrated activity as antagonists of the CGRP receptor with Ki or IC<sub>50</sub> values generally less than about 50 μM. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

**CC** 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

**IT** Drug delivery systems

(carriers; tricyclic anilide spirolactam compds. as CGRP antagonists useful in prevention and treatment of such diseases in which CGRP is involved)

**IT** 5-HT agonists

Analgesics

Anti-inflammatory agents

Anticonvulsants

Antihypertensives

Antimigraine agents  
Combination chemotherapy  
Headache  
Human

(tricyclic anilide spirolactam compds. as CGRP antagonists useful in prevention and treatment of such diseases in which CGRP is involved)

IT 50-33-9, Phenylbutazone, biological studies 50-78-2, Aspirin 53-86-1, Indomethacin 61-68-7, Mefenamic acid 103-90-2, Acetaminophen 113-15-5, Ergotamine 129-20-4, Oxyphenbutazone 511-12-6, Dihydroergotamine 530-78-9, Flufenamic acid 552-94-3, Salsalate 599-79-1, Sulfasalazine 644-62-2, Meclofenamic acid 13539-59-8, Apazone 13710-19-5, Tolfenamic acid 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 21256-18-8, Oxaprozin 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4, Diflunisal 26171-23-3, Tolmetin 29679-58-1, Fenoprofen 36322-90-4, Piroxicam 38194-50-2, Sulindac 41340-25-4, Etodolac 42924-53-8, Nabumetone 51803-78-2, Nimesulide 59804-37-4, Tenoxicam 60142-96-3, Gabapentin 68291-97-4, Zonisamide 70374-39-9, Lornoxicam 71125-38-7, Meloxicam 74103-06-3, Ketorolac 76584-70-8, Divalproex sodium 84057-84-1, Lamotrigine 93384-43-1, Botulinum toxin A 93384-44-2, Botulinum toxin B 97240-79-4, Topiramate 102767-28-2, Levetiracetam 103628-46-2, Sumatriptan 115103-54-3, Tiagabine 120210-48-2, Tenidap 121679-13-8, Naratriptan 139264-17-8, Zolmitriptan 143322-58-1, Eletriptan 144034-80-0, Rizatriptan 148553-50-8, Pregabalin 151140-96-4, Avitriptan 154323-57-6, Almotriptan 158747-02-5, Frovatriptan 182563-08-2, LY334370 185243-69-0, Etanercept 187665-65-2, PNU-142633

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substances for use in combination chemotherapy with tricyclic anilide spirolactam compds. in treatment of diseases in which CGRP is involved)

L31 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:269508 CAPLUS

DOCUMENT NUMBER: 144:331420

TITLE: Preparation of bicyclic anilide spirolactam cgrp receptor antagonists

INVENTOR(S): Bell, Ian M.; Theberge, Cory R.; Stump, Craig A.; Zhang, Xufang; Gallicchio, Steven N.; Zartman, C. Blair

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006031610	A2	20060323	WO 2005-US32041	20050909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-609292P P 20040913  
OTHER SOURCE(S): MARPAT 144:331420  
ED Entered STN: 23 Mar 2006  
GI



AB Title compds. I [A1 and A2 independently = bond or CR13R14, where one of A1 and A2 is optionally absent; B = (un)substituted bicycloheterocycle; J = =C(R6a)-; CR13R14, and CO; K = =C(R6b), CR13R14, CO, etc.; R4 = H, (un)substituted alkyl, benzyl, etc.; R5a, R5b, and R5c = H, alkyl, alkoxy, halo, etc.; R6a and R6b independently = H, OH, halo, (un)substituted alkyl, etc.; R13 and R14 = H or (un)substituted alkyl; m = 1 or 2; n = 1 or 2], and their pharmaceutically acceptable salts, useful as antagonists of calcitonin gene-related peptide (CGRP) receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. Thus, e.g., II was prepared by reaction of 5-amino-1,3-dihydro-2'H,5'H-spiro[indene-2,3'-pyrrolidine]-2',5'-dione (preparation given) with 5-amino-1,3-dihydrospiro[indene-2,3'-pyrrolido[2,3-b]pyridin]-2'(1'H)-one (preparation given). I demonstrated activity as antagonists of the CGRP receptor with Ki or IC50 values generally less than about 50  $\mu$ M. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT Drug delivery systems

(carriers; preparation of bicyclic anilide spirolactam cgrp receptor antagonists)

IT 5-HT agonists

5-HT reuptake inhibitors

Analgesics

Anti-inflammatory agents

**Anticonvulsants**



Antidepressants  
Antiemetics  
Antihypertensives  
Antipsychotics  
Anxiolytics  
Calcium channel blockers  
Leukotriene antagonists  
Prokinetic agents  
Tranquilizers

(substances for use in combination chemotherapy with bicyclic anilide spirolactam compds. in prevention and treatment of diseases associated with CGRP receptor)

IT 50-33-9, Phenylbutazone, biological studies 50-47-5, Desipramine  
50-48-6, Amitriptyline 50-49-7, Imipramine 50-53-3, biological studies  
50-78-2, Aspirin 52-53-9, Verapamil 53-86-1, Indomethacin 58-25-3,  
Chlorodiazepoxide 58-38-8 61-68-7, Mefenamic acid 72-69-5,  
Nortriptyline 103-90-2, Acetaminophen 113-15-5, Ergotamine 129-20-4,  
Oxyphenbutazone 303-49-1, Clomipramine 438-60-8, Protriptyline  
439-14-5, Diazepam 511-12-6, Dihydroergotamine 525-66-6, Propranolol  
530-78-9, Flufenamic acid 548-73-2, Droperidol 552-94-3, Salsalate  
599-79-1, Sulfasalazine 644-62-2, Meclofenamic acid 739-71-9,  
Trimipramine 1668-19-5, Doxepin 13539-59-8, Apazone 13710-19-5,  
Tolfenamic acid 15307-86-5, Diclofenac 15687-27-1, Ibuprofen  
15722-48-2, Olsalazine 21256-18-8, Oxaprozin 21829-25-4, Nifedipine  
22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4, Diflunisal  
25775-90-0, Civamide 26171-23-3, Tolmetin 26839-75-8, Timolol  
28981-97-7, Alprazolam 29122-68-7, Atenolol 29679-58-1, Fenoprofen  
36322-90-4, Piroxicam 38194-50-2, Sulindac 41340-25-4, Etodolac  
42200-33-9, Nadolol 42399-41-7, Diltiazem 42924-53-8, Nabumetone  
51384-51-1, Metoprolol 51803-78-2, Nimesulide 52468-60-7, Flunarizine  
54910-89-3, Fluoxetine 59729-33-8, Citalopram 59804-37-4, Tenoxicam  
60142-96-3, Gabapentin 61869-08-7, Paroxetine 62571-86-2, Captopril  
63675-72-9, Nisoldipine 66085-59-4, Nimodipine 68291-97-4, Zonisamide  
70374-39-9, Lornoxicam 71125-38-7, Meloxicam 72509-76-3, Felodipine  
74103-06-3, Kеторолак 75695-93-1, Isradipine 75847-73-3, Enalapril  
76547-98-3, Lisinopril 76584-70-8, Divalproex sodium 79617-96-2,  
Sertraline 82834-16-0, Perindopril 84057-84-1, Lamotrigine  
85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril  
87679-37-6, Trandolapril 88150-42-9, Amlodipine 93384-43-1, Botulinum  
toxin A 93384-44-2, Botulinum toxin B 93413-69-5, Venlafaxine  
97240-79-4, Topiramate 101477-55-8, Lomerizine 102767-28-2,  
Levetiracetam 103628-46-2, Sumatriptan 107753-78-6, Zafirlukast  
111974-69-7, Quetiapine 114798-26-4, Losartan 115103-54-3, Tiagabine  
116539-59-4, Duloxetine 120210-48-2, Tenidap 121679-13-8, Naratriptan  
128196-01-0, Escitalopram 132539-06-1, Olanzapine 133040-01-4,  
Eprosartan 137862-53-4, Valsartan 138402-11-6, Irbesartan  
139264-17-8, Zolmitriptan 139481-59-7, Candesartan 143322-58-1,  
Eletriptan 144034-80-0, Rizatriptan 144689-24-7, Olmesartan  
144689-63-4, Olmesartan medoxomil 144701-48-4, Telmisartan  
145040-37-5, Candesartan cilexetil 148553-50-8, Pregabalin  
151140-96-4, Avitriptan 154323-57-6, Almotriptan 158747-02-5,  
Frovatriptan 158966-92-8, Montelukast 182563-08-2, LY334370  
185243-69-0, Etanercept 187665-65-2, PNU-142633  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(substances for use in combination chemotherapy with bicyclic anilide  
spirolactam compds. in prevention and treatment of diseases associated  
with CGRP receptor)

L31 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2006:268948 CAPLUS  
 DOCUMENT NUMBER: 144:331434  
 TITLE: Preparation of tricyclic anilide spirohydantoin CGRP  
 receptor antagonists  
 INVENTOR(S): Bell, Ian M.; Gallicchio, Steven N.; Zartman, C.  
 Blair; Theberge, Cory R.; Zhang, Xufang  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 84 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006031676	A2	20060323	WO 2005-US32288	20050909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2004-609294P	P 20040913
OTHER SOURCE(S):	MARPAT	144:331434		
ED Entered STN:	Entered STN:	23 Mar 2006		
GI				



AB Title compds. I [A1 and A2 independently = bond or CR1R14, where one of A1 and A2 is optionally absent; B1 and B4 independently = C when double bond present, CR1 or N; B2 and B3 independently = bond, CR1R2, CO, CS, O, S, etc., where one of B2 and B3 is optionally absent; D1 and D2 independently = O, S, SO<sub>2</sub>, CR1R2, CO, etc.; T, U and V independently = =C(R1)- and =N-, wherein at least one of T, U, and V = =C(R1)-; W, X, Y, and Z = bond, CR1R2, CS, O, etc.; R1 and R2 = H, (un)substituted alkyl, cycloalkyl, alkynyl, etc.; R4 = H, (un)substituted alkyl, benzyl, etc.; R5a, R5b, and R5c = H, alkyl, alkoxy, halo, etc.; R6 = H, (un)substituted alkyl, cycloalkyl, etc.; R13 and R14 = H, OH, halo, and (un)substituted alkyl; m = 1 or 2; n = 1 or 2], and their pharmaceutically acceptable salts, useful as antagonists of calcitonin gene-related peptide (CGRP) receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. Thus, e.g., II was prepared by reaction of (-)-5'-amino-3-methylspiro[imidazolidine-4,2'-indane]-2,5-dione (preparation given) with sodium (2,5-dioxo-5,6-dihydro-4H-imidazo[1,5,4-de]quinoxalin-1(2H)yl)acetate (preparation given). I demonstrated activity as antagonists of the CGRP receptor with Ki or IC<sub>50</sub> values generally less than about 50 μM. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

IT Drug delivery systems  
(carriers; tricyclic anilide spirolactam compds. as CGRP antagonists useful in prevention and treatment of such diseases in which CGRP is involved)

IT 5-HT agonists  
Analgesics  
Anti-inflammatory agents  
Anticonvulsants  
Antihypertensives  
Antimigraine agents  
Combination chemotherapy  
Headache  
Human  
(tricyclic anilide spirolactam compds. as CGRP antagonists useful in prevention and treatment of such diseases in which CGRP is involved)

IT 50-33-9, Phenylbutazone, biological studies 50-47-5, Desipramine  
50-48-6, Amitriptyline 50-49-7, Imipramine 50-53-3, biological studies  
50-78-2, Aspirin 52-53-9, Verapamil 53-86-1, Indomethacin 58-25-3,  
Chlorodiazepoxide 58-38-8 61-68-7, Mefenamic acid 72-69-5,  
Nortriptyline 103-90-2, Acetaminophen 113-15-5, Ergotamine 129-20-4,  
Oxyphenbutazone 303-49-1, Clomipramine 438-60-8, Protriptyline  
439-14-5, Diazepam 511-12-6, Dihydroergotamine 525-66-6, Propranolol  
530-78-9, Flufenamic acid 548-73-2, Droperidol 552-94-3, Salsalate  
599-79-1, Sulfasalazine 644-62-2, Meclofenamic acid 739-71-9,  
Trimipramine 1668-19-5, Doxepin 13539-59-8, Apazone 13710-19-5,  
Tolfenamic acid 15307-86-5, Diclofenac 15687-27-1, Ibuprofen  
15722-48-2, Olsalazine 21256-18-8, Oxaprozin 21829-25-4, Nifedipine  
22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4, Diflunisal  
25775-90-0, Civamide 26171-23-3, Tolmetin 26839-75-8, Timolol  
28981-97-7, Alprazolam 29122-68-7, Atenolol 29679-58-1, Fenoprofen  
36322-90-4, Piroxicam 38194-50-2, Sulindac 41340-25-4, Etodolac  
42200-33-9, Nadolol 42399-41-7, Diltiazem 42924-53-8, Nabumetone  
51384-51-1, Metoprolol 51803-78-2, Nimesulide 52468-60-7, Flunarizine  
54910-89-3, Fluoxetine 59729-33-8, Citalopram 59804-37-4, Tenoxicam  
60142-96-3, Gabapentin 61869-08-7, Paroxetine 62571-86-2, Captopril

63675-72-9, Nisoldipine 66085-59-4, Nimodipine 68291-97-4, Zonisamide  
 70374-39-9, Lornoxicam 71125-38-7, Meloxicam 72509-76-3, Felodipine  
 74103-06-3, Ketorolac 75695-93-1, Isradipine 75847-73-3, Enalapril  
 76547-98-3, Lisinopril 76584-70-8, Divalproex sodium 79617-96-2,  
 Sertraline 82834-16-0, Perindopril 84057-84-1, Lamotrigine  
 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril  
 87679-37-6, Trandolapril 88150-42-9, Amlodipine 93384-43-1, Botulinum  
 toxin A 93384-44-2, Botulinum toxin B 93413-69-5, Venlafaxine  
 97240-79-4, Topiramate 101477-55-8, Lomerizine 102767-28-2,  
 Levetiracetam 103628-46-2, Sumatriptan 107753-78-6, Zafirlukast  
 111974-69-7, Quetiapine 114798-26-4, Losartan 115103-54-3, Tiagabine  
 116539-59-4, Duloxetine 120210-48-2, Tenidap 121679-13-8, Naratriptan  
 128196-01-0, Escitalopram 132539-06-1, Olanzapine 133040-01-4,  
 Eprosartan 137862-53-4, Valsartan 138402-11-6, Irbesartan  
 139264-17-8, Zolmitriptan 139481-59-7, Candesartan 143322-58-1,  
 Eletriptan 144034-80-0, Rizatriptan 144689-24-7, Olmesartan  
 144689-63-4, Olmesartan medoxomil 144701-48-4, Telmisartan  
 145040-37-5, Candesartan cilexetil 148553-50-8, Pregabalin  
 151140-96-4, Avitriptan 154323-57-6, Almotriptan 158747-02-5,  
 Frovatriptan 158966-92-8, Montelukast 182563-08-2, LY334370  
 185243-69-0, Etanercept 187665-65-2, PNU-142633  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (substances for use in combination chemotherapy with tricyclic anilide  
 spirolactam compds. in prevention and treatment of diseases associated  
 with CGRP receptor)

L31 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:152711 CAPLUS  
 DOCUMENT NUMBER: 144:226261  
 TITLE: Alpha-ketoglutarates and their use as therapeutic  
 agents for the treatment of cancer and other disorders  
 INVENTOR(S): Gottlieb, Eyal; Selak, Mary A.; Mackenzie, Elaine D.;  
 Watson, David G.  
 PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK  
 SOURCE: PCT Int. Appl., 106 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006016143	A1	20060216	WO 2005-GB3119	20050809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			GB 2004-17715	A 20040809
			GB 2004-21921	A 20041001
OTHER SOURCE(S):	MARPAT	144:226261		

ED Entered STN: 17 Feb 2006  
AB The present invention relates to  $\alpha$ -ketoglutarates of general formula R<sub>2</sub>OOCCH<sub>2</sub>CH<sub>2</sub>COOR<sub>1</sub> (wherein R<sub>1</sub> and R<sub>2</sub> = H or a hydrophobic moiety; with the proviso that R<sub>1</sub> and R<sub>2</sub> are not both H) and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemical protected forms, and prodrugs thereof. These compds. activate HIF $\alpha$  hydroxylase or prolyl hydroxylase or increase the level of  $\alpha$ -ketoglutarate and are useful in the treatment of cancer (e.g., cancer in which the activity of one of the enzymes in the tricarboxylic acid (TCA) cycle is down regulated) or in the treatment of angiogenesis (e.g., hypoxia-induced angiogenesis).  
IC ICM C07C069-716  
ICS C07D311-72; A61K031-225; A61P035-00  
CC 1-6 (Pharmacology)  
Section cross-reference(s): 23, 25, 27  
IT **Anticonvulsants**  
(addnl. therapeutic agents; alpha-ketoglutarates and their use as therapeutic agents for treatment of cancer and other disorders in combination with other agents)  
IT 50-06-6, Phenobarbital, biological studies 50-18-0, Cyclophosphamide  
50-78-2, Aspirin 50-81-7, Ascorbic Acid, biological studies  
50-99-7, D-Glucose, biological studies 52-28-8 54-05-7,  
Chloroquine 56-75-7, Chloramphenicol 57-41-0, Phenytoin 57-48-7,  
Fructose, biological studies 58-15-1, Amidopyrine 58-95-7,  
 $\alpha$ -Tocopherol acetate 59-30-3, Folic Acid, biological studies  
64-17-5, Ethanol, biological studies 65-23-6, Pyridoxine 68-89-3,  
Dipyrone 69-53-4, Ampicillin 70-51-9, Deferoxamine 77-41-8,  
Methsuximide 77-67-8, Ethosuximide 80-08-0, Dapsone 86-34-0,  
Phensuximide 98-96-4, Pyrazinamide 103-90-2, Paracetamol 114-07-8,  
Erythromycin 115-67-3, Paramethadione 123-56-8D, Succinimide, derivs.  
125-28-0, Dihydrocodeine 125-33-7, Primidone 126-07-8, Griseofulvin  
129-20-4, Oxyphenbutazone 298-46-4, Carbamazepine 299-78-5,  
Allylisopropylacetamide 379-79-3, Ergotamine Tartrate 439-14-5,  
Diazepam 461-72-3D, Hydantoin, derivs. 479-92-5, Propyphenazone  
480-30-8, Dichloralphenazone 514-78-3, Canthaxanthin 1404-90-6,  
Vancomycin 5250-39-5, Flucloxacillin 6190-39-2, Dihydroergotamine-Mesylate 7235-40-7,  $\beta$  Carotene 7439-89-6, Iron, biological studies 7440-43-9, Cadmium, biological studies 13539-59-8,  
Azapropazone 15307-79-6, Diclofenac sodium 25451-15-4, Felbamate 29094-61-9, Glipizide 51568-18-4, Succinylacetone 79236-56-9,  
N-Methylprotoporphyrin IX 84057-84-1, Lamotrigine 100438-92-4,  
Heme arginate 115103-54-3, Tiagabine  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(addnl. therapeutic agents; alpha-ketoglutarates and their use as therapeutic agents for treatment of cancer and other disorders in combination with other agents)  
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1356150 CAPLUS  
DOCUMENT NUMBER: 145:770  
TITLE: Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder  
AUTHOR(S): Chang, Chuan-Chia; Shiah, I-Shin; Chang, Hsin-An; Huang, San-Yuan  
CORPORATE SOURCE: Department of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan  
SOURCE: Progress in Neuro-Psychopharmacology & Biological

Psychiatry (2006), 30(1), 147-150  
 CODEN: PNPPD7; ISSN: 0278-5846

PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

ED Entered STN: 30 Dec 2005

AB Toxic epidermal necrolysis (TEN) is the most severe and potentially life-threatening cutaneous reaction associated with lamotrigine. The risk of developing TEN during lamotrigine therapy is low and previously reported cases most involved epileptic patients. However, the risk of TEN with combination lamotrigine and valproate is greater than with monotherapy. We present here the emergence of TEN in a 32-yr-old bipolar woman who was concomitantly treated with lamotrigine and valproate. The patient developed high fever, pharyngitis, cervical lymphadenopathy, mucosal sloughing, generalized erythematous eruptions and more than 40% epidermal detachment of the total body **surface area** (TBSA) after we added lamotrigine to her medications of valproate and trazodone. The patient's illness course was protracted and accompanied with hepatitis, pneumonitis and hematol. abnormalities. In the beginning of her illness course, our patient did not respond to antihistamine treatment. However, she made a full recovery without any sequela after she had received systemic corticosteroid and intensive resuscitation. Our case suggests that early use of systemic corticosteroid might be beneficial in treating TEN patients, if there is not any clin. contraindication.

CC 1-11 (Pharmacology)

IT Anticonvulsants

(emergence of toxic epidermal necrolysis was observed with anticonvulsant lamotrigine and valproate treatment while systemic corticosteroid and intensive resuscitation made full recovery without sequela in patient with bipolar II depression)

IT 99-66-1 84057-84-1, Lamotrigine

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (emergence of toxic epidermal necrolysis was observed with combined lamotrigine and valproate treatment while systemic corticosteroid and intensive resuscitation made full recovery without any sequela in patient with bipolar II depression)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1290048 CAPLUS

DOCUMENT NUMBER: 144:17195

TITLE: Treating **seizures** using ice inhibitors

INVENTOR(S): Vezzani, Annamaria; Randle, John C. R.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115362	A1	20051208	WO 2005-US17177	20050516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,				

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG

US 2006128696 A1 20060615 US 2005-130659 20050516

PRIORITY APPLN. INFO.: US 2004-571314P P 20040515

ED Entered STN: 09 Dec 2005

AB The invention relates to methods and compns. for treating or preventing seizures.

IC ICM A61K031-00

ICS A61K031-551; A61K031-4025; A61K031-40; A61P025-08

CC 1-11 (Pharmacology)

ST caspase ICE inhibitor pharmaceutical anticonvulsant  
epilepsy combination therapy

IT Anticonvulsants

Combination chemotherapy

Convulsion

Epilepsy

Human

Seizures

(ICE inhibitors for treatment and prevention of seizures)

IT Interleukin 1

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(ICE inhibitors for treatment and prevention of seizures)

IT Drug delivery systems

(carriers; ICE inhibitors for treatment and prevention of seizures)

IT Brain

(hippocampus; ICE inhibitors for treatment and prevention of seizures)

IT Drug delivery systems

(intracranial; ICE inhibitors for treatment and prevention of seizures)

IT Drug delivery systems

(oral; ICE inhibitors for treatment and prevention of seizures )

IT Drug delivery systems

(parenterals; ICE inhibitors for treatment and prevention of seizures)

IT Drug delivery systems

(tablets; ICE inhibitors for treatment and prevention of seizures)

IT 122191-40-6, Interleukin-converting enzyme 186322-81-6, Caspase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(ICE inhibitors for treatment and prevention of seizures)

IT 57-33-0 57-41-0, Phenytoin 77-41-8, Methylsuximide 77-67-8,  
Ethosuximide 99-66-1 115-38-8, Mephobarbital 125-33-7, Primidone  
298-46-4, Carbamazepine 439-14-5, Diazepam 461-72-3, Hydantoin  
846-49-1, Lorazepam 1622-61-3, Clonazepam 1744-22-5, Riluzole  
15687-27-1, Ibuprofen 23887-31-2, Clorazepate 25451-15-4, Felbamate  
60142-96-3, Gabapentin 68506-86-5, Vigabatrin 76584-70-8  
84057-84-1, Lamotrigine 93390-81-9, Fosphenytoin 97240-79-4,  
Topiramate 115103-54-3, Tiagabine 148553-50-8, Pregabalin  
192755-52-5 192756-07-3 244133-31-1 273404-36-7 273404-37-8  
853017-36-4 853017-37-5 853017-38-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(ICE inhibitors for treatment and prevention of seizures)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1241184 CAPLUS  
 DOCUMENT NUMBER: 143:483161  
 TITLE: Mouth dissolvable and meltable, and water dispersable delivery formulation for antiepileptics  
 INVENTOR(S): Chakravorty, Saibal; Hariharan, V.  
 PATENT ASSIGNEE(S): Rpg Life Sciences Limited, India  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005109990	A2	20051124	WO 2005-IN101	20050404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: IN 2004-MU419 A 20040406

ED Entered STN: 24 Nov 2005

AB A mouth dissolvable and meltable, and water dispersable delivery system for oral administration consisting of an antiepileptic drug, one or more swelling agents, one or more of fillers, one or more of disintegrating agents, and one or more of binders is disclosed. The swelling agent is powdered cellulose, filler is spray dried mannitol, disintegrating agent is crosslinked polyvinyl pyrrolidone and binder is maltodextrin. This system optionally comprises one or more of other excipients selected from the group comprising lubricants, sweeteners and flavoring agent.

IC ICM A61K

CC 63-6 (Pharmaceuticals)

ST mouth dissolvable delivery antiepileptic binder filler disintegrating agent

IT Acacia

Anticonvulsants

Binders

Dissolution

Fillers

Mouth

Particle size

(mouth dissolvable tablets containing antiepileptics and cellulose and mannitol and disintegrating agents and binders)

IT Drug delivery systems

(oral; mouth dissolvable tablets containing antiepileptics and cellulose and mannitol and disintegrating agents and binders)

IT Drug delivery systems  
(tablets; mouth dissolvable tablets containing antiepileptics and cellulose and mannitol and disintegrating agents and binders)  
IT 9003-39-8, Polyvinyl pyrrolidone  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(crosslinked; mouth dissolvable tablets containing antiepileptics and cellulose and mannitol and disintegrating agents and binders)  
IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose,  
biological studies 57-48-7, Fructose, biological studies 69-65-8,  
Mannitol 69-79-4, Maltose 9004-34-6, Cellulose, biological studies  
9005-25-8, Corn starch, biological studies 9050-36-6, Maltodextrin  
11138-66-2, Xanthan gum 74811-65-7, Croscarmellose sodium  
84057-84-1, Lamotrigine  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(mouth dissolvable tablets containing antiepileptics and cellulose and mannitol and disintegrating agents and binders)

L31 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:761734 CAPLUS  
DOCUMENT NUMBER: 143:279127  
TITLE: Scopolamine-induced convulsions in fasted mice after food intake: effects of glucose intake, antimuscarinic activity and anticonvulsant drugs  
AUTHOR(S): Enginar, Nurhan; Nurten, Asiye; Yamantuerk Celik, Pinar; Acikmese, Baris  
CORPORATE SOURCE: Department of Pharmacology and Clinical Pharmacology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turk.  
SOURCE: Neuropharmacology (2005), 49(3), 293-299  
CODEN: NEPHBW; ISSN: 0028-3908  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
ED Entered STN: 15 Aug 2005  
AB The present study was performed to further evaluate the contribution of antimuscarinic activity and hypoglycemia to the development of scopolamine-induced convulsions in fasted mice after food intake. The effects of anticonvulsant drugs on convulsions were also evaluated. Antimuscarinic drugs atropine (3 mg/kg) and biperiden (10 mg/kg) were given i.p. to animals fasted for 48 h. Like scopolamine, both drugs induced convulsions after animals were allowed to eat ad libitum. Another group of animals was given glucose (5%) in drinking water during fasting. These animals, although they had normoglycemic blood levels after fasting, also developed convulsions after treated with scopolamine i.p. (3 mg/kg), atropine (3 mg/kg) or biperiden (10 mg/kg) and allowed to eat ad libitum. Among the drugs studied, only valproate (340 mg/kg), gabapentin (50 mg/kg) and diazepam (2.5 and 5 mg/kg) markedly reduced the incidence of scopolamine-induced convulsions. The present results indicate that antimuscarinic activity, but not hypoglycemia, underlies these convulsions which do not respond to most of the conventional anticonvulsant drugs.  
CC 1-11 (Pharmacology)  
ST scopolamine convulsion food intake glucose antimuscarinic anticonvulsant drug  
IT Anticonvulsants  
    Convulsion  
    Feeding  
    Hypoglycemia  
    Muscarinic antagonists  
        (scopolamine-induced convulsions in fasted mice after food

intake and effects of glucose intake, antimuscarinic activity and  
anticonvulsant drugs)

IT 114-49-8, Scopolamine hydrobromide  
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
 (scopolamine-induced convulsions in fasted mice after food  
 intake and effects of glucose intake, antimuscarinic activity and  
 anticonvulsant drugs)

IT 50-06-6, Phenobarbital, biological studies 55-48-1, Atropine sulfate  
 57-41-0, Phenytoin 99-66-1 298-46-4, Carbamazepine 439-14-5,  
 Diazepam 514-65-8, Biperiden 60142-96-3, Gabapentin 84057-84-1  
 , Lamotrigine  
 RL: PAC (Pharmacological activity); BIOL (Biological study)  
 (scopolamine-induced convulsions in fasted mice after food  
 intake and effects of glucose intake, antimuscarinic activity and  
 anticonvulsant drugs)

IT 50-99-7, D-Glucose, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (transport; scopolamine-induced convulsions in fasted mice  
 after food intake and effects of glucose intake, antimuscarinic  
 activity and anticonvulsant drugs)

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:612064 CAPLUS

DOCUMENT NUMBER: 143:139157

TITLE: Preparation of rigid liposomal cochleate

INVENTOR(S): Krause-Elsmore, Sara L.; Mannino, Raphael J.

PATENT ASSIGNEE(S): Biodelivery Sciences International, Inc., USA

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063213	A1	20050714	WO 2004-US42927	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-531546P	P 20031219
			US 2004-565120P	P 20040423

ED Entered STN: 15 Jul 2005

AB Employing liposomes having a high transition temperature at least partially disposed in a matrix, compns. are provided that can be used to deliver one or more cargo moieties, e.g., a drug, a nutrient, an imaging agent and/or nonsteroidal anti-inflammatory drug. The matrix can be a lipid precipitate and/or a cationic bridge. Methods of making and using these compns. preferably cochleates, are also disclosed. Rigid liposomes were obtained from distearoylphosphatidylserine and dextran.

IC ICM A61K009-127  
ICS A61K047-02  
CC 63-6 (Pharmaceuticals)  
Section cross-reference(s): 17  
IT Adenoma  
Alopecia  
Alzheimer's disease  
Anesthetics  
Animal cell  
Animal virus  
Anti-inflammatory agents  
Antibiotics  
    **Anticonvulsants**  
Antidepressants  
Antihistamines  
Antimicrobial agents  
Antioxidants  
Antipsychotics  
Antitumor agents  
Antiviral agents  
Autoimmune disease  
Biliary tract, neoplasm  
Blood coagulation disorders  
Carcinoma  
Cholinergic antagonists  
Citrus  
Decongestants  
Eczema  
Esophagus, neoplasm  
Eubacteria  
Expectorants  
Flavoring materials  
Fungicides  
Ginkgo  
Graves' disease  
Herb  
Hypercholesterolemia  
Hyperglycemia  
Hypericum  
Hypertension  
Hyssopus officinalis  
Imaging agents  
Immune disease  
Immunostimulants  
Immunosuppressants  
Inflammation  
Leukemia  
Leukemia  
Leukotriene antagonists  
Lymphoma  
Malnutrition  
Mammary gland, neoplasm  
Melanoma  
Multiple sclerosis  
Myasthenia gravis  
Mycosis  
Neuroglia, neoplasm  
Nutrients  
Obesity  
Organelle

Origanum  
Ovary, neoplasm  
Pain  
Pancreas, neoplasm  
Parasite  
Parkinson's disease  
Pepper (spice)  
Pigments, nonbiological  
Plant cell  
Plasmids  
Poisons, nonbiological source  
Prostate gland, neoplasm  
Psoriasis  
Salvia  
Sarcoma  
Schizophrenia  
Skin, disease  
Spices  
Stomach, neoplasm  
Sweetening agents  
Tea products  
Testis, neoplasm  
Tranquilizers  
Uterus, neoplasm  
Vanilla  
Vasoconstrictors  
Vasodilators

(preparation of rigid liposomal cochleate)

IT 50-02-2 50-06-6, Phenobarbital, biological studies 50-12-4,  
Mephenytoin 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-48-6,  
Amitriptyline 50-49-7, Imipramine 50-78-2 50-81-7, Vitamin C,  
biological studies 50-99-7, Glucose, biological studies  
51-61-6, Dopamine, biological studies 52-53-9, Verapamil 53-06-5,  
Cortisone 53-86-1, Indomethacin 54-11-5 57-41-0 57-48-7, Fructose,  
biological studies 57-50-1, Sucrose, biological studies 57-92-1,  
Streptomycin, biological studies 58-22-0 58-82-2, Bradykinin  
58-85-5, Biotin 59-01-8, Kanamycin A 59-43-8, Vitamin B1, biological  
studies 62-49-7, Choline 66-71-7, 1,10-Phenanthroline 67-20-9,  
Nitrofurantoin 68-19-9, Vitamin B12 69-79-4, Maltose 72-69-5,  
Nortriptyline 77-41-8, Methsuximide 77-67-8, Ethosuximide 79-09-4,  
Propionic acid, biological studies 81-07-2, Saccharin 83-88-5, Vitamin  
B2, biological studies 86-34-0, Phensuximide 86-35-1, Ethotoxin  
87-89-8, Inositol 89-57-6, Mesalamine 98-92-0, Vitamin B3 103-90-2  
110-91-8D, Morpholine, derivs. 112-38-9, Undecylenic acid  
113-15-5 113-53-1, Dothiepin 117-39-5, Quercetin 124-07-2, Caprylic  
acid, biological studies 125-33-7, Primidone 126-07-8, Griseofulvin  
127-40-2, Lutein 127-48-0, Trimethadione 128-46-1, Dihydrostreptomycin  
130-26-7, Clioquinol 144-68-3 148-82-3 298-46-4, Carbamazepine  
302-79-4, Vitamin A acid 303-49-1, Clomipramine 379-68-0 439-14-5,  
Diazepam 446-72-0, Genistein 458-37-7 501-36-0, Resveratrol  
512-64-1, Echinomycin 536-59-4, Perillyl alcohol 618-39-3, Benzamidine  
645-05-6, Hexamethylmelamine 777-11-7, Haloprogin 1397-89-3,  
Amphotericin B 1400-61-9, Nystatin 1403-66-3, Gentamycin 1404-04-2,  
Neomycin 1404-55-3, Ristocetin 1404-90-6, Vancomycin 1406-16-2,  
Vitamin D 1406-18-4, Vitamin E 1421-14-3, Propanidid 1668-19-5,  
Doxepin 1695-77-8, Spectinomycin 2022-85-7, Flucytosine 2078-54-8,  
Propofol 2398-96-1, Tolnaftate 2644-64-6 2809-21-4 2954-45-2,  
Dimyristoylphosphatidylserine 3036-82-6 3947-65-7 4478-93-7,  
Sulforaphane 4537-77-3 4539-70-2 4696-76-8, Kanamycin B 5681-36-7  
7235-40-7,  $\beta$ -Carotene 7261-97-4, Dantrolene 7439-89-6, Iron,

biological studies 7439-95-4, Magnesium, biological studies 7439-96-5, Manganese, biological studies 7440-09-7, Potassium, biological studies 7440-22-4, Silver, biological studies 7440-39-3, Barium, biological studies 7440-42-8, Boron, biological studies 7440-47-3, Chromium, biological studies 7440-50-8, Copper, biological studies 7440-62-2, Vanadium, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 7488-56-4, Selenium sulfide 7542-37-2, Paromomycin 7681-93-8 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 8067-82-1, Alphadione 9002-60-2, Corticotropin, biological studies 9004-10-8, Insulin, biological studies 9005-25-8, Starch, biological studies 9007-12-9, Calcitonin 9034-40-6, LHRH 9041-90-1, Angiotensin I 9050-36-6, Maltodextrin 9076-44-2, Chymostatin 10417-94-4, Eicosapentaenoic acid 11000-17-2, Vasopressin 11056-06-7, Bleomycin 11103-57-4, Vitamin A 11128-99-7, Angiotensin II 12001-76-2, Vitamin B 12001-79-5, Vitamin K 12687-51-3, Angiotensin III 13292-46-1, Rifampin 14268-17-8 15307-86-5, Diclofenac 15687-27-1 19698-29-4 19794-93-5, Trazodone 20255-95-2 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22204-53-1 22832-87-7 22839-47-0, Aspartame 22888-70-6, Silibinin 22916-47-8, Miconazole 23047-25-8, Lofepramine 23593-75-1, Clotrimazole 24305-27-9, Thyroid releasing hormone 25316-40-9, Adriamycin 25451-15-4, Felbamate 25546-65-0, Ribostamycin 27220-47-9, Econazole 27774-13-6, Vanadyl sulfate 28721-07-5, Oxcarbazepine 29767-20-2, Teniposide 30562-34-6, Geldanamycin 32986-56-4, Tobramycin 33069-62-4, Taxol 33507-63-0, Substance P 36322-90-4, Piroxicam 36357-77-4, Phosphoramidon 37321-09-8, Apramycin 37332-99-3, Avoparcin 37517-28-5, Amikacin 37691-11-5, Antipain 39319-82-9, Actinoidin 39324-30-6, Pepstatin 41621-49-2, Ciclopirox olamine 42924-53-8, Nabumetone 51050-59-0, 3,4-Dichloroisocoumarin 51110-01-1, Somatostatin 51798-45-9, Elastatinal 53123-88-9, Rapamycin 54651-05-7, Echinocandin B 54910-89-3, Fluoxetine 55123-66-5, Leupeptin 56391-56-1, Netilmicin 58391-28-9, Leucokinin 58814-86-1, Aculeacin A 58970-76-6, Bestatin 59277-89-3 59729-33-8, Citalopram 60617-12-1,  $\beta$ -Endorphin 61036-62-2, Teicoplanin 61318-90-9 61869-08-7, Paroxetine 64211-45-6, Oxiconazole 64519-82-0, Isomalt 64872-76-0, Butoconazole 65277-42-1, Ketoconazole 65472-88-0, Naftifine 67655-94-1, Amastatin 67915-31-5, Terconazole 68291-97-4, Zonisamide 70288-86-7, Ivermectin 71125-38-7, Meloxicam 71620-89-8 74913-18-1, Dynorphin 78628-80-5, Terbinafine hydrochloride 79217-60-0, Cyclosporin 79404-91-4, Cilofungin 79617-96-2, Sertraline 84057-84-1, Lamotrigine 84625-61-6, Itraconazole 85650-52-8, Mirtazapine 86386-73-4, Fluconazole 92216-05-2, Distearoylphosphatidylserine 93390-81-9, Fosphenytoin 93413-69-5, Venlafaxine 97240-79-4, Topiramate 101828-21-1, Butenafine 102767-28-2, Levetiracetam 105462-24-6 110588-57-3, Saperconazole 114977-28-5, Taxotere 127779-20-8, Saquinavir 137234-62-9, Voriconazole 150378-17-9, Indinavir 155213-67-5, Ritonavir 159445-62-2, Orientiparvin 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 162011-90-7, Rofecoxib 162808-62-0, Caspofungin 166663-25-8, Anidulafungin 235114-32-6, Micafungin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of rigid liposomal cochleate)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:493490 CAPLUS  
DOCUMENT NUMBER: 143:32332  
TITLE: Water dispersible tablet  
INVENTOR(S): Gupta, Vinod Kumar; Vaya, Navin; Sougata, Pramanick

PATENT ASSIGNEE(S) : Torrent Pharmaceuticals Limited, India  
 SOURCE: PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051350	A2	20050609	WO 2004-IN312	20041007
WO 2005051350	A3	20050818		
WO 2005051350	B1	20050929		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: IN 2003-MU1128 A 20031028  
 ED Entered STN: 10 Jun 2005  
 AB This invention relates to a water-dispersible formulation of an active pharmaceutical ingredient or pharmaceutically acceptable salt hereof and one or more adjuvants without the use of swellable clay. More particularly, the invention comprises a dispersible formulation of anti-epileptic drug - lamotrigine. This invention further relates to a process for the preparation of said formulation.  
 IC ICM A61K009-00  
 CC 63-6 (Pharmaceuticals)  
 IT Drug delivery systems  
     (carriers; water-dispersible lamotrigine tablet)  
 IT Anticonvulsants  
     Binders  
     Dispersion (of materials)  
     Dyes  
     Flavoring materials  
     Particle size distribution  
     Sieving  
     (water-dispersible lamotrigine tablet)  
 IT 84057-84-1, Lamotrigine  
     RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);  
     USES (Uses)  
     (water-dispersible lamotrigine tablet)

L31 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:325504 CAPLUS  
 DOCUMENT NUMBER: 142:379390  
 TITLE: Pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability  
 INVENTOR(S): Chickering, Donald E.; Reese, Shaina; Narasimhan, Sridhar; Straub, Julie A.; Bernstein, Howard; Altreuter, David; Huang, Eric K.; Brito, Luis A.; Jain, Rajeev A.

PATENT ASSIGNEE(S) : USA  
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S.  
Ser. No. 324,550.  
CODEN: USXXCO

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005079138	A1	20050414	US 2004-955261	20040930
US 2004121003	A1	20040624	US 2002-324558	20021219
PRIORITY APPLN. INFO.:				US 2002-324558 A2 20021219

ED Entered STN: 15 Apr 2005

AB Methods are provided for making a dry powder blend pharmaceutical formulation, comprising the steps of: (a) providing microparticles which comprise a pharmaceutical agent; (b) blending the microparticles with at least one excipient in the form of particles to form a powder blend; and (c) jet milling the powder blend to form a dry powder blend pharmaceutical formulation having improved dispersibility, suspendability, or wettability as compared to the microparticles of step (a) or the powder blend of step (b). The method can further include dispersing the dry powder blend pharmaceutical formulation in a liquid pharmaceutically acceptable vehicle to make an formulation suitable for injection. Alternatively, the method can further include processing the dry powder blend pharmaceutical formulation into a solid oral dosage form. In one embodiment, the microparticles of step (a) are formed by a solvent precipitation or crystallization process. PLGA microspheres containing mannitol and Tween 80

having number average particle size of 1.96  $\mu\text{m}$ , and volume average particle size of 4.04  $\mu\text{m}$  were prepared. The jet milling provided significant particle deagglomeration.

IC ICM A61L009-04  
IC S A61K009-14

INCL 424046000; 424489000; 241018000

CC 63-6 (Pharmaceuticals)

IT Antiasthmatics  
Antibacterial agents  
Anticonvulsants  
Antihistamines  
Antimicrobial agents  
Antipsychotics  
Antitumor agents  
Antiviral agents  
Anxiety  
Anxiolytics  
Asthma  
Bronchodilators  
Calcium channel blockers  
Epilepsy  
Fungicides  
Hypnotics and Sedatives  
Immunosuppressants  
Immunosuppression  
Mycosis  
Neoplasm  
Particle size distribution  
Sleep  
(methods for making pharmaceutical formulations comprising

microparticles with improved dispersibility, suspendability or wettability)

IT 50-28-2, Estradiol, biological studies 55-98-1, Busulfan 57-41-0, Phenytoin 57-83-0, Progesterone, biological studies 58-22-0, Testosterone 76-25-5, Triamcinolone acetonide 89-57-6, Mesalamine 298-46-4, Carbamazepine 439-14-5, Diazepam 599-79-1, Sulfasalazine 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 846-49-1, Lorazepam 1951-25-3, Amiodarone 2078-54-8, Propofol 3385-03-3, Flunisolide 5534-09-8, Beclomethasone dipropionate 5786-21-0, Clozapine 8064-90-2, Bactrim 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 10118-90-8, Minocycline 18559-94-9, Albuterol 26787-78-0, Amoxicillin 28721-07-5, Oxcarbazepine 28981-97-7, Alprazolam 33069-62-4, Paclitaxel 34346-01-5, Lactic acid glycolic acid copolymer 41340-25-4, Etodolac 42924-53-8, Nabumetone 49562-28-9, Fenofibrate 51110-01-1, Somatostatin 51322-75-9, Tizanidine 51333-22-3, Budesonide 52352-27-9, Poly(hydroxybutyric acid) 53123-88-9, Sirolimus 53714-56-0, Leuprolide 59277-89-3, Acyclovir 59865-13-3, Cyclosporine 68475-42-3, Anagrelide 68693-11-8, Modafinil 70524-20-8 71125-38-7, Meloxicam 72558-82-8, Ceftazidime 73573-87-2, Formoterol 79794-75-5, Loratadine 80474-14-2, Fluticasone propionate 81103-11-9, Biaxin 82410-32-0, Ganciclovir 83799-24-0, Fexofenadine 84057-84-1, Lamotrigine 84625-61-6, Itraconazole 85721-33-1, Ciprofloxacin 86639-52-3, SN 38 89365-50-4, Salmeterol 92665-29-7, Cefprozil 95058-81-4, Gemcitabine 102190-94-3, Poly(hydroxyvaleric acid) 103370-86-1, Parathyroid hormone-related peptide 104227-87-4, Famciclovir 104987-11-3, Tacrolimus 105102-22-5, Mometasone 107753-78-6, Zafirlukast 111406-87-2, Zileuton 114977-28-5, Docetaxel 115103-54-3, Tiagabine 132539-06-1, Olanzapine 137234-62-9, Voriconazole 137862-53-4, Valsartan 143011-72-7, Granulocyte colony-stimulating factor 146939-27-7, Ziprasidone 155213-67-5, Ritonavir 159989-65-8, Nelfinavir mesylate 162011-90-7, Rofecoxib 169590-42-5, Celecoxib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(methods for making pharmaceutical formulations comprising  
microparticles with improved dispersibility, suspendability or  
wettability)

L31 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:216629 CAPLUS  
DOCUMENT NUMBER: 142:285200  
TITLE: Nanoparticles for drug delivery  
INVENTOR(S): Turos, Edward; Shim, Jeung-Yeop  
PATENT ASSIGNEE(S): University of South Florida, USA  
SOURCE: PCT Int. Appl., 144 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020933	A2	20050310	WO 2004-US28995	20040902
WO 2005020933	A3	20050609		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-499904P P 20030902  
US 2003-500750P P 20030904  
US 2004-568746P P 20040506

ED Entered STN: 11 Mar 2005

AB This invention relates to a unique process for the preparation of polymeric nanoparticles with target mols. bonded to the surface of the particles and having sizes of up to 1000 nm, preferably 1-400 nm, more preferably 1-200 nm, that are dispersed homogeneously in aqueous solution. To accomplish the above objective, the polymeric nanoparticles of the subject invention are prepared using a novel technique of microemulsion polymerization. The resulting aqueous solution of polymeric nanoparticles is comprised of about 1-100 parts per weight of water or buffer, about 1-80 parts per weight of polymeric nanoparticles, which the bioactive mols. are conjugated, about 0.001-10 parts per weight of emulsifier, and about 0.00001-5 parts per weight of radical initiator based on the weight of the solution. In the method of this invention, the target drug/target substance is covalently bonded to the polymeric nanoparticles to secure them from outer intervention in vivo or cell culture in vitro until they are exposed at the target site within the cell. Nanoparticles of ethylacrylate-N-methylthiolated 3-lactam copolymer were prepared by a radical polymerization using potassium persulfate as the initiator and the sodium salt of dodecyl sulfate as the surfactant. The particle size was 40-80 nm. The antibacterial activity of the nanoparticles is shown.

IC ICM A61K

CC 63-6 (Pharmaceuticals)

IT Analgesics

Anesthetics

Anthelmintics

Anti-inflammatory agents

Antiarrhythmics

Antiasthmatics

Antibacterial agents

Antibiotics

Anticoagulants

**Anticonvulsants**

Antidepressants

Antidiabetic agents

Antihistamines

Antihypertensives

Antioxidants

Antipsychotics

Antipyretics

Antithyroid agents

Antitumor agents

Antitussives

Antiviral agents

Anxiolytics

Bacterium (genus)

Blood products

Bronchodilators

Buffers

Chemotherapy

Diuretics  
Dopamine agonists  
Drug delivery systems  
Emulsifying agents  
Eukaryota  
Expectorants  
Fungicides  
Hemostatics  
Hypnotics and Sedatives  
Immunostimulants  
Immunosuppressants  
Muscarinic antagonists  
Muscle relaxants  
Prokaryota  
Surfactants  
(nanoparticles for drug delivery)

IT 50-28-2, Estradiol, biological studies 54-31-9, Furosemide 57-41-0,  
Phenytoin 58-32-2, Dipyridamole 59-30-3, Folic acid, biological  
studies 61-33-6, Penicillin G, biological studies 61-68-7, Mefenamic  
acid 69-89-6D, Xanthine, derivs. 77-26-9, Butalbital 83-43-2,  
Methylprednisolone 87-33-2, Isosorbide dinitrate 99-66-1, Valproic  
acid 124-94-7, Triamcinolone 298-46-4, Carbamazepine 439-14-5,  
Diazepam 446-86-6, Azathioprine 520-85-4, Medroxyprogesterone  
846-49-1, Lorazepam 990-73-8, Fentanyl citrate 1406-05-9, Penicillin  
1622-61-3, Clonazepam 1951-25-3, Amiodarone 3385-03-3, Flunisolide  
4419-39-0, Beclomethasone 4759-48-2, Isotretinoin 5104-49-4,  
Flurbiprofen 5786-21-0, Clozapine 10238-21-8, Glyburide 11041-12-6,  
Cholestyramine 15307-79-6, Diclofenac sodium 15663-27-1, Cisplatin  
15686-71-2, Cephalexin 15687-27-1, Ibuprofen 20830-75-5, Digoxin  
21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22204-53-1, Naproxen  
27848-84-6, Nicergoline 28860-95-9, Carbidopa 28981-97-7, Alprazolam  
29094-61-9, Glipizide 29122-68-7, Atenolol 33069-62-4, Paclitaxel  
33419-42-0, Etoposide 34368-04-2, Dobutamine 36322-90-4, Piroxicam  
38194-50-2, Sulindac 41340-25-4, Etodolac 42924-53-8, Nabumetone  
50679-08-8, Terfenadine 51333-22-3, Budesonide 52485-79-7,  
Buprenorphine 53179-11-6, Loperamide 54739-18-3, Fluvoxamine  
58581-89-8, Azelastine 59467-70-8, Midazolam 63527-52-6, Cefotaxime  
65277-42-1, Ketoconazole 68844-77-9, Atemizole 70458-96-7,  
Norfloxacin 72509-76-3, Felodipine 73590-58-6, Omeprazole  
74191-85-8, Doxazosin 75330-75-5, Lovastatin 75695-93-1, Isradipine  
75847-73-3, Enalapril 76584-70-8 76824-35-6, Famotidine 79217-60-0,  
Cyclosporin 79617-96-2, Sertraline 79794-75-5, Loratadine  
79902-63-9, Simvastatin 81098-60-4, Cisapride 81103-11-9,  
Clarithromycin 82626-48-0, Zolpidem 83799-24-0, Fexofenadine  
84057-84-1, Lamotrigine 84625-61-6, Itraconazole 85441-61-8,  
Quinapril 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole  
87333-19-5, Ramipril 88150-42-9, Amlodipine 91161-71-6, Terbinafine  
98319-26-7, Finasteride 103577-45-3, Lansoprazole 105102-22-5,  
Mometasone 106266-06-2, Risperidone  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(nanoparticles for drug delivery)

L31 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1047608 CAPLUS

DOCUMENT NUMBER: 142:254377

TITLE: Valproate decreases inositol biosynthesis

AUTHOR(S): Shaltiel, Galit; Shamir, Alon; Shapiro, Joseph; Ding,  
Daobin; Dalton, Emma; Bialer, Meir; Harwood, Adrian  
J.; Belmaker, Robert H.; Greenberg, Miriam L.; Agam,

CORPORATE SOURCE: Galila  
Stanley Research Center and Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beersheva, Israel

SOURCE: Biological Psychiatry (2004), 56(11), 868-874  
CODEN: BIPCBF; ISSN: 0006-3223

PUBLISHER: Elsevier Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 07 Dec 2004

AB Lithium and valproate (VPA) are used for treating bipolar disorder. The mechanism of mood stabilization has not been elucidated, but the role of inositol has gained substantial support. Lithium inhibition of inositol monophosphatase, an enzyme required for inositol recycling and de novo synthesis, suggested the hypothesis that lithium depletes brain inositol and attenuates phosphoinositide signaling. Valproate also depletes inositol in yeast, Dictyostelium, and rat neurons. This raised the possibility that the effect is the result of myo-inositol-1-phosphate (MIP) synthase inhibition. Inositol was measured by gas chromatog. Human prefrontal cortex MIP synthase activity was assayed in crude homogenate. INO1 was assessed by Northern blotting. Growth cones **morphol.** was evaluated in cultured rat neurons. We found a 20% in vivo reduction of inositol in mouse frontal cortex after acute VPA administration. As hypothesized, inositol reduction resulted from decreased MIP synthase activity: .21-.28 mmol/LVPA reduced the activity by 50%. Among psychotropic drugs, the effect is specific to VPA. Accordingly, only VPA upregulates the yeast INO1 gene coding for MIP synthase. The VPA derivative N-methyl-2,2,3,3,-tetramethyl-cyclopropane carboxamide reduces MIP synthase activity and has an affect similar to that of VPA on rat neurons, whereas another VPA derivative, valpromide, poorly affects the activity and has no effect on neurons. The rate-limiting step of inositol biosynthesis, catalyzed by MIP synthase, is inhibited by VPA; inositol depletion is a first event shown to be common to lithium and VPA.

CC 1-11 (Pharmacology)

IT Anticonvulsants

(anticonvulsant mood stabilizers carbamazepine, phenytoin, lamotrigine did not show significant human brain myo-inositol-1-phosphate synthase activity)

IT 84057-84-1, Lamotrigine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(lamotrigine did not show significant human brain myo-inositol-1-phosphate synthase activity)

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:999687 CAPLUS  
DOCUMENT NUMBER: 141:416046  
TITLE: Analeptic and drug combinations  
INVENTOR(S): Hughes, Rodney J.; Vaught, Jeffry L.  
PATENT ASSIGNEE(S): Cephalon Inc, USA  
SOURCE: U.S. Pat. Appl. Publ., 8 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2004229943	A1	20041118	US 2004-845836	20040514
AU 2004241110	A1	20041202	AU 2004-241110	20040517
CA 2524870	AA	20041202	CA 2004-2524870	20040517
WO 2004103359	A1	20041202	WO 2004-US15408	20040517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1635807	A1	20060322	EP 2004-752424	20040517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1791397	A	20060621	CN 2004-80013407	20040517
NO 2005005173	A	20051212	NO 2005-5173	20051103
PRIORITY APPLN. INFO.:				
			US 2003-471302P	P 20030516
			US 2004-845836	A 20040514
			WO 2004-US15408	W 20040517

ED Entered STN: 19 Nov 2004

AB Compns. and methods for the treatment of disorders through the administration of modafinil with M-drugs (modafinil adjunct drugs) are disclosed.

IC ICM A61K031-343

ICS A61K031-165

INCL 514469000; 514617000; 514649000; 514220000; 514259310; 514221000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 15

IT Anticonvulsants

Antidepressants

Antipsychotics

Antitumor agents

Cardiovascular agents

Dopamine agonists

Human

Nervous system stimulants

(analeptic and drug combinations containing modafinil)

IT Drug delivery systems

(carriers; analeptic and drug combinations containing modafinil)

IT 52-53-9, Verapamil 57-22-7, Vincristine 57-41-0, Phenytoin 298-46-4, Carbamazepine 357-70-0, Galantamine 5786-21-0, Clozapine 15663-27-1, Cisplatin 19216-56-9, Prazosin 20830-75-5, Digoxin 21829-25-4, Nifedipine 25614-03-3, Bromocriptine 33069-62-4, Taxol 36894-69-6, Labetalol 42399-41-7, Diltiazem 60142-96-3, Gabapentin 62571-86-2, Captopril 66104-22-1, Pergolide 68693-11-8, Modafinil 68693-11-8D, Modafinil, salts 75847-73-3, Enalapril 84057-84-1, Lamotrigine 91374-21-9, Ropinirole 97240-79-4, Topiramate 104632-26-0, Pramipexole 106266-06-2, Risperidone 112111-43-0 114798-26-4, Losartan 114977-28-5, Docetaxel 115103-54-3, Tiagabine 120014-06-4, Donepezil 132539-06-1, Olanzapine 145155-23-3 145258-61-3, Interferon  $\beta$ 1 (human fibroblast protein moiety)

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);

USES (Uses)

(analeptic and drug combinations containing modafinil)

L31 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:902155 CAPLUS  
 DOCUMENT NUMBER: 141:384286  
 TITLE: Novel encochleation methods, cochleates and methods of use  
 INVENTOR(S): Mannino, Raphael J.; Gould-Fogerite, Susan;  
 Krause-Elsmore, Sara L.; Delmarre, David; Lu, Ruying  
 Biodelivery Sciences International, Inc., USA;  
 University of Medicine and Dentistry of New Jersey  
 SOURCE: PCT Int. Appl., 195 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091578	A2	20041028	WO 2004-US11026	20040409
WO 2004091578	C1	20050127		
WO 2004091578	A3	20050331		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
US 2005013854	A1	20050120	US 2004-822230	20040409
EP 1624858	A2	20060215	EP 2004-759375	20040409
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK		
PRIORITY APPLN. INFO.:			US 2003-461483P	P 20030409
			US 2003-463076P	P 20030415
			US 2003-499247P	P 20030828
			US 2003-502557P	P 20030911
			US 2003-532755P	P 20031224
			US 2004-537252P	P 20040115
			US 2004-556192P	P 20040324
			WO 2004-US11026	W 20040409

ED Entered STN: 28 Oct 2004  
 AB The invention generally relates to cochleate drug delivery vehicles.  
 Disclose are novel methods for making cochleates and cochleate compns.  
 that include introducing a cargo moiety to a liposome in the presence of a  
 solvent. Also disclosed are cochleates and cochleate compns. that include  
 an aggregation inhibitor, and optionally, a cargo moiety. Addnl., anhydrous  
 cochleates that include a protonized cargo moiety, a divalent metal cation  
 and a neg. charge lipid are disclosed. Methods of using the cochleate  
 compns. of the invention, including methods of administration, are also  
 disclosed.  
 IC ICM A61K009-127  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1, 2, 17, 18  
 IT Drug delivery systems  
 (carriers; novel encochleation methods and cochleates and

methods of use for delivery of drugs and other agents using liposomes  
and aggregation inhibitors)

IT Adenoma  
Aggregation  
Alopecia  
Alzheimer's disease  
Analgesics  
Anesthetics  
Animal virus  
Anti-Alzheimer's agents  
Anti-infective agents  
Antiarthritis  
Antiasthmatics  
Antibacterial agents  
Antibiotics  
Anticholesteremic agents  
Anticoagulants  
    **Anticonvulsants**  
Antidepressants  
Antidiabetic agents  
Antihistamines  
Antihypertensives  
Antihypotensives  
Antimicrobial agents  
Antiobesity agents  
Antioxidants  
Antiparkinsonian agents  
Antipsychotics  
Antirheumatic agents  
Antitumor agents  
Antiviral agents  
Arthritis  
Asthma  
Atherosclerosis  
Autoimmune disease  
Biliary tract, neoplasm  
Blood coagulation disorders  
Carcinoma  
Carcinoma  
Cations  
Chelating agents  
Cholinergic antagonists  
Cognition enhancers  
Cystic fibrosis  
Cytoprotective agents  
Cytotoxic agents  
Dairy products  
Decongestants  
Detergents  
Eczema  
Esophagus, neoplasm  
Expectorants  
Flavoring materials  
Fungicides  
Gene therapy  
Genetic vectors  
Ginkgo  
Gout  
Graves' disease  
Gums and Mucilages

Headache  
Hemophilia  
Hemostatics  
Hypercholesterolemia  
Hyperglycemia  
Hypericum  
Hypertension  
Hypolipemic agents  
Hypotension  
Imaging agents  
Immune disease  
Immunostimulants  
Immunosuppressants  
Infection  
Inflammation  
Leukemia  
Leukotriene antagonists  
Lung, neoplasm  
Lymphoma  
Malnutrition  
Mammary gland, neoplasm  
Melanoma  
Milk  
Mouthwashes  
Multiple sclerosis  
Muscular dystrophy  
Myasthenia gravis  
Mycosis  
Neoplasm  
Neuroglia, neoplasm  
Nutrients  
Obesity  
Organelle  
Osteoarthritis  
Ovary, neoplasm  
Packaging materials  
Pain  
Pancreas, neoplasm  
Parasiticides  
Parkinson's disease  
Pigments, biological  
Plasmids  
Prostate gland, neoplasm  
Psoriasis  
Psychotropics  
Rheumatoid arthritis  
Sarcoma  
Schizophrenia  
Skin, disease  
Stomach, neoplasm  
Sweetening agents  
Testis, neoplasm  
Tranquilizers  
Transplant rejection  
Uterus, neoplasm  
Vaccines  
Vasoconstrictors  
Vasodilators  
(novel encochleation methods and cochleates and methods of use for  
delivery of drugs and other agents using liposomes and aggregation

inhibitors)

IT 50-02-2, Dexamethasone 50-06-6, Phenobarbital, biological studies  
 50-12-4, Mephenytoin 50-23-7, Hydrocortisone 50-24-8, Prednisolone  
 50-48-6, Amitriptyline 50-49-7, Imipramine 51-61-6, Dopamine,  
 biological studies 52-53-9, Verapamil 53-06-5, Cortisone 53-86-1,  
 Indomethacin 54-11-5, Nicotine 57-41-0, Phenytoin 57-92-1,  
 Streptomycin, biological studies 58-22-0, Testosterone 58-82-2,  
 Bradykinin 59-01-8, Kanamycin A 66-71-7, 1,10-Phenanthroline  
 67-20-9, Nitrofurantoin 72-69-5, Nortriptyline 77-41-8, Methsuximide  
 77-67-8, Ethosuximide 79-09-4, Propionic acid, biological studies  
 86-34-0, Phensuximide 86-35-1, Ethotoin 89-57-6, Mesalamine  
 103-90-2, Acetaminophen 110-91-8D, Morpholine, derivs.  
 112-38-9, Undecylenic acid 113-15-5D, Ergotamine, derivs. 113-53-1,  
 Dothiepin 124-07-2, Caprylic acid, biological studies 125-33-7,  
 Primidone 126-07-8, Griseofulvin 127-48-0, Trimethadione 128-46-1,  
 Dihydrostreptomycin 130-26-7, Clioquinol 148-82-3, Melphalan  
 298-46-4, Carbamazepine 302-79-4, Vitamin A acid 303-49-1,  
 Clomipramine 379-68-0, 18-Hydroxydeoxycorticosterone 439-14-5,  
 Diazepam 458-37-7, Curcumin 512-64-1, Echinomycin 618-39-3,  
 Benzamidine 645-05-6, Hexamethylmelamine 777-11-7, Haloprogin  
 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1403-66-3, Gentamycin  
 1404-04-2, Neomycin 1404-55-3, Ristocetin 1404-90-6, Vancomycin  
 1421-14-3, Propanidid 1668-19-5, Doxepin 1695-77-8, Spectinomycin  
 2022-85-7, Flucytosine 2078-54-8, Propofol 2398-96-1, Tolnaftate  
 2809-21-4 3947-65-7, Neamine 4696-76-8, Kanamycin B 7261-97-4,  
 Dantrolene 7488-56-4, Selenium sulfide 7542-37-2, Paromomycin  
 7681-93-8, Natamycin 8067-82-1, Alphadione 9002-60-2, ACTH, biological  
 studies 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin  
 9034-40-6, LH-RH 9041-90-1, Angiotensin I 9076-44-2, Chymostatin  
 11000-17-2, Vasopressin 11056-06-7, Bleomycin 11128-99-7, Angiotensin  
 II 12687-51-3, Angiotensin III 13292-46-1, Rifampin 14074-80-7, Zinc  
 tetraphenyl porphyrin 15307-86-5, Diclofenac 15687-27-1, Ibuprofen  
 19794-93-5, Trazodone 21829-25-4, Nifedipine 22071-15-4, Ketoprofen  
 22204-53-1, Naproxen 22832-87-7, Miconazole nitrate 22916-47-8,  
 Miconazole 23047-25-8, Lofepramine 23593-75-1, Clotrimazole  
 24305-27-9, Thyroid releasing hormone 25316-40-9, Adriamycin  
 25451-15-4, Felbamate 25546-65-0, Ribostamycin 27220-47-9, Econazole  
 28721-07-5, Oxcarbazepine 29767-20-2, Teniposide 30562-34-6,  
 Geldanamycin 32986-56-4, Tobramycin 33069-62-4, Taxol 33507-63-0,  
 Substance P (peptide) 36322-90-4, Piroxicam 36357-77-4, Phosphoramidon  
 37321-09-8, Apramycin 37332-99-3, Avoparcin 37517-28-5, Amikacin  
 37691-11-5, Antipain 39319-82-9, Actinoidin 39324-30-6, Pepstatin  
 41621-49-2, Ciclopirox olamine 42924-53-8, Nabumetone 51050-59-0,  
 3,4-Dichloroisocoumarin 51110-01-1, Somatostatin 51798-45-9,  
 Elastatinal 53123-88-9, Rapamycin 54651-05-7, Echinocandin B 54910-8  
 9-3, Fluoxetine 55123-66-5, Leupeptin 56391-56-1, Netilmicin  
 58391-28-9, Leucokinin 58814-86-1, Aculeacin A 58970-76-6, Bestatin  
 59277-89-3, Acyclovir 59729-33-8, Citalopram 59865-13-3, Cyclosporin  
 60617-12-1,  $\beta$ -Endorphin 61036-62-2, Teicoplanin 61318-90-9,  
 Sulconazole 61869-08-7, Paroxetine 64211-45-6, Oxiconazole  
 64872-76-0, Butoconazole 65277-42-1, Ketoconazole 65472-88-0,  
 Naftifine 67655-94-1, Amastatin 67915-31-5, Terconazole 68291-97-4,  
 Zonisamide 70288-86-7, Ivermectin 71125-38-7, Meloxicam 71620-89-8,  
 Reboxetine 74913-18-1, Dynorphin 78628-80-5, Terbinafine hydrochloride  
 79404-91-4, Cilofungin 79617-96-2, Sertraline 80619-41-6, Echinocandin  
 84057-84-1, Lamotrigine 84625-61-6, Itraconazole 85650-52-8,  
 Mirtazapine 86386-73-4, Fluconazole 93390-81-9, Fosphenytoin  
 93413-69-5, Venlafaxine 97240-79-4, Topiramate 101828-21-1, Butenafine  
 102767-28-2, Levetiracetam 105462-24-6 110588-57-3, Saperconazole  
 114977-28-5, Taxotere 118850-71-8 118850-72-9 118850-73-0

127779-20-8, Saquinavir 135882-23-4, Pneumocandin A4 137234-62-9,  
Voriconazole 150378-17-9, Indinavir 155213-67-5, Ritonavir  
159445-62-2, Orientiparcin 159989-64-7, Nelfinavir 161814-49-9,  
Amprenavir 162011-90-7, Rofecoxib 162808-62-0, Caspofungin  
166663-25-8, Anidulafungin 235114-32-6, Micafungin  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(novel encochleation methods and cochleates and methods of use for  
delivery of drugs and other agents using liposomes and aggregation  
inhibitors)

IT 50-99-7, Glucose, biological studies 57-50-1, Sucrose,  
biological studies 69-79-4, Maltose 81-07-2, Saccharine 9050-36-6,  
Maltodextrin 22839-47-0, Aspartame 64519-82-0, Isomalt  
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
(sweetening agent; novel encochleation methods and cochleates and  
methods of use for delivery of drugs and other agents using liposomes  
and aggregation inhibitors)

L31 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:778053 CAPLUS

DOCUMENT NUMBER: 142:107203

TITLE: The effect of Vigabatrin, Lamotrigine and Gabapentin  
on the fertility, weights, sex hormones and  
biochemical profiles of male rats

AUTHOR(S): Daoud, A. S.; Bataineh, H.; Otoom, S.; Abdul-Zahra, E.

CORPORATE SOURCE: Departments of Neuroscience, College of Medicine,  
Jordan University of Science and Technology, Irbid,  
Jordan

SOURCE: Neuroendocrinology Letters (2004), 25(3), 178-183  
CODEN: NLETDU; ISSN: 0172-780X

PUBLISHER: Society of Integrated Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 24 Sep 2004

AB PURPOSE: A case control study was conducted to assess the effect of Sabril  
(Vigabatrin), Lamictal (Lamotrigine) and Neurontin (Gabapentin) on  
fertility in male rats. Their effect on the body and organs weight and  
certain biochem. profiles including total serum protein, cholesterol,  
triglycerides, serum glutamic oxaloacetic transaminase (SCOT), serum  
glutamic pyruvic transaminase (SGPT), serum testosterone, and FSH levels  
were also measured. METHODS: several parameters, concerning fertility  
were measured in 40 albino male rats of Sprague Dawley strain, they were  
divided into 4 groups, group one received vehicle (distilled water), group  
two received Vigabatrin in a dose of 200 mg/kg body weight, group three  
received Lamotrigine in a dose of 30 mg/kg body weight, and group four  
received Gabapentin 100 mg/kg body weight All the male rats in these groups  
received the different medications for a complete reproductive cycle (60  
days). After 24 h of the last dose, the animals were weighed and  
autopsied under light ether anesthesia. Parameter of fertility that has  
been measured in this study includes: sperm count and motility, weight of  
different reproductive organs, germ cell and interstitial cell population,  
serum testosterone and FSH levels and assessment of pregnancies in females  
mixed with tested males. Biochem. profiles such as serum cholesterol,  
serum triglycerides, serum bilirubin, SCOT, SGPT level are all measured.  
The results of the histol., histometrical studies and biochem. profiles  
were compared to that of the control group, and the significance of these  
results was measured using student's "t" test. RESULTS,: There was  
significant reduction in the body weight and the weight of the testes,  
epididymis,  
seminal vesicles, ventral prostate, and vas deferens in the antiepileptic

fed male rats in comparison to the control group ( $p>0.001$ ). There was significant reduction in testicular cells population dynamics including both germinal cell types and interstitial cell types in the antiepileptic fed male rats in comparison to the control group. There was also significant reduction in histometrical parameters and sperm dynamics in the antiepileptic fed male rats histologies in comparison to the control group. There was significant reduction in both testosterone and FSH levels ( $p<0.001$ ) in the antiepileptics fed male rats in comparison to the control group. There was also significant reduction in pregnancy rate observed in female rats exposed

to the tested male rats among antiepileptic fed male rats compared to controls. The results of biochem. profiles assessment showed significant reduction in serum glucose, serum cholesterol, serum triglycerides levels and significant increase in serum bilirubin, SCOT, and SGPT levels in antiepileptics fed male rats in comparison to the control group.

CONCLUSIONS: Fertility rate and other parameters concerned with fertility, sex hormones and certain biochem. profiles were significantly disturbed in male rats fed with three of the second-generation antiepileptic drugs Vigabatrin, Lamotrigine, and Gabapentin, indicating a possible toxic effect of these three medications on sexual organs, liver, and lipid metabolism

CC 1-11 (Pharmacology)

ST vigabatrin lamotrigine gabapentin antiepileptic fertility body  
wt sex hormone

IT Anticonvulsants

(AEDs vigabatrin, lamotrigine, gabapentin decreased organ, body weight, fertility rate, fertility parameters, sex hormones, certain biochem. profiles, suggesting possible toxicity on sexual organs, liver, lipid metabolism in male rat)

IT 84057-84-1, Lamictal

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(AED lamotrigine significantly decreased organ, body weight, fertility rate and other fertility parameters, sex hormones, certain biochem. profiles, suggesting possible toxic effect on sexual organs, liver, lipid metabolism in male rat)

IT 50-99-7, D-Glucose, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(blood; vigabatrin, lamotrigine, gabapentin treatment showed significant reduction in serum glucose levels in male rat)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:971868 CAPLUS

DOCUMENT NUMBER: 140:19871

TITLE: Delayed release drug delivery systems containing polymers and method for preparation by mixing and compacting

INVENTOR(S): Hanshermann, Franke; Lennartz, Peter; Raimer, Joern

PATENT ASSIGNEE(S): Desitin Arzneimittel GmbH, Germany

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2003101428	A1	20031211	WO 2003-EP5115	20030515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10224170	A1	20031211	DE 2002-10224170	20020531
CA 2485080	AA	20031211	CA 2003-2485080	20030515
AU 2003236658	A1	20031219	AU 2003-236658	20030515
BR 2003011512	A	20050222	BR 2003-11512	20030515
EP 1509205	A1	20050302	EP 2003-735396	20030515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005528428	T2	20050922	JP 2004-508786	20030515
NO 2004005386	A	20041209	NO 2004-5386	20041209
US 2005202088	A1	20050915	US 2005-516268	20050527
PRIORITY APPLN. INFO.:			DE 2002-10224170	A 20020531
			WO 2003-EP5115	W 20030515

ED Entered STN: 14 Dec 2003

AB The invention relates to a pharmaceutical composition, which has a delayed active substance release and can be obtained by means of a special compacting method for which organic solvents and water are not required. Said pharmaceutical composition preferably exists in the form of individual active substance compartments or breaks down into compartments of this type when brought into contact with aqueous media. Various types of drugs can be formulated with acrylic copolymers. Thus 30 kg of oxcarbazepine and 9 kg of Eudragit RSPO were mixed in a quick mixer (Diosna P 100); the mixture was compacted using a Gerteis 3 W-Polygran roller compactor applying 15-40 kN/cm at 80°C. The product was disintegrated by forced sieving and classified through a mesh. The particles were encapsulated in hard gel capsules.

IC ICM A61K009-14

CC 63-6 (Pharmaceuticals)

IT Analgesics

Antiarrhythmics

Anticonvulsants

Antidepressants

Antimigraine agents

Antiparkinsonian agents

Antipsychotics

Antirheumatic agents

Cholinergic antagonists

Cognition enhancers

Compaction

Dopamine antagonists

Hypnotics and Sedatives

Mixing

Pressure

Temperature

Tranquilizers

(delayed release drug delivery systems containing polymers and method for preparation by mixing and compacting)

IT 61-56-3, Sultiam 79-10-7D, Acrylic acid, esters, polymers 99-66-1,  
Valproic acid 298-46-4, Carbamazepin 84057-84-1, Lamotrigine  
102767-28-2, Levetiracetam

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (delayed release drug delivery systems containing polymers and method for  
 preparation by mixing and compacting)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:875073 CAPLUS

DOCUMENT NUMBER: 139:354488

TITLE: Pharmaceutical composition containing lamotrigine  
 particles of defined morphology

INVENTOR(S): Aronhime, Judith; Samburski, Guy

PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva  
 Pharmaceuticals USA, Inc.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090693	A2	20031106	WO 2003-US13002	20030423
WO 2003090693	A3	20040108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483103	AA	20031106	CA 2003-2483103	20030423
AU 2003234240	A1	20031110	AU 2003-234240	20030423
EP 1496864	A2	20050119	EP 2003-728552	20030423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005238724	A1	20051027	US 2004-511987	20041021
PRIORITY APPLN. INFO.:			US 2002-374923P	P 20020423
			WO 2003-US13002	W 20030423

ED Entered STN: 07 Nov 2003

AB The present invention provides a pharmaceutical composition comprising a plurality of lamotrigine particles having a sp. surface area of from about two to about three and a half meters per g. Pharmaceutical compns. falling within the surface area criteria for the lamotrigine particles include those having a particle diameter equal to or less than about 100 µm, preferably about 50 µm, and most preferably 10 µm. The pharmaceutical composition can be formulated into a wide variety of dosage forms for treatment of seizures.

IC ICM-A61K

CC 63-6 (Pharmaceuticals)

ST lamotrigine particle morphol seizure  
 treatment

IT Phenols, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (1,6-dialkyl; pharmaceutical composition containing lamotrigine

← Application

particles of defined morphol. and excipients  
)  
IT Alcohols, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(C16-18; pharmaceutical composition containing lamotrigine particles  
of defined morphol. and excipients)  
IT Quaternary ammonium compounds, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(alkylbenzylidemethyl, chlorides; pharmaceutical composition containing  
lamotrigine particles of defined morphol. and  
excipients)  
IT Drug delivery systems  
(liqs., oral; pharmaceutical composition containing lamotrigine  
particles of defined morphol. and excipients  
)  
IT Drug delivery systems  
(particles; pharmaceutical composition containing lamotrigine  
particles of defined morphol. and excipients  
)  
IT Acacia  
Anticonvulsants  
Chondrules  
Egg yolk  
Human  
Seizures  
(pharmaceutical composition containing lamotrigine particles of  
defined morphol. and excipients)  
IT Alcohols, biological studies  
Bentonite, biological studies  
Carbohydrates, biological studies  
Caseins, biological studies  
Gelatins, biological studies  
Kaolin, biological studies  
Polyoxyalkylenes, biological studies  
Tocopherols  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical composition containing lamotrigine particles of  
defined morphol. and excipients)  
IT Drug delivery systems  
(solids, oral; pharmaceutical composition containing lamotrigine  
particles of defined morphol. and excipients  
)  
IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable, hydrogenated; pharmaceutical composition containing lamotrigine  
particles of defined morphol. and excipients  
)  
IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable; pharmaceutical composition containing lamotrigine particles  
of defined morphol. and excipients)  
IT 9003-01-4D, crosslinked  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Carbomer; pharmaceutical composition containing lamotrigine particles  
of defined morphol. and excipients)  
IT 9003-39-8D, crosslinked  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Crosppovidone; pharmaceutical composition containing lamotrigine  
particles of defined morphol. and excipients  
)

IT 99-96-7D, alkyl esters  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Parabens; pharmaceutical composition containing lamotrigine particles  
 of defined morphol. and excipients)

IT 7631-86-9, Colloidal silicon dioxide, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (colloidal; pharmaceutical composition containing lamotrigine particles  
 of defined morphol. and excipients)

IT 9004-34-6, Cellulose, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; pharmaceutical composition containing lamotrigine  
 particles of defined morphol. and excipients  
 )

IT 50-21-5, Lactic acid, biological studies 50-70-4, Sorbitol, biological  
 studies 50-99-7, Dextrose, biological studies  
 56-81-5, Glycerin, biological studies 57-15-8, Chlorobutanol 57-48-7,  
 Fructose, biological studies 57-50-1, Sucrose, biological studies  
 57-55-6, Propylene glycol, biological studies 57-88-5, Cholesterol,  
 biological studies 60-00-4, Ethylenediamine tetraacetic acid, biological  
 studies 60-12-8, Phenethyl alcohol 63-42-3, Lactose 64-17-5, Ethyl  
 alcohol, biological studies 64-19-7, Acetic acid, biological studies  
 69-65-8, Mannitol 72-17-3, Sodium lactate 77-92-9, Citric acid,  
 biological studies 79-41-4D, Methacrylic acid, polymers 81-07-2,  
 Saccharin 87-69-4, biological studies 100-51-6, Benzyl alcohol,  
 biological studies 108-32-7, Propylene carbonate 121-54-0,  
 Benzethonium chloride 127-09-3, Sodium acetate 128-37-0, Butylated  
 hydroxy toluene, biological studies 128-44-9, Sodium saccharin  
 471-34-1, Calcium carbonate, biological studies 526-95-4, Gluconic acid  
 527-07-1, Sodium gluconate 532-32-1, Sodium benzoate 546-93-0,  
 Magnesium carbonate 994-36-5, Sodium citrate 1309-48-4, Magnesium  
 oxide, biological studies 1327-43-1, Magnesium aluminum silicate  
 7447-40-7, Potassium chloride, biological studies 7631-90-5, Sodium  
 bisulfite 7647-14-5, Sodium chloride, biological studies 7681-57-4,  
 Sodium metabisulfite 7758-87-4, Tribasic calcium phosphate 7778-18-9,  
 Calcium sulfate 7789-77-7, Dibasic calcium phosphate dihydrate  
 8013-17-0, Invert sugar 8027-56-3, Liquid glucose 9000-30-0, Guar gum  
 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-89-5, Polyvinyl alcohol  
 9003-39-8, Povidone 9004-32-4, Carboxymethylcellulose sodium  
 9004-53-9, Dextrin 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl  
 cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl  
 methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch,  
 biological studies 9005-32-7, Alginic acid 9005-37-2, Propylene glycol  
 alginate 9005-38-3, Sodium alginate 9050-04-8 9050-36-6,  
 Maltodextrin 9063-38-1, Sodium starch glycolate 11138-66-2, Xanthan  
 gum 14807-96-6, Talc, biological studies 22839-47-0, Aspartame  
 25013-16-5, Butylated hydroxyanisole 25322-68-3, Polyethylene glycol  
 36653-82-4, Cetyl alcohol 39404-33-6, Dextrates 54182-62-6D,  
 Polacrilin, potassium form 74811-65-7, Croscarmellose sodium  
 84057-84-1, Lamotrigine  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical composition containing lamotrigine particles of  
 defined morphol. and excipients)

L31 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:757508 CAPLUS  
 DOCUMENT NUMBER: 139:255389  
 TITLE: Norepinephrine- and serotonin-reuptake inhibitors for  
 treating visceral pain syndromes  
 INVENTOR(S): Rao, Srinivas G.; Kranzler, Jay D.  
 PATENT ASSIGNEE(S): Cypress Bioscience, Inc., USA

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077897	A1	20030925	WO 2003-US8155	20030317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479350	AA	20030925	CA 2003-2479350	20030317
AU 2003225837	A1	20030929	AU 2003-225837	20030317
US 2003203055	A1	20031030	US 2003-391110	20030317
EP 1485078	A1	20041215	EP 2003-744697	20030317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005526079	T2	20050902	JP 2003-575950	20030317
NO 2004004345	A	20041203	NO 2004-4345	20041013
PRIORITY APPLN. INFO.:			US 2002-364531P	P 20020315
			WO 2003-US8155	W 20030317

OTHER SOURCE(S): MARPAT 139:255389

ED Entered STN: 26 Sep 2003

AB The invention provides a method for treating a visceral pain syndrome in a mammal. The method includes administering an effective amount of a selective norepinephrine (NE)-serotonin (5-HT) reuptake inhibitor (NSRI), e.g., milnacipran.

IC ICM A61K031-165

ICS A61K031-00; A61P025-00

CC 1-11 (Pharmacology)

IT 5-HT reuptake inhibitors

Analgesics

Anti-inflammatory agents

Anti-ischemic agents

Anticonvulsants

Antidepressants

Antidiarrheals

Antiuclcer agents

Appetite depressants

Calcium channel blockers

Cholinergic antagonists

Diarrhea

Drug delivery systems

Gastrointestinal agents

Hypnotics and Sedatives

Ischemia

Laxatives

Nervous system stimulants

(norepinephrine-serotonin reuptake inhibitors for treating visceral pain syndromes, and use with other agents)

IT 50-99-7, D-Glucose, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(glucose-electrolyte solution; norepinephrine-serotonin reuptake inhibitors for treating visceral pain syndromes, and use with other agents)

IT 50-06-6, Phenobarbital, biological studies 51-55-8, , Atropine, biological studies 55-63-0, Nitroglycerin 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 59-66-5, Acetazolamide 59-92-7, biological studies 63-42-3, , Lactose 67-52-7D, 2,4,6(1H,3H,5H)-Pyrimidinetrione, derivs. 69-72-7D, Salicylic acid, salicylates, biological studies 76-57-3, Codeine 77-09-8, Phenolphthalein 77-19-0, Dicyclomine 77-67-8, Ethosuximide 79-09-4, Propionic acid, biological studies 91-20-3D, Naphthalene, naphthylalkanones 91-40-7D, Fenamic acid, fenamates 99-66-1 101-31-5, Hyoscymine 120-72-9D, Indole, derivs. 123-30-8D, p-Aminophenol, derivs. 125-33-7, , Primidone 137-58-6, Lidocaine 288-13-1D, Pyrazole, derivs. 298-46-4, Carbamazepine 300-62-9, Amphetamine 439-14-5, Valium 1622-61-3, , Clonazepam 8029-99-0, Paregoric 8063-16-9, , Psyllium 12794-10-4, Benzodiazepine 19794-93-5, Trazodone 27203-92-5, Tramadol 43200-80-2, Zopiclone 51322-75-9, Tizanidine 53179-11-6, Loperamide 60142-96-3, , Gabapentin 68693-11-8, Modafinil 82626-48-0, Zolpidem 83150-76-9, , Octreotide 84057-84-1, Lamotrigine 89565-68-4, Tropisetron 92623-85-3, Milnacipran 93390-81-9, Fosphenytoin 97240-79-4, Topiramate 104632-26-0, , Pramipexole 106650-56-0, Sibutramine 122852-42-0, , Alosetron 145158-71-0, Tegaserod 148553-50-8, Pregabalin 216382-88-6, Imidazopyridine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(norepinephrine-serotonin reuptake inhibitors for treating visceral pain syndromes, and use with other agents)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2003:584855 CAPLUS  
DOCUMENT NUMBER: 140:104464  
TITLE: Pharmacokinetic drug interactions in children taking oxcarbazepine  
AUTHOR(S): Sallas, William M.; Milosavljev, Slavica; D'Souza, Joseph; Hossain, Mohammad  
CORPORATE SOURCE: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA  
SOURCE: Clinical Pharmacology & Therapeutics (St. Louis, MO, United States) (2003), 74(2), 138-149  
CODEN: CLPTAT; ISSN: 0009-9236  
PUBLISHER: Mosby, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
ED Entered STN: 30 Jul 2003  
AB Our objective was to evaluate the drug-drug interactions of oxcarbazepine with coadministered antiepileptic drugs in children. In a clin. trial, pediatric patients receiving an oxcarbazepine dose titrated to 30 to 46 mg · kg<sup>-1</sup> · d<sup>-1</sup> given twice daily had 1 to 4 blood samples collected per patient for population pharmacokinetic anal. of oxcarbazepine's major bioactive 10-monohydroxy metabolite. With the use of NONMEM, 7 concomitant antiepileptic drugs and 12 addnl. covariates were examined for their effects on the pharmacokinetics of 10-monohydroxy metabolite. In addition, for each concomitant antiepileptic drug, the ratio of its mean concentration with coadministration of oxcarbazepine to that without

coadministration at baseline was calculated to evaluate the effect of oxcarbazepine on the coadministered antiepileptic drugs. The population pharmacokinetic data for 10-monohydroxy metabolite consisted of a total of 376 observations from 109 patients, aged 3 to 17 yr. Body surface area and 3 antiepileptic drugs (carbamazepine, phenobarbital, and phenytoin) were significant predictors of the apparent clearance of 10-monohydroxy metabolite, whereas height was a significant predictor of apparent volume. Weight-normalized clearance of 10-monohydroxy metabolite was higher in young children than in older children and adults. Carbamazepine, phenobarbital, or phenytoin administered with oxcarbazepine increased the apparent clearance of 10-monohydroxy metabolite by 31% to 35%, whereas carbamazepine levels decreased by 15% and phenobarbital levels increased by 14%. Oxcarbazepine has a low propensity to inhibit or induce oxidative enzymes. Young children could be given higher milligrams-per-kilogram oxcarbazepine doses than older children and adults to achieve the same mean steady-state concentration of 10-monohydroxy metabolite.

The adjustment is based simply on body size.

CC 1-4 (Pharmacology)

ST oxcarbazepine antiepileptic pharmacokinetic interaction  
seizure child body size

IT Anticonvulsants

Human

**Seizures**

(pharmacokinetic drug interactions in children taking oxcarbazepine)

IT 50-06-6, Phenobarbital, biological studies 57-41-0, Phenytoin 99-66-1  
298-46-4, Carbamazepine 28721-07-5, Oxcarbazepine 60142-96-3,  
Gabapentin 84057-84-1, Lamotrigine  
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological  
study); USES (Uses)

(pharmacokinetic drug interactions in children taking oxcarbazepine)

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:319348 CAPLUS

DOCUMENT NUMBER: 138:331688

TITLE: Methods of suppressing microglial activation and  
systemic inflammatory responses

INVENTOR(S): Laskowitz, Daniel T.; Matthew, William D.; McMillian,  
Michael

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 48 pp., Cont.-in-part of U.S.  
Ser. No. 957,909.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003077641	A1	20030424	US 2002-252120	20020923
US 2002164789	A1	20021107	US 2001-957909	20010921
PRIORITY APPLN. INFO.:			US 1998-77551P	P 19980311
			US 1999-260430	B2 19990301
			US 2001-957909	A2 20010921

ED Entered STN: 25 Apr 2003

AB Methods of suppressing the activation of microglial cells in the Central  
Nervous System (CNS), methods of ameliorating or treating the neurol.

effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. ApoE receptor binding peptides that may be used in the methods of the invention are also described, as are methods of using such peptides to treat peripheral inflammatory conditions such as sepsis. Also described are methods of screening compds. for the ability to suppress or reduce microglial activation. Injection of ApoE (133-149) in mice suppressed serum levels of TNF $\alpha$  and IL-6 following LPS administration.

IC ICM A61K038-17  
ICS A61K038-10; C12Q001-68; A61K038-00; C12N007-00; C12N007-01;  
C12N005-00; C12N005-02; A61K039-12  
INCL 435006000; 514013000; 435235100; 435325000; 424186100  
CC 1-7 (Pharmacology)  
IT Anti-Alzheimer's agents  
    Anticonvulsants  
    Antioxidants  
    Antiparkinsonian agents  
    Brain, disease  
    Central nervous system  
    Dopamine antagonists  
    Drug delivery systems  
    Drug screening  
    Glutamate antagonists  
    Human  
    Mammalia  
        (ApoE receptor binding peptides suppressing microglial activation and systemic inflammatory responses)  
IT Drug delivery systems  
    (carriers, across blood-brain barrier, conjugates; ApoE receptor binding peptides suppressing microglial activation and systemic inflammatory responses)  
IT Alzheimer's disease  
Atherosclerosis  
Encephalitis  
    Epilepsy  
Multiple sclerosis  
Parkinson's disease  
Schizophrenia  
Sepsis  
    (treatment of; ApoE receptor binding peptides suppressing microglial activation and systemic inflammatory responses)  
IT 57-41-0, Phenytoin 77-67-8, Ethosuximide 99-66-1, Valproic acid 298-46-4, Carbamazepine 4368-28-9, Tetrodotoxin 25451-15-4, Felbamate 60142-96-3, Gabapentin 84057-84-1, Lamotrigine  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
    (anticonvulsant; ApoE receptor binding peptides suppressing microglial activation and systemic inflammatory responses)

L31 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2003:154224 CAPLUS  
DOCUMENT NUMBER: 138:193294  
TITLE: Expandable gastric retention device containing pharmaceutical compositions  
INVENTOR(S): Ayres, James W.  
PATENT ASSIGNEE(S): The State of Oregon Acting by and Through the State Board of Higher Education On Behalf of Oregon State University, USA

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015745	A1	20030227	WO 2001-US46146	20011022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2456976	AA	20030227	CA 2001-2456976	20011022
EP 1416914	A1	20040512	EP 2001-995328	20011022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001017123	A	20040928	BR 2001-17123	20011022
CN 1543337	A	20041103	CN 2001-823544	20011022
JP 2005501097	T2	20050113	JP 2003-520705	20011022
NO 200400611	A	20040416	NO 2004-611	20040211
US 2004219186	A1	20041104	US 2004-778917	20040213
ZA 2004002066	A	20050509	ZA 2004-2066	20040315
PRIORITY APPLN. INFO.:			US 2001-313078P	P 20010816
			WO 2001-US46146	W 20011022

ED Entered STN: 28 Feb 2003

AB The present application concerns gastric retention devices formed from compns. comprising polymeric materials, such as polysaccharides, and optional addnl. materials including excipients, therapeutics, and diagnostics, that reside in the stomach for a controlled and prolonged period of time. Dry powders of xanthan gum and locust bean gum were mixed intimately were converted to dried films. The dried films were compressed with the help of specially made punches and dies. A series of dies with decreasingly narrow internal diams. were used. A punch pushes the film from one die into the next die, followed by pushing of the film by another punch into the next die. This process takes place in succession until a point is reached where the film is small enough to put into a desired capsule size.

IC ICM A61K009-00

ICS A61K009-20; A61K047-36

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

IT Adrenoceptor agonists

Adrenoceptor antagonists

Analgesics

Anesthetics

Antacids

Anti-AIDS agents

Anti-Alzheimer's agents

Anti-infective agents

Antiarrhythmics

Antibiotics

Anticonvulsants

Antidepressants

Antidiabetic agents  
Antidotes  
Antiemetics  
Antihistamines  
Antihypertensives  
Antimicrobial agents  
Antimigraine agents  
Antiobesity agents  
Antiparkinsonian agents  
Antipsychotics  
Antirheumatic agents  
Antitumor agents  
Appetite depressants  
Appetite stimulants  
Cardiovascular agents  
Cholinergic agonists  
Cholinergic antagonists  
Contraceptives  
Cystic fibrosis  
Deodorants (personal)  
Dietary supplements  
Digestive tract  
Dissolution  
Diuretics  
Dizziness  
Dopamine agonists  
Drug bioavailability  
Fungicides  
Gastric juice  
Human  
Hypnotics and Sedatives  
Imaging agents  
Immunomodulators  
Immunosuppressants  
Intestinal juice  
Ion exchangers  
Medical goods  
Muscle relaxants  
Nervous system stimulants  
Plasticizers  
Psychotropics  
Stomach  
Urinary system  
Vagina  
Vasodilators  
Wilson's disease  
(expandable gastric retention device containing pharmaceutical compns.)  
IT 50-44-2, Mercaptopurine 50-53-3, Chlorpromazine, biological studies  
51-63-8, Dextroamphetamine sulfate 52-01-7, Spironolactone 54-31-9,  
Furosemide 58-14-0, Pyrimethamine 58-38-8, Prochlorperazine 59-66-5,  
Acetazolamide 63-89-8, Colfosceril palmitate 71-27-2, Succinylcholine  
chloride 89-57-6, Mesalazine 148-82-3, Melphalan 154-42-7,  
Thioguanine 305-03-3, Chlorambucil 315-30-0, Allopurinol 396-01-0,  
Triamterene 440-17-5, Trifluoperazine hydrochloride 554-13-2, Lithium  
carbonate 637-32-1, Proguanil hydrochloride 813-93-4, Bismuth citrate  
1508-76-5, Procyclidine hydrochloride 2152-44-5, Betamethasone valerate  
5534-09-8, Beclomethasone dipropionate 8064-90-2, Co-trimoxazole  
9000-40-2, Locust bean gum 9004-65-3, HPMC 11138-66-2, Xanthan gum  
12650-69-0, Mupirocin 13492-01-8, Tranylcypromine sulfate 18559-94-9,  
Albuterol 20830-75-5, Digoxin 25122-46-7, Clobetasol propionate

25953-19-9, Cefazolin 26787-78-0, Amoxicillin 29457-07-6, Ticarcillin disodium 30516-87-1, Zidovudine 31677-93-7, Bupropion hydrochloride 35121-78-9, Epoprostenol 42924-53-8, Nabumetone 51481-61-9, Cimetidine 54965-21-8, Albendazole 55268-75-2, Cefuroxime 59277-89-3, Acyclovir 61177-45-5, Clavulanate potassium 61336-70-7, Amoxicillin trihydrate 64211-46-7, Oxiconazole nitrate 64228-81-5, Atracurium besylate 66357-35-5, Ranitidine 66357-59-3, Ranitidine hydrochloride 70059-30-2, Cimetidine hydrochloride 71486-22-1, Vinorelbine 72558-82-8, Ceftazidime 72956-09-3, Carvedilol 73590-58-6, Omeprazole 76095-16-4, Enalapril maleate 78246-49-8, Paroxetine hydrochloride 79902-63-9, Simvastatin 80474-14-2, Fluticasone propionate 84057-84-1, Lamotrigine 89365-50-4, Salmeterol 91374-20-8, Ropinirole hydrochloride 94749-08-3, Salmeterol xinafoate 95233-18-4, Atovaquone 96946-42-8, Cisatracurium besylate 99614-01-4, Ondansetron hydrochloride 103628-46-2, Sumatriptan 119413-54-6, Topotecan hydrochloride 121679-13-8, Naratriptan 124750-99-8, Losartan potassium 124832-27-5, Valacyclovir hydrochloride 134678-17-4, Lamivudine 139110-80-8, Zanamivir 142373-60-2, Tirofiban hydrochloride 155141-29-0, Rosiglitazone maleate 161814-49-9, Amprenavir 161973-10-0, Esomeprazole magnesium 162011-90-7, Rofecoxib 179463-17-3, Caspofungin acetate 188062-50-2, Abacavir sulfate  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(expandable gastric retention device containing pharmaceutical compns.)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:133030 CAPLUS  
 DOCUMENT NUMBER: 138:163577  
 TITLE: Improving neurological functions  
 INVENTOR(S): Chez, Michael G.  
 PATENT ASSIGNEE(S): Carn-Aware LLC, USA  
 SOURCE: PCT Int. Appl., 74 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013514	A1	20030220	WO 2002-US22341	20020715
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2006052428	A1	20060309	US 2005-486077	20050210
PRIORITY APPLN. INFO.:			US 2001-310710P	P 20010808
			US 2001-325136P	P 20010927
			WO 2002-US22341	W 20020715

OTHER SOURCE(S): MARPAT 138:163577

ED Entered STN: 21 Feb 2003

AB The present invention relates to materials and methods for treating neurol. diseases and disorders including but not limited to epilepsy and

autism, as well as general cognitive problems. Preferred compds. include carnosine and homocarnosine and N-acetyl, methylated (anserine, ophididine), decarboxylated (carcinine) and tauryl derivs. of carnosine and homocarnosine.

IC ICM A61K031-415  
ICS A61P025-00  
CC 1-11 (Pharmacology)  
IT Alzheimer's disease  
Anti-Alzheimer's agents  
    **Anticonvulsants**  
    Antidepressants  
    Cognition enhancers  
    Cognitive disorders  
    Down's syndrome  
    Drug delivery systems  
    Drug interactions  
    **Epilepsy**  
    Human  
    Nervous system, disease  
    Nervous system agents  
    Psychostimulants  
        (agents for improving neurol. functions such as carnosine derivs. and combination with other agents)  
IT Drug delivery systems  
    (carriers; agents for improving neurol. functions such as carnosine derivs. and combination with other agents)  
IT Drug delivery systems  
    (excipients; agents for improving neurol. functions such as carnosine derivs. and combination with other agents)  
IT 50-06-6, Phenobarbital, biological studies 50-12-4, Mephenytoin  
56-12-2, GABA, biological studies 57-41-0, Phenytoin 59-66-5,  
Acetazolamide 77-67-8, Ethosuximide 86-35-1, Ethotoin 99-66-1,  
Valproic Acid 115-38-8, Mephobarbital 125-33-7, Primidone 127-48-0,  
Trimethadione 298-46-4, Carbamazepine 439-14-5, Diazepam 846-49-1,  
Lorazepam 1622-61-3, Clonazepam 23887-31-2, Clorazepate 25451-15-4,  
Felbamate 28721-07-5, Oxcarbazepine 60142-96-3, Gabapentin  
68506-86-5, Vigabatrin 84057-84-1, Lamotrigine 97240-79-4,  
Topiramate 102767-28-2, Levetiracetam 115103-54-3, Tiagabine  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
    (anticonvulsant; agents for improving neurol. functions such as carnosine derivs. and combination with other agents)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2003:28550 CAPLUS  
DOCUMENT NUMBER: 139:17479  
TITLE: Neuroprotective effects of **anticonvulsants**  
in rat hippocampal slice cultures exposed to  
oxygen/glucose deprivation  
AUTHOR(S): Rekling, Jens C.  
CORPORATE SOURCE: Department 828, Biological Research, H. Lundbeck A/S,  
Valby, DK-2500, Den.  
SOURCE: Neuroscience Letters (2003), 335(3), 167-170  
CODEN: NELED5; ISSN: 0304-3940  
PUBLISHER: Elsevier Science Ireland Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
ED Entered STN: 13 Jan 2003

AB Some anticonvulsants show neuroprotective effects, and may be of use in reducing neuronal death resulting from stroke or traumatic brain injury. Here I report that a broad range of anticonvulsants protect cells in hippocampal slice cultures from death induced by oxygen/glucose deprivation (OGD). Hippocampal slice cultures were submitted to 1 h OGD and the resulting cell death was quantified 24 h later using a novel automated fluorescent scanning method. The classical anticonvulsants phenobarbital, phenytoin, ethosuximide, chlordiazepoxide and midazolam all significantly and dose-dependently reduced cell death induced by OGD. The newer anticonvulsants carbamazepine, felbamate, lamotrigine, tiagabine, and oxcarbazepine also had significant neuroprotective effects, but gabapentin, valproic acid (10 mM), levetiracetam and retigabine were not neuroprotective at a concentration up to 300  $\mu$ M. In conclusion, several classical and newer anticonvulsants have neuroprotective properties in an in vitro model that simulates cerebral ischemia.

CC 1-11 (Pharmacology)

Section cross-reference(s) : 14

ST neuroprotectant anticonvulsant hippocampus oxygen glucose

IT Ischemia  
(cerebral; neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation)

IT Nerve, disease  
(death; neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation)

IT Brain  
(hippocampus; neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation)

IT Brain, disease  
(ischemia; neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation)

IT Cell death  
(neuron; neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation)

IT Anti-ischemic agents  
**Anticonvulsants**  
Disease models  
(neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation)

IT Cytoprotective agents  
(neuroprotective; neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation)

IT Brain, disease  
(trauma; neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation)

IT 7782-44-7, Oxygen, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation)

IT 50-06-6, Phenobarbital, biological studies 57-41-0, Phenytoin 58-25-3, Chlordiazepoxide 77-67-8, Ethosuximide 99-66-1, Valproic acid 298-46-4, Carbamazepine 25451-15-4, Felbamate 28721-07-5, Oxcarbazepine 59467-70-8, Midazolam 60142-96-3, Gabapentin 84057-84-1, Lamotrigine 102767-28-2, Levetiracetam 115103-54-3, Tiagabine 150812-12-7, Retigabine  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation)

IT 50-99-7, D-Glucose, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (transport; neuroprotective effects of anticonvulsants in rat  
 hippocampal slice cultures exposed to oxygen/glucose deprivation)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:676002 CAPLUS  
 DOCUMENT NUMBER: 137:222039  
 TITLE: New crystal forms of lamotrigine and processes for their preparations  
 INVENTOR(S): Garti, Nissim; Berkovich, Yana; Dolitzky, Ben-Zion;  
 Aronhime, Judith; Singer, Claude; Lieberman, Anita;  
 Gershon, Neomi  
 PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.  
 SOURCE: PCT Int. Appl., 65 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068398	A1	20020906	WO 2002-US6160	20020227
WO 2002068398	C2	20021121		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2439468	AA	20020906	CA 2002-2439468	20020227
US 2003018030	A1	20030123	US 2002-86157	20020227
US 6861426	B2	20050301		
EP 1390355	A2	20040225	EP 2002-706471	20020227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004526714	T2	20040902	JP 2002-567912	20020227
US 2005171107	A1	20050804	US 2005-45355	20050131
PRIORITY APPLN. INFO.:			US 2001-271688P	P 20010227
			US 2002-86157	A1 20020227
			WO 2002-US6160	W 20020227

ED Entered STN: 08 Sep 2002  
 AB The present invention relates to lamotrigine, a useful agent for anti-epilepsia. New crystal forms of lamotrigine-containing mols. of the solvent in stoichiometric ratios are disclosed. Processes for preparing the new crystal forms of lamotrigine and dosage forms are also provided. For example, 2 g of lamotrigine anhydrous and about 80 mL of ethanol were charged in a three-necked bottomed round flask equipped with a mech. stirrer, a condenser and a thermometer. The suspension was stirred for about 24 h without heating at about 25° and the solid phase was separated by filtration, producing lamotrigine Form H, i.e., lamotrigine ethanol monosolvate.  
 IC ICM C07D253-075.

CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1, 75  
 ST lamotrigine crystal form prepn hydrate solvate antiepileptic  
 IT Anticonvulsants  
 Crystal morphology  
 Drug delivery systems  
 Polymorphism (crystal)  
 (preparation of crystal forms of lamotrigine as antiepileptic)  
 IT 67-66-3, Chloroform, uses 108-88-3, Toluene, uses  
 RL: NUU (Other use, unclassified); USES (Uses)  
 (precipitation by; preparation of crystal forms of lamotrigine as antiepileptic)  
 IT 375347-20-9, Lamotrigine hydrate 454695-00-2  
 RL: CPS (Chemical process); FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process); USES (Uses)  
 (preparation of crystal forms of lamotrigine as antiepileptic)  
 IT 64-17-5, Ethanol, processes 67-56-1, Methanol, processes 67-63-0, Isopropanol, processes 67-64-1, Acetone, processes 68-12-2, Dimethylformamide, processes 108-10-1, Methyl isobutyl ketone 1634-04-4, Methyl tert-butyl ether  
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PROC (Process)  
 (preparation of crystal forms of lamotrigine as antiepileptic)  
 IT 84057-84-1, Lamotrigine  
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (preparation of crystal forms of lamotrigine as antiepileptic)  
 IT 454695-02-4 454695-03-5 454695-04-6  
 454695-05-7 454695-06-8 454695-07-9  
 454695-08-0 454695-09-1 454695-10-4  
 454695-11-5 454695-12-6 454695-13-7  
 454695-15-9  
 RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)  
 (preparation of crystal forms of lamotrigine as antiepileptic)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2001:396644 CAPLUS  
 DOCUMENT NUMBER: 135:24671  
 TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions  
 INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing  
 PATENT ASSIGNEE(S): Lipocine, Inc., USA  
 SOURCE: PCT Int. Appl., 107 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 13  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
 ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6248363 B1 20010619 US 1999-447690 19991123

CA 2391923 AA 20010531 CA 2000-2391923 20001122

EP 1233756 A1 20020828 EP 2000-980761 20001122

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003517470 T2 20030527 JP 2001-539423 20001122

PRIORITY APPLN. INFO.: US 1999-447690 A 19991123  
 WO 2000-US32255 W 20001122

ED Entered STN: 01 Jun 2001

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A composition contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IC ICM A61K009-14

ICS A61K009-16; A61K009-20; A61K009-46; A61K009-48; A61K009-50;  
 A61K009-54

CC 63-6 (Pharmaceuticals)

IT Drug delivery systems

(capsules; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Drug delivery systems

(controlled-release; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Polyoxyalkylenes, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (esters; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Glycerides, biological studies

Sterols

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (ethoxylated; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Mucopolysaccharides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (heparinoids; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Drug delivery systems

(implants; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Sexual behavior

(impotence; solid carriers for improved delivery of active

ingredients in pharmaceutical compns.)

IT Drug delivery systems  
(lozenges; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Drug delivery systems  
(microspheres; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Drug delivery systems  
(nanocapsules; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Drug delivery systems  
(oral; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Antioxidants  
(pharmaceutical; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Analgesics  
Anti-inflammatory agents  
Anticoagulants  
    Anticonvulsants  
    Antidepressants  
    Antidiabetic agents  
    Antihistamines  
    Antihypertensives  
    Antimalarials  
    Antipsychotics  
    Antitumor agents  
    Anxiolytics  
    Fungicides  
    Hypnotics and Sedatives  
    Immunosuppressants  
    Muscarinic antagonists  
    Muscle relaxants  
    Plasticizers  
    Protozoacides  
    Sweetening agents  
    Tranquilizers  
    Vaccines  
        (solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Enkephalins  
Fatty acids, biological studies  
Growth factors, animal  
Interferons  
Interleukins  
Macrolides  
Nucleic acids  
Nucleotides, biological studies  
Opioids  
Peptides, biological studies  
Platelet-derived growth factors  
Tocopherols  
Toxoids  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Drug delivery systems  
(solids; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Drug delivery systems

(syrups; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Drug delivery systems  
(tablets; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Drug delivery systems  
(topical; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Fusion proteins (chimeric proteins)  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tumor necrosis factor receptor:Fc region; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Drug delivery systems  
(vaginal; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable, hydrogenated, ethoxylated; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT 9001-92-7, Protease 329900-75-6, Cyclooxygenase 2  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT 50-14-6, Ergocalciferol 50-24-8, Prednisolone 50-28-2, Estradiol, biological studies 50-34-0, Propantheline bromide 50-56-6, Oxytocin, biological studies 51-15-0, Pralidoxime chloride 51-43-4, Epinephrine 51-48-9, L-Thyroxine, biological studies 51-55-8, Atropine, biological studies 51-60-5, Neostigmine methyl sulfate 52-01-7, Spironolactone 52-24-4, Thiotepea 53-43-0, Dehydroepiandrosterone 55-98-1, Busulphan 57-13-6, Urea, biological studies 57-22-7, Vincristine 57-64-7, Physostigmine salicylate 57-83-0, Progesterone, biological studies 57-94-3, Tubocurarine chloride 59-05-2, Methotrexate 60-31-1, Acetylcholine chloride 62-31-7, Dopamine hydrochloride 63-91-2, L-Phenylalanine, biological studies 65-28-1, Phentolamine mesylate 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 68-19-9, Vitamin b12 69-65-8, D-Mannitol 70-51-9, Deferoxamine 71-27-2, Suxamethonium chloride 74-89-5, Methanamine, biological studies 76-57-3, Codeine 76-90-4, Mepenzolate bromide 76-99-3, Methadone 77-19-0, Dicyclomine 87-33-2, Isosorbide dinitrate 89-57-6, Mesalamine 90-82-4, Pseudoephedrine 101-26-8, Pyridostigmine bromide 104-31-4, Benzonatate 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-40-2, Lutein 129-06-6, Warfarin sodium 131-49-7, Diatrizoate meglumine 140-64-7, Pentamidine isethionate 147-94-4, Cytarabine 154-21-2, Lincomycin 155-97-5, Pyridostigmine 298-46-4, Carbamazepine 298-57-7, Cinnarizine 298-81-7, Methoxsalen 299-42-3, Ephedrine 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 303-53-7, Cyclobenzaprine 303-98-0, Coenzyme Q10 321-64-2, Tacrine 359-83-1, Pentazocine 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 502-65-8, Lycopene 511-12-6, Dihydroergotamine 520-85-4, Medroxyprogesteron 577-11-7, Sodium docusate 595-33-5 596-51-0, Glycopyrrolate 616-91-1, Acetylcysteine 665-66-7, Amantadine hydrochloride 737-31-5, Diatrizoate sodium 865-21-4, Vinblastine 911-45-5, Clomiphene 1115-70-4, Metformin hydrochloride 1134-47-0,

Baclofen 1264-72-8, Colistin sulfate 1319-82-0, Aminocaproic acid 1397-89-3, Amphotericin b 1403-66-3, Gentamycin 1404-90-6, Vancomycin 1405-20-5, Polymyxin B sulfate 1405-37-4, Capreomycin sulfate 1405-87-4, Bacitracin 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1492-18-8, Leucovorin calcium 1501-84-4, Rimantadine hydrochloride 1684-40-8, Tacrine hydrochloride 1695-77-8, Spectinomycin 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2016-88-8, Amiloride hydrochloride 3056-17-5, Stavudine 3485-62-9, Clidinium bromide 3778-73-2, Isofosfamide 3930-20-9, Sotalol 4291-63-8, Cladribine 4419-39-0, Beclomethasone 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5534-95-2, Pentagastrin 6493-05-6, Pentoxyfylline 7261-97-4, Dantrolene 7414-83-7, Disodium etidronate 7481-89-2, Zalcitabine 7648-98-8, Ambenonium 7689-03-4, Camptothecin 8068-28-8, Colistimethate sodium 9001-27-8, Factor VIII 9001-28-9, Factor IX 9002-01-1, Streptokinase 9002-60-2, Corticotropin, biological studies 9002-61-3, Chorionic gonadotropin 9004-17-5, NPH insulin 9004-99-3, Polyethylene glycol stearate 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9007-92-5, Glucagon, biological studies 9015-68-3, Asparaginase 9034-40-6, Gonadotropin-releasing hormone 9039-53-6, Urokinase 9041-08-1, Dalteparin sodium 9041-93-4, Bleomycin sulfate 9087-70-1, Aprotinin 10238-21-8, Glibenclamide 10540-29-1, Tamoxifen 10596-23-3, Clodronic acid 11000-17-2, Vasopressin 11061-68-0, Insulin (human) 11103-57-4, Vitamin A 12001-79-5, Vitamin K 12584-58-6, Porcine insulin 13265-10-6, Methscopolamine 15307-86-5, Diclofenac 15500-66-0, Pancuronium bromide 15574-96-6, Pizotifen 15663-27-1, Cisplatin 15686-51-8, Clemastine 15686-71-2, Cephalexin 15687-27-1, Ibuprofen 15826-37-6, Cromolyn sodium 16679-58-6, Desmopressin 16960-16-0, Cosyntropin 17230-88-5, Danazol 18323-44-9, Clindamycin 18559-94-9, Albuterol 18883-66-4, Streptozocin 19356-17-3, Calcifediol 20537-88-6, Amifostine 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21215-62-3, Human calcitonin 21256-18-8, Oxaprozin 21679-14-1, Fludarabine 21829-25-4, Nifedipine 22254-24-6, Ipratropium bromide 22916-47-8, Miconazole 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probucol 24356-60-3, Cephapirin sodium 25126-32-3, Sincalide 25322-68-3D, PEG, esters 25523-97-1, Dexchlorpheniramine 25618-55-7D, Polyglycerol, fatty acid esters 25812-30-0, Gemfibrozil 26839-75-8, Timolol 27164-46-1, Cefazolin sodium 27203-92-5, Tramadol 27215-38-9, Glycerol monolaurate 29094-61-9, Glipizide 29122-68-7, Atenolol 29767-20-2, Teniposide 30516-87-1, Zidovudine 32222-06-3, Calcitriol 33069-62-4, Paclitaxel 33419-42-0, Etoposide 33515-09-2, Gonadorelin 33564-30-6, Cefoxitin sodium 34787-01-4, Ticarcillin 34911-55-2, Bupropion 35607-66-0, Cefoxitin 36791-04-5, Ribavirin 38304-91-5, Minoxidil 41340-25-4, Etodolac 41575-94-4, Carboplatin 42057-22-7, Mezlocillin sodium 42540-40-9, Cefamandole nafate 42924-53-8, Nabumetone 43200-80-2, Zopiclone 47931-85-1, Salmon calcitonin 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 50700-72-6, Vecuronium bromide 51110-01-1, Somatostatin 51322-75-9, Tizanidine 51333-22-3, Budesonide 51384-51-1, Metoprolol 51481-61-9, Cimetidine 53123-88-9, Sirolimus 53179-11-6, Loperamide 53230-10-7, Mefloquine 53910-25-1, Pentostatin 54063-53-5, Propafenone 54910-89-3, Fluoxetine 54965-21-8, Albendazole 55142-85-3, Ticlopidine 56180-94-0, Acarbose 57248-88-1, Pamidronate disodium 59277-89-3, Acyclovir 59467-70-8, Midazolam 59703-84-3, Piperacillin sodium 59865-13-3, Cyclosporine 60142-96-3, Neurontin 61270-78-8, Cefonicid sodium 61379-65-5, Rifapentine 61869-08-7, Paroxetine 62013-04-1, Dirithromycin 62893-19-0, Cefoperazone 63585-09-1, Foscarnet sodium 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 64228-81-5, Atracurium besylate 64544-07-6, Cefuroxime axetil 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 66376-36-1, Alendronate 68099-86-5, Bepridil hydrochloride 68401-81-0, Ceftizoxime

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (solid carriers for improved delivery of active ingredients  
 in pharmaceutical compns.)

IT 68506-86-5, Vigabatrin 69049-74-7, Nedocromil sodium 69655-05-6,  
 Didanosine 69756-53-2, Halofantrine 70288-86-7, Ivermectin  
 70458-92-3, Pefloxacin 70458-96-7, Norfloxacin 71486-22-1, Vinorelbine  
 72432-03-2, Miglitol 72559-06-9, Rifabutine 73384-59-5, Ceftriaxone  
 73590-58-6, Omeprazole 73963-72-1, Cilostazol 74011-58-8, Enoxacin  
 74103-06-3, Ketorolac 74356-00-6, Cefotetan disodium 74381-53-6,  
 Leuprolide acetate 75330-75-5, Lovastatin 75706-12-6, Leflunomide  
 76420-72-9, Enalaprilat 76470-66-1, Loracarbef 76547-98-3, Lisinopril  
 76824-35-6, Famotidine 76963-41-2, Nizatidine 78110-38-0, Aztreonam  
 79350-37-1, Cefixime 79517-01-4, Octreotide acetate 79617-96-2,  
 Sertraline 79794-75-5, Loratadine 79902-63-9, Simvastatin  
 81093-37-0, Pravastatin 81098-60-4, Cisapride 81103-11-9,  
 Clarithromycin 81161-17-3, Esmolol hydrochloride 82410-32-0,  
 Ganciclovir 82419-36-1, Ofloxacin 82626-48-0, Zolpidem 82952-64-5,  
 Trimetrexate glucuronate 83799-24-0, Fexofenadine 83869-56-1,  
 Granulocyte-macrophage colony stimulating factor 83881-51-0, Cetirizine  
 83905-01-5, Azithromycin 84057-84-1, Lamotrigine 84371-65-3,  
 Mifepristone 84449-90-1, Raloxifene 84625-61-6, Itraconazole  
 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86541-75-5,  
 Benazepril 87679-37-6, Trandolapril 88150-42-9, Amlodipine  
 88669-04-9, Trospectomycin 89778-26-7, Toremifene 89987-06-4,  
 Tiludronate 90357-06-5, Bicalutamide 91161-71-6, Terbinafine  
 93390-81-9, Fosphenytoin 93413-69-5, Venlafaxine 93479-97-1,  
 Glimepiride 93957-54-1, Fluvastatin 94749-08-3, Salmeterol xinafoate  
 95233-18-4, Atovaquone 97240-79-4, Topiramate 97322-87-7, Troglitazone  
 97682-44-5, Irinotecan 98079-51-7, Lomefloxacin 98319-26-7,  
 Finasteride 100986-85-4, Levofloxacin 101828-21-1, Butenafine  
 103577-45-3, Lansoprazole 103628-46-2, Sumatriptan 104227-87-4,  
 Famciclovir 104987-11-3, Tacrolimus 105462-24-6, Risedronic acid  
 106133-20-4, Tamsulosin 106392-12-5, Oxirane, polymer with  
 methyloxirane, block 106650-56-0, Sibutramine 106819-53-8, Doxacurium  
 chloride 106861-44-3, Mivacurium chloride 107648-80-6, Cefepime  
 hydrochloride 107753-78-6, Zafirlukast 109319-16-6, Factor VIII  
 110871-86-8, Sparfloxacin 111025-46-8, Pioglitazone 111406-87-2,  
 Zileuton 112965-21-6, Calcipotriene 113427-24-0 113665-84-2,  
 Clopidogrel 113852-37-2, Cidofovir 115103-54-3, Tiagabine  
 116094-23-6, Insulin aspart 117976-89-3, Rabeprazole 118072-93-8,  
 Zoledronate 118292-40-3, Tazarotene 119914-60-2, Grepaflloxacin  
 120014-06-4, Donepezil 121368-58-9, Olpadronate 121679-13-8,  
 Naratriptan 122320-73-4, Rosiglitazone 123948-87-8, Topotecan  
 124832-26-4, Valaciclovir 127759-89-1, Lobucavir 127779-20-8,  
 Saquinavir 129497-78-5, Verteporfin 131918-61-1, Paricalcitol  
 133040-01-4, Eprosartan 133107-64-9, Insulin lispro 134523-00-5,  
 Atorvastatin 134678-17-4, Lamivudine 135062-02-1, Repaglinide  
 137862-53-4, Valsartan 138402-11-6, Irbesartan 139110-80-8, Zanamivir  
 139264-17-8, Zolmitriptan 139481-59-7, Candesartan 139639-23-9, Tissue  
 type plasminogen activator 142128-59-4, Terzolin 143003-46-7,  
 Alglucerase 143011-72-7, Granulocyte colony stimulating factor  
 143831-71-4 144034-80-0, Rizatriptan 144494-65-5, Tirofiban  
 144701-48-4, Telmisartan 145599-86-6, Cerivastatin 145941-26-0,  
 Oprelvekin 146961-76-4, Alatrofloxacin 147059-72-1, Trovaflloxacin  
 148553-50-8, Pregabalin 151126-32-8, Pramlintide 153559-49-0,  
 Targretin 154361-50-9, Capecitabine 154598-52-4, Efavirenz  
 155213-67-5, Ritonavir 157810-81-6, Indinavir sulfate 158747-02-5,  
 Frovatriptan 158966-92-8, Montelukast 159989-64-7, Nelfinavir  
 160337-95-1, Insulin glargine 162011-90-7, Rofecoxib 165101-51-9,  
 Bevacizumab 169148-63-4, Insulin detemir 169590-42-5, Celecoxib

171599-83-0, Sildenafil citrate 173146-27-5, Denileukin diftitox  
191588-94-0, TNK-tPA

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solid carriers for improved delivery of active ingredients  
in pharmaceutical compns.)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:320910 CAPLUS

DOCUMENT NUMBER: 135:267035

TITLE: Valproate, but not lamotrigine, induces ovarian  
morphological changes in Wistar rats

AUTHOR(S): Roste, Line Sveberg; Tauboll, Erik; Berner, Aasmund;  
Isojarvi, Jouko It; Gjerstad, Leif

CORPORATE SOURCE: Department of Neurology, Rikshospitalet/The National  
Hospital, University of Oslo, Oslo, N-0027, Norway

SOURCE: Experimental and Toxicologic Pathology (2001), 52(6),  
545-552

CODEN: ETPAEK; ISSN: 0940-2993

PUBLISHER: Urban & Fischer Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 06 May 2001

AB Valproate (VPA) medication is associated with development of polycystic ovaries, menstrual disorders and hormonal changes in women with epilepsy. We sought to determine if changes in the ovaries also occurred in an animal model without epilepsy, and whether this effect could be related to a carcinogenic effect expressed by overexpression of p53. A potentially alternative antiepileptic drug, lamotrigine (LTG), was evaluated simultaneously. To this end, female Wistar rats were fed perorally with VPA 400 mg/kg/day (n = 15), VPA 600 mg/kg/day (n = 20), LTG 10 mg/kg/day (n = 15) or control solution (n = 15) for 90-95 days. There was a significant, dose-dependent increase in the number of follicular cysts, reduction

in the number of corpora lutea and reduction of ovarian weight in the VPA group. No

ovarian pathol. was observed in the LTG group. In neither of the groups were morphol. changes seen in other organs, nor was there any overexpression of the tumor suppressor gene p53 found. An alternative antiepileptic drug, LTG, showed no ovarian pathol., and there were no light microscopic changes in other organs, or evidence of pathol. p53 overexpression in the LTG-treated animals.

CC 1-11 (Pharmacology)

ST anticonvulsant valproate lamotrigine p53 gene ovary

IT Gene, animal

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(TP53; valproate, but not lamotrigine, induces ovarian morphol.  
. changes in Wistar rats)

IT Ovary, disease

(cyst; valproate, but not lamotrigine, induces ovarian morphol.  
. changes in Wistar rats)

IT Anticonvulsants

Carcinogens

Menstrual disorder

(valproate, but not lamotrigine, induces ovarian morphol.  
. changes in Wistar rats)

IT 99-66-1 84057-84-1, Lamotrigine

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(valproate, but not lamotrigine, induces ovarian morphol.  
changes in Wistar rats)

REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1997:493923 CAPLUS  
DOCUMENT NUMBER: 127:203891  
TITLE: NMDA receptor-mediated pilocarpine-induced seizures: characterization in freely moving rats by microdialysis  
AUTHOR(S): Smolders, Ilse; Khan, Ghous M.; Manil, Jacqueline; Ebinger, Guy; Michotte, Yvette  
CORPORATE SOURCE: Department of Physiology and Physiopathology, Vrije Universiteit Brussel, Brussels, 1090, Belg.  
SOURCE: British Journal of Pharmacology (1997), 121(6), 1171-1179  
CODEN: BJPCBM; ISSN: 0007-1188  
PUBLISHER: Stockton  
DOCUMENT TYPE: Journal  
LANGUAGE: English

ED Entered STN: 06 Aug 1997

AB Pilocarpine administration has been used as an animal model for temporal lobe epilepsy since it produces several morphol. and synaptic features in common with human complex partial seizures. Little is known about changes in extracellular neurotransmitter concns. during the seizures provoked by pilocarpine, a non-selective muscarinic agonist. Focally evoked pilocarpine-induced seizures in freely moving rats were provoked by intrahippocampal pilocarpine (10 mM for 40 min at a flow rate of 2  $\mu$ l min<sup>-1</sup>) administration via a microdialysis probe. Concomitant changes in extracellular hippocampal glutamate,  $\gamma$ -aminobutyric acid (GABA) and dopamine levels were monitored and simultaneous electrocorticog. was performed. The animal model was characterized by intrahippocampal perfusion with the muscarinic receptor antagonist atropine (20 mM), the sodium channel blocker tetrodotoxin (1  $\mu$ M) and the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 ( dizocilpine maleate, 100  $\mu$ M). The effectiveness of locally (600  $\mu$ M) or systemically (10 mg kg<sup>-1</sup> day<sup>-1</sup>) applied lamotrigine against the pilocarpine-induced convulsions was evaluated. Pilocarpine initially decreased extracellular hippocampal glutamate and GABA levels. During the subsequent pilocarpine-induced limbic convulsions, extracellular glutamate, GABA and dopamine concns. in hippocampus were significantly increased. Atropine blocked all changes in extracellular transmitter levels during and after co-administration of pilocarpine. All pilocarpine-induced increases were completely prevented by simultaneous tetrodotoxin perfusion. Intrahippocampal administration of MK-801 and lamotrigine resulted in an elevation of hippocampal dopamine levels and protected the rats from the pilocarpine-induced seizures. Pilocarpine-induced convulsions developed in the rats which received lamotrigine perorally. Pilocarpine-induced seizures are initiated via muscarinic receptors and further mediated via NMDA receptors. Sustained increases in extracellular glutamate levels after pilocarpine perfusion are related to the limbic seizures. These are arguments in favor of earlier described NMDA receptor-mediated excitotoxicity. Hippocampal dopamine release may be functionally important in epileptogenesis and may participate in the anticonvulsant effects of MK-801 and lamotrigine. The pilocarpine-stimulated hippocampal GABA, glutamate and dopamine levels

reflect neuronal vesicular release.

CC 14-10 (Mammalian Pathological Biochemistry)  
Section cross-reference(s): 1

ST NMDA receptor pilocarpine **seizure** neurotransmitter hippocampus;  
anticonvulsant pilocarpine **seizure** neurotransmitter  
hippocampus

IT **Anticonvulsants**  
**Convulsion**  
**Disease models**  
(NMDA receptor-mediated pilocarpine-induced **seizures** and  
characterization in freely moving rats by microdialysis in relation to  
neurotransmitters of hippocampus and **anticonvulsants** and  
muscarinic receptors)

IT **Muscarinic receptors**  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)  
(NMDA receptor-mediated pilocarpine-induced **seizures** and  
characterization in freely moving rats by microdialysis in relation to  
neurotransmitters of hippocampus and **anticonvulsants** and  
muscarinic receptors)

IT **Glutamate receptors**  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)  
(NMDA-binding; NMDA receptor-mediated pilocarpine-induced  
**seizures** and characterization in freely moving rats by  
microdialysis in relation to neurotransmitters of hippocampus and  
**anticonvulsants** and muscarinic receptors)

IT **Brain**  
(hippocampus; NMDA receptor-mediated pilocarpine-induced  
**seizures** and characterization in freely moving rats by  
microdialysis in relation to neurotransmitters of hippocampus and  
**anticonvulsants** and muscarinic receptors)

IT 92-13-7, **Pilocarpine**  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(NMDA receptor-mediated pilocarpine-induced **seizures** and  
characterization in freely moving rats by microdialysis in relation to  
neurotransmitters of hippocampus and **anticonvulsants** and  
muscarinic receptors)

IT 51-55-8, **Atropine**, biological studies 4368-28-9, **Tetrodotoxin**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); BIOL (Biological study)  
(NMDA receptor-mediated pilocarpine-induced **seizures** and  
characterization in freely moving rats by microdialysis in relation to  
neurotransmitters of hippocampus and **anticonvulsants** and  
muscarinic receptors)

IT 77086-22-7, (+)-**MK-801** 84057-84-1, **Lamotrigine**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)  
(NMDA receptor-mediated pilocarpine-induced **seizures** and  
characterization in freely moving rats by microdialysis in relation to  
neurotransmitters of hippocampus and **anticonvulsants** and  
muscarinic receptors)

IT 51-61-6, **Dopamine**, biological studies 56-12-2, **GABA**, biological studies  
56-86-0, **Glutamic acid**, biological studies  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)  
(NMDA receptor-mediated pilocarpine-induced **seizures** and  
characterization in freely moving rats by microdialysis in relation to  
neurotransmitters of hippocampus and **anticonvulsants** and

muscarinic receptors)

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:440156 CAPLUS

DOCUMENT NUMBER: 119:40156

TITLE:

New method for the determination of four antiepileptic drugs in human plasma by high performance liquid chromatography

AUTHOR(S): Meyler, M.; Kelly, M. T.; Smyth, M. R.

CORPORATE SOURCE: Sch. Chem. Sci., Dublin City Univ., Dublin, Ire.

SOURCE: Chromatographia (1993), 36, 27-32

CODEN: CHRGB7; ISSN: 0009-5893

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 07 Aug 1993

AB The concurrent administration of several antiepileptic drugs for the treatment of seizure disorders has become common practice. Lamotrigine is a new antiepileptic given in combination with other antiepileptic drugs, but which is not routinely measured in clin. labs. An isocratic high-performance liquid chromatog. method is described for the simultaneous measuring lamotrigine, carbamazepine, phenobarbital and phenytoin within 10 min. The chromatog. system used an Hichrom Spherisorb CN column (20 cm x 4 mm, i.d., 5 µm particle size), a µBondapak CN precolumn, and a mobile phase consisting of methanol : acetonitrile : 5 mM sodium acetate (5 : 20 75: by volume, pH adjusted to 6.3 with acetic acid). BWA 725C was used as internal standard. The drugs were extracted from 200 µL

of plasma with Et acetate, acetonitrile and 5 mM sodium acetate. After evaporation of the organic layer and reconstitution in mobile phase, 25 µL of extract was eluted with mobile phase at a flow rate of 1.2 mL/min. The eluted drugs were detected by their absorption at 205 nm and quantified from their peak heights. The method was found to be rapid, relatively simple to perform and sufficiently sensitive to determine each drug over its entire therapeutic range. Lower limits of detection varied from 50-100 ng/mL, absolute recoveries from 93-98%, and mean intra- and inter-assay CVs were <3.0%.

CC 1-1 (Pharmacology)

ST antiepileptic simultaneous detn blood HPLC; liq chromatog  
antiepileptic simultaneous detn blood; lamotrigine carbamazepine  
phenobarbital phenytoin blood HPLC

IT Blood analysis

(simultaneous determination of several antiepileptics in human, by isocratic HPLC method)

IT Anticonvulsants and Antiepileptics

(simultaneous determination of, in human plasma by HPLC)

IT Chromatography, column and liquid

(high-performance, simultaneous determination of several antiepileptics in human plasma by isocratic)

IT 50-06-6, Phenobarbital, analysis 57-41-0, Phenytoin 298-46-4,  
Carbamazepine 84057-84-1, Lamotrigine

RL: ANT (Analyte); ANST (Analytical study)

(determination of, in human plasma by HPLC, in concurrent administration of other antiepileptics)

L31 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:93715 CAPLUS

DOCUMENT NUMBER: 118:93715

TITLE: A liquid chromatographic assay using a high-speed

AUTHOR(S) : Fazio, A.; Artesi, C.; Russo, M.; Trio, R.; Oteri, G.; Pisani, F.

CORPORATE SOURCE: 1st Neurol. Clin., Univ. Messina, Messina, Italy

SOURCE: Therapeutic Drug Monitoring (1992), 14(6), 509-12

CODEN: TDMODV; ISSN: 0163-4356

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 19 Mar 1993

AB A sensitive, specific and rapid liquid-chromatog. method for the determination of the new antiepileptic drug lamotrigine (LTG) in human plasma is described. The method involves the use of a com. available 3-μm particle size normal-phase column and a microflow-cell-equipped UV detector. Extraction is carried out with Et acetate after alkalization on a 100-μL plasma sample containing LTG and 3,5-diamino-6-(2-methoxyphenyl)-1,2,4-triazine as internal standard. The residue is reconstituted with 50 μL of ethanol, and 5 μL of the final solution is injected into the column. Elution is carried out at 34° using n-hexane/absolute ethanol/35% ammonia (80:20:0.25 by volume) as mobile phase at a flow rate of 2.0 mL/min. Detection is at 313 nm. The chromatog. separation requires <3 min and the sensitivity limit is <0.01 mg/L. Recovery is 88-96.2%, whereas within-day and day-to-day coeffs. of variation are between 4.1 and 7.7%.

CC 1-1 (Pharmacology)

IT 84057-84-1, Lamotrigine

RL: ANT (Analyte); ANST (Analytical study)  
(determination of, in human blood by HPLC)

L38 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:322096 CAPLUS  
DOCUMENT NUMBER: 144:369762

TITLE: Preparation of biphenyl derivatives and analogs thereof as cannabinoid receptor ligands and methods of use

INVENTOR(S): Dolle, Roland E.; Worm, Karin; Zhou, Q. Jean

PATENT ASSIGNEE(S): Adolor Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 81 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006074086	A1	20060406	US 2005-242318	20051003
WO 2006041841	A1	20060420	WO 2005-US35677	20051004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				



CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-616024P P 20041005  
 US 2005-242318 A 20051003

OTHER SOURCE(S): MARPAT 144:369762

ED Entered STN: 07 Apr 2006

GI



AB Title compds. I [R1-4 independently = H, alkyl, alkoxy, etc.; R5 and R6 independently = H, alkyl or taken together with the carbon atom to which they are attached to form a 3-8-membered carbocyclic or heterocyclic ring; each R7 and R8 independently = H, alkyl, halo, etc.; J = N or (un)substituted C, provided that no more than two of A, B, D, E and J are N; A, B, D and E independently = N or (un)substituted C; G = alkyl, acyl, aryl, etc.; W = bond, O, S, CH<sub>2</sub>, etc.; X = bond, O, -CH=CH-, etc.; m and n independently = 1-5], and their pharmaceutical salts, are prepared and disclosed as cannabinoid receptor ligands. Thus, e.g., II was prepared by Suzuki coupling of 2-aminophenylboronic acid with resin bound bromophenol derivative (preparation described). Tested compds. were found to bind to

human CB1

and/or CB2 receptor with affinity ranging from 0.1-5000 nM. Further, pharmaceutical compns. containing these compds., and methods for their pharmaceutical use are disclosed. In certain embodiments, the compds. are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, genitourinary disorders, inflammation, glaucoma, auto-immune diseases, ischemic conditions, immune-related disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, and as an appetite stimulant.

INCL 514237500; 544161000

CC 25-2 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)  
 Section cross-reference(s): 1, 63

IT 50-48-6 57-27-2, biological studies 57-41-0 57-42-1 59-92-7,  
 biological studies 76-41-5 76-42-6 76-57-3 76-99-3 77-07-6  
 125-28-0 125-29-1 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide  
 359-83-1 437-38-7 466-99-9 469-62-5 768-94-5,  
 Tricyclo[3.3.1.13,7]decane-1-amine 1972-08-3 2323-36-6 13956-29-1  
 15686-91-6 20594-83-6 27203-92-5, Tramadol 28860-95-9, Carbidopa

42408-82-2 52485-79-7 53179-11-6 53648-55-8 56030-54-7  
 60142-96-3 71195-58-9 84057-84-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(compds. for use in co-administration; preparation of biphenyl derivs. and  
 analogs thereof as cannabinoid receptor ligands)

IT 110-78-1 110-91-8, Morpholine, reactions 372-09-8,  
 Cyanoacetic acid 1795-48-8, Isopropyl isocyanate 5570-18-3,  
 2-Aminophenylboronic acid 15159-40-7, N-Chlorocarbonylmorpholine  
 30418-59-8, 3-Aminophenylboronic acid 30992-29-1 61147-43-1,  
 3-Benzylxybenzonitrile 76566-95-5 214360-75-5 380430-66-0  
 882038-99-5 882039-00-1 882039-01-2  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of biphenyl derivs. and analogs thereof as cannabinoid receptor  
 ligands)

L38 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:673292 CAPLUS  
 DOCUMENT NUMBER: 143:172866  
 TITLE: Preparation of isothiazole dioxides as CXC- and  
 CC-chemokine receptor ligands  
 INVENTOR(S): Taveras, Arthur G.; Zheng, Junying; Biju, Purakkattel  
 J.; Yu, Younong; Chao, Jianhua; Fine, Jay; Lundell,  
 Daniel; Priestley, Tony; Reggiani, Angelo; Merritt, J.  
 Robert; Baldwin, John J.; Lai, Gaifa; Wu, Minglang  
 PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia Drug  
 Discovery, Inc.  
 SOURCE: PCT Int. Appl., 427 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068460	A1	20050728	WO 2004-US42720	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006025453	A1	20060202	US 2004-17505	20041220
PRIORITY APPLN. INFO.:			US 2003-531693P	P 20031222
OTHER SOURCE(S):	MARPAT	143:172866		
ED Entered STN:	Entered STN:	29 Jul 2005		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Disclosed are novel compds. I [D, E = N, CR50; provided that D and E are

not the same (one is N and the other is CR50); R50 = H, CF<sub>3</sub>, CN, etc.; A = (hetero)aryl, (hetero)arylalkyl; B = (hetero)aryl] and the pharmaceutically acceptable salts and solvates thereof. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound I. Although the methods of preparation are not claimed, hundreds of example preps. and/or characterization data are included. For example, II was prepared in 68% yield from the isothiazoledioxide III and the amine IV.pTSA (preparation of reactants given). Antagonist activities of some examples of I towards CXCR1, CXCR2 and CCR7 are given.

IC ICM C07D417-12  
 ICS C07D275-02; C07D417-14; A61K031-427; A61P035-00; A61P029-00  
 CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 IT 50-18-0, Cyclophosphamide 50-48-6, Amitriptyline 51-21-8,  
 5-Fluorouracil 53-03-2, Prednisone 53-86-1, Indomethacin 57-22-7,  
 Vincristine 59-05-2, Methotrexate 72-69-5, Nortriptyline 298-46-4,  
 Carbamazepine 378-44-9,  $\beta$ -Methasone 446-86-6, Azothioprine  
 599-79-1, Sulfasalazine 9005-49-6, Heparin, biological studies  
 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen  
 33069-62-4, Paclitaxel 36322-90-4, Piroxicam 60142-96-3, Gabapentin  
 65271-80-9, Mitoxantrone 75706-12-6, Leflunomide 79217-60-0,  
 Cyclosporin 84057-84-1, Lamotrigine 85622-93-1, Temozolomide  
 95058-81-4, Gemcitabine 105857-23-6, Alteplase 143653-53-6, Abciximab  
 147245-92-9, Glatiramer acetate 148553-50-8, Pregabalin 162011-90-7,  
 Rofecoxib 169590-42-5, Celecoxib 188627-80-7, Eftifibatide  
 191588-94-0, Tenecteplase  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (co-drug; preparation of isothiazole dioxides as CXC- and CC-chemokine  
 receptor ligands)  
 IT 50-85-1 62-53-3, Phenylamine, reactions 67-36-7 67-47-0 67-64-1,  
 Acetone, reactions 71-43-2, Benzene, reactions 75-31-0,  
 Isopropylamine, reactions 75-64-9, tert-Butylamine, reactions 77-55-4  
 78-81-9, Isobutylamine 78-82-0, Isobutyronitrile 78-96-6 79-46-9,  
 2-Nitropropane 85-38-1, 3-Nitrosalicylic acid 86-51-1,  
 2,3-Dimethoxybenzaldehyde 88-15-3 89-55-4 89-56-5, 5-Methylsalicylic  
 acid 89-98-5, 2-Chlorobenzaldehyde 92-54-6 93-02-7,  
 2,5-Dimethoxybenzaldehyde 95-54-5, 1,2-Phenylenediamine, reactions  
 98-01-1, 2-Furancarboxaldehyde, reactions 98-03-3, 2-Formylthiophene  
 98-09-9, Phenylsulfonyl chloride 98-80-6, Phenylboronic acid 98-86-2,  
 Acetophenone, reactions 98-88-4, Benzoyl chloride 98-98-6, Picolinic  
 acid 100-10-7 100-46-9, Benzylamine, reactions 100-49-2,  
 Cyclohexylmethanol 100-52-7, Benzaldehyde, reactions 100-58-3,  
 Phenylmagnesium bromide 100-60-7 103-49-1, Dibenzylamine 103-67-3,  
 N-Benzyl-N-methylamine 106-41-2, p-Bromophenol 108-23-6, Isopropyl  
 chloroformate 108-91-8, Cyclohexylamine, reactions 109-61-5, Propyl  
 chloroformate 109-73-9, Butylamine, reactions 109-83-1 109-89-7,  
 Diethylamine, reactions 110-73-6 110-78-1, Propyl isocyanate  
 110-85-0, Piperazine, reactions 110-89-4, Piperidine, reactions  
 110-91-8, Morpholine, reactions 111-42-2, reactions 111-49-9  
 120-14-9, 3,4-Dimethoxybenzaldehyde 120-21-8, 4-Diethylaminobenzaldehyde  
 120-43-4 120-57-0, 1,3-Benzodioxole-5-carboxaldehyde 121-51-7  
 121-90-4 121-92-6, 3-Nitrobenzoic acid 122-98-5 123-11-5,  
 4-Methoxybenzaldehyde, reactions 123-38-6, Propionaldehyde, reactions  
 123-75-1, Pyrrolidine, reactions 135-00-2 135-02-4,  
 2-Methoxybenzaldehyde 140-28-3, N,N'-Dibenzylethane-1,2-diamine  
 142-25-6 149-73-5, Trimethylorthoformate 321-14-2, 5-Chlorosalicylic

acid 344-25-2, D-Proline 349-43-9 406-87-1, 4,4,4-  
Trifluorobutyraldehyde 420-90-6 434-45-7 446-36-6 446-52-6,  
2-Fluorobenzaldehyde 447-61-0, 2-Trifluoromethylbenzaldehyde 454-89-7,  
3-Trifluoromethylbenzaldehyde 456-48-4, 3-Fluorobenzaldehyde 459-57-4,  
4-Fluorobenzaldehyde 460-40-2 498-60-2, 3-Furaldehyde 498-62-4,  
3-Formylthiophene 498-94-2, 4-Piperidinecarboxylic acid 498-95-3,  
3-Piperidinecarboxylic acid 503-29-7, Azetidine 527-69-5,  
2-Furancarbonyl chloride 529-20-4, 2-Methylbenzaldehyde 534-22-5,  
2-Methylfuran 535-75-1, 2-Piperidinecarboxylic acid 554-14-3,  
2-Methylthiophene 567-61-3 585-70-6 587-04-2, 3-Chlorobenzaldehyde  
591-31-1, 3-Methoxybenzaldehyde 594-19-4, tert-Butyllithium 606-18-8  
611-20-1, 2-Cyanophenol 611-24-5 613-69-4, 2-Ethoxybenzaldehyde  
616-24-0, 3-Pantanamine 616-34-2, Methyl glycinate 616-44-4,  
3-Methylthiophene 618-27-9 619-19-2, 4-Nitrosalicylic acid 620-02-0  
621-31-8 624-78-2 625-45-6, Methoxyacetic acid 626-56-2 630-19-3,  
2,2-Dimethylpropanal 651-70-7, 2-(Trifluoroacetyl)thiophene 656-42-8  
659-28-9, 4-Trifluoromethoxybenzaldehyde 698-63-5, reactions 704-38-1  
765-30-0, Cyclopropylamine 920-39-8, Isopropylmagnesium bromide  
927-77-5, Propylmagnesium bromide 930-27-8, 3-Methylfuran 931-50-0,  
Cyclohexylmagnesium bromide 1003-09-4, 2-Bromothiophene 1003-31-2,  
2-Thiophenecarbonitrile 1068-55-9, Isopropylmagnesium chloride  
1072-67-9, 3-Amino-5-methylisoxazole 1122-60-7 1192-58-1 1204-60-0,  
[1,1'-Biphenyl]-3-carboxaldehyde 1423-26-3, 3-  
Trifluoromethylphenylboronic acid 1484-84-0, 2-Piperidineethanol  
1692-15-5, 4-Pyridinylboronic acid 1692-25-7, Pyridin-3-ylboronic acid  
1700-37-4 1722-12-9, 2-Chloropyrimidine 1730-25-2, Allylmagnesium  
bromide 1857-20-1 1874-23-3, Methyl 5-nitro-2-furoate 1885-14-9,  
Phenyl chloroformate 1888-75-1, Isopropyllithium 1899-24-7 2026-48-4  
2032-35-1 2039-67-0 2133-40-6 2211-64-5 2402-95-1 2562-38-1  
2627-86-3 2689-59-0 2759-28-6, N-Benzylpiperazine 2762-32-5,  
2-Piperazinecarboxylic acid 2786-07-4, 2-Thienyllithium 2799-21-5  
2987-16-8 3002-94-6, Cyclopropyllithium 3082-64-2 3405-77-4  
3433-37-2, 2-Piperidinemethanol 3674-13-3, 2,3-Dibromopropionic acid  
ethyl ester 3694-52-8, 3-Nitro-1,2-phenylenediamine 3789-59-1  
3886-69-9 4138-26-5, 3-Piperidinecarboxamide 4265-16-1,  
2-Benzofurancarboxaldehyde 4276-09-9, D-Valinol 4333-56-6,  
Cyclopropylbromide 4418-61-5, 1H-Tetrazol-5-amine 4606-65-9,  
3-Piperidinemethanol 4747-21-1, N-Isopropyl-N-methylamine 5006-62-2  
5271-67-0, 2-Thiophenecarbonyl chloride 5333-83-5 5382-16-1,  
4-Piperidinol 5473-12-1, Methyl N-methylglycinate 5779-95-3,  
3,5-Dimethylbenzaldehyde 5834-16-2 5856-62-2 5856-63-3 5973-71-7,  
3,4-Dimethylbenzaldehyde 6165-69-1, 3-Thiopheneboronic acid 6193-47-1  
6250-76-6 6287-38-3, 3,4-Dichlorobenzaldehyde 6542-60-5,  
Cyclopropylacetonitrile 6662-17-5 6859-99-0, 3-Piperidinol  
6921-34-2, Benzylmagnesium chloride 6973-60-0, 1-Methyl-2-  
pyrrolecarboxylic acid 7051-34-5, Cyclopropylmethylbromide 7210-75-5  
7311-34-4, 3,5-Dimethoxybenzaldehyde 10200-59-6, 2-  
Thiazolecarboxaldehyde 10203-08-4, 3,5-Dichlorobenzaldehyde 10242-08-7  
10242-10-1 13349-82-1 13515-93-0 13679-70-4 13679-75-9  
13734-41-3 13808-64-5 13889-98-0 14305-17-0 14321-27-8,  
N-Benzyl-N-ethylamine 14610-37-8, N-Methyl-N-tert-butylamine  
15231-41-1 15433-83-7 16114-47-9 16466-97-0 17249-80-8,  
3-Chlorothiophene 17573-92-1 17766-28-8 19524-06-2, 4-Bromopyridine  
hydrochloride 20173-04-0 20409-48-7 20980-22-7 20989-17-7  
21921-76-6 22078-59-7 22838-58-0 23074-10-4 23356-96-9  
29138-64-5 29668-44-8 30084-91-4 32085-88-4, 3,5-  
Difluorobenzaldehyde 32559-18-5 33208-98-9 33240-34-5,  
Cyclopentylmagnesium bromide 34035-04-6 34036-07-2,  
3,4-Difluorobenzaldehyde 34328-61-5, 3-Chloro-4-fluorobenzaldehyde  
34592-47-7 34803-66-2 39515-51-0 39890-42-1 40114-49-6,

N-Benzylpiperid-3-one 40172-95-0 42142-52-9  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of isothiazole dioxides as CXC- and CC-chemokine receptor ligands)

IT 42142-55-2 45347-82-8, 3-Azetidinol 52130-30-0 52480-43-0  
 52771-21-8, 3-Trifluoromethoxybenzaldehyde 55745-70-5 55745-96-5  
 56286-73-8 57260-67-0 57260-71-6 57699-45-3, 4-tert-Butoxybenzaldehyde 62348-13-4, 5-Isoxazolecarbonyl chloride 64951-50-4  
 65058-23-3 66414-02-6 68820-12-2 68832-13-3 70753-36-5  
 77873-76-8, 3-Morpholinecarboxylic acid 79852-25-8  
 81097-48-5 81661-26-9 84538-33-0 94098-56-3 94651-33-9,  
 2-Trifluoromethoxybenzaldehyde 95201-93-7 100243-39-8 103003-01-6,  
 2-Morpholinemethanol 104706-47-0 110013-19-9 119461-40-4  
 119692-41-0 123221-93-2 123297-88-1, 6-Benzofurancarboxaldehyde  
 128796-39-4, 4-Trifluoromethylphenylboronic acid 135217-58-2  
 135427-08-6 147701-78-8 152932-57-5 177971-32-3 180736-67-8  
 184637-48-7 188816-39-9 189321-66-2 204339-72-0 300582-83-6, 2-Morpholinecarboxylic acid 473734-69-9 473734-71-3  
 473734-74-6 608537-49-1 608537-54-8 608537-74-2 612541-21-6  
 654683-69-9 654683-71-3 681510-00-9 731006-06-7 779340-46-4  
 860805-90-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of isothiazole dioxides as CXC- and CC-chemokine receptor ligands)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:638859 CAPLUS  
 DOCUMENT NUMBER: 143:153384  
 TITLE: Preparation of diaminothiadiazoles as CXC- and CC-chemokine receptor ligands  
 INVENTOR(S): Biju, Purakkattle J.; Taveras, Arthur G.; Yu, Younong; Zheng, Junying; Chao, Jianhua; Aki, Cynthia J.; Fine, Jay; Lundell, Daniel; Priestley, Tony; Reggiani, Angelo; Merritt, J. Robert; Baldwin, John J.  
 PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia Drug Discovery, Inc.  
 SOURCE: PCT Int. Appl., 593 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066147	A1	20050721	WO 2004-US42060	20041216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-531311P P 20031219

OTHER SOURCE(S) : MARPAT 143:153384  
 ED Entered STN: 22 Jul 2005  
 GI



AB Disclosed are diaminothiadiazoles I [A = (hetero)aryl, (hetero)arylmethyl (substituted at CH<sub>2</sub>), etc.; B = (hetero)aryl] and the pharmaceutically acceptable salts and solvates thereof. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using I. Although the methods of preparation are not claimed, hundreds of example preps. and/or characterization data are included. For example, II was prepared in 43% yield from its monooxide III (preparation given). Antagonist activities of some examples of I towards CXCR1, CXCR2 and CCR7 are given.

IC ICM C07D285-10

ICS C07D417-12; C07D417-14; A61K031-433; A61K031-4436

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63

IT 50-48-6, Amitriptyline 53-86-1, Indomethacin 72-69-5, Nortriptyline 298-46-4, Carbamazepine 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 36322-90-4, Piroxicam 60142-96-3, Gabapentin 84057-84-1, Lamotrigine 148553-50-8, Pregabalin 162011-90-7, Rofecoxib 169590-42-5, Celecoxib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (co-drug; preparation of diaminothiadiazoles as CXC- and CC-chemokine receptor ligands)

IT 50-85-1 62-53-3, Benzenamine, reactions 67-36-7 67-47-0 71-43-2,  
 Benzene, reactions 75-31-0, 2-Propanamine, reactions 75-64-9,  
 reactions 77-55-4 78-81-9 78-82-0 78-96-6 79-44-7 79-46-9  
 85-38-1 86-51-1 88-15-3 89-55-4 89-56-5 89-98-5 92-54-6  
 93-02-7 95-54-5, 1,2-Benzenediamine, reactions 98-01-1,  
 2-Furancarboxaldehyde, reactions 98-03-3, 2-Thiophenecarboxaldehyde  
 98-09-9, Benzenesulfonyl chloride 98-80-6 98-86-2, reactions  
 98-88-4, Benzoyl chloride 98-98-6, 2-Pyridinecarboxylic acid 100-10-7  
 100-46-9, Benzenemethanamine, reactions 100-49-2, Cyclohexanemethanol  
 100-52-7, Benzaldehyde, reactions 100-58-3 100-60-7 103-49-1  
 103-67-3 103-71-9, reactions 106-41-2 106-48-9 108-23-6  
 108-91-8, Cyclohexanamine, reactions 109-01-3 109-61-5 109-83-1  
 109-89-7, reactions 109-90-0 110-73-6 110-78-1 110-85-0,  
 Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8,  
**Morpholine**, reactions 111-42-2, reactions 111-49-9 120-14-9  
 120-21-8 120-43-4 120-57-0, 1,3-Benzodioxole-5-carboxaldehyde  
 120-83-2 121-51-7 121-88-0 121-90-4 121-92-6 122-98-5  
 123-11-5, reactions 123-38-6, Propanal, reactions 123-75-1,  
 Pyrrolidine, reactions 135-00-2 135-02-4 140-28-3 142-25-6  
 321-14-2 344-25-2, D-Proline 349-43-9 406-87-1 420-90-6 434-45-7  
 446-36-6 446-52-6 447-61-0 454-89-7 456-48-4 459-57-4 460-40-2  
 498-60-2, 3-Furancarboxaldehyde 498-62-4, 3-Thiophenecarboxaldehyde  
 498-94-2, 4-Piperidinecarboxylic acid 498-95-3, 3-Piperidinecarboxylic  
 acid 503-29-7, Azetidine 527-69-5, 2-Furancarbonyl chloride 529-20-4  
 534-22-5 535-75-1, 2-Piperidinecarboxylic acid 554-14-3 567-61-3  
 585-70-6 587-04-2 591-20-8 591-31-1 594-19-4 606-18-8 609-70-1  
 611-20-1 611-24-5 611-71-2 613-69-4 616-24-0, 3-Pantanamine  
 616-44-4 620-02-0 621-31-8 624-78-2 625-45-6 626-56-2 630-19-3  
 651-70-7 656-42-8 659-28-9 698-63-5, reactions 704-38-1  
 765-30-0, Cyclopropanamine 872-31-1 920-39-8 927-77-5 930-27-8  
 931-50-0 1003-09-4 1003-31-2, 2-Thiophenecarbonitrile 1072-67-9  
 1111-92-8 1122-60-7 1192-58-1 1204-60-0, [1,1'-Biphenyl]-3-  
 carboxaldehyde 1423-26-3 1484-84-0, 2-Piperidineethanol 1589-82-8  
 1692-15-5 1692-25-7 1700-37-4 1722-12-9 1730-25-2 1857-20-1  
 1874-23-3 1885-14-9 1888-75-1 1899-24-7 2026-48-4 2039-67-0  
 2133-40-6 2402-95-1 2562-38-1 2627-86-3 2689-59-0 2759-28-6  
 2762-32-5, 2-Piperazinecarboxylic acid 2786-07-4 2799-21-5 2987-16-8  
 3002-94-6 3082-64-2 3173-56-6 3405-77-4 3433-37-2,  
 2-Piperidinemethanol 3674-13-3 3694-52-8 3789-59-1 3886-69-9  
 4138-26-5, 3-Piperidinecarboxamide 4265-16-1, 2-Benzofurancarboxaldehyde  
 4276-09-9 4333-56-6 4412-91-3, 3-Furanmethanol 4418-61-5,  
 1H-Tetrazol-5-amine 4606-65-9, 3-Piperidinemethanol 4747-21-1  
 4747-71-1 5006-62-2 5271-67-0, 2-Thiophenecarbonyl chloride  
 5333-83-5 5382-16-1, 4-Piperidinol 5473-12-1 5680-79-5 5779-95-3  
 5834-16-2 5856-62-2 5856-63-3 5973-71-7 6165-69-1 6193-47-1  
 6250-76-6 6287-38-3 6542-60-5, Cyclopropaneacetonitrile 6662-17-5  
 6859-99-0, 3-Piperidinol 6973-60-0 7051-34-5 7210-75-5 7311-34-4  
 10200-59-6, 2-Thiazolecarboxaldehyde 10203-08-4 10242-08-7  
 10242-10-1 13349-82-1 13515-93-0 13679-70-4 13679-75-9  
 13734-41-3 13808-64-5 13889-98-0 13952-84-6, 2-Butanamine  
 14321-27-8 14610-37-8 15012-74-5 15231-41-1 15433-83-7  
 16114-47-9 16466-97-0 17249-80-8 17573-92-1 17766-28-8  
 19524-06-2 20173-04-0 20409-48-7 20980-22-7 20989-17-7  
 21921-76-6 22078-59-7 22838-58-0 23074-10-4 23095-05-8  
 23356-96-9 23473-12-3 28250-45-5 29138-64-5 29668-44-8  
 30084-91-4 32085-88-4 33208-98-9 33240-34-5  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of diaminothiadiazoles as CXC- and CC-chemokine receptor  
 ligands)  
 IT 34035-04-6 34036-07-2 34328-61-5 34803-66-2 39515-51-0

39890-42-1 40172-95-0 40357-87-7 42142-52-9 43189-45-3  
45121-22-0 45347-82-8, 3-Azetidinol 45521-09-3 50606-58-1  
52130-30-0 52480-43-0 52771-21-8 54012-73-6, 3-Piperidinamine  
55745-70-5 55745-96-5 56286-73-8 57260-67-0 57260-71-6  
57699-45-3 59413-60-4 62348-13-4, 5-Isoxazolecarbonyl chloride  
67608-57-5 68820-12-2 68832-13-3 70753-36-5 77873-76-8, 3-  
**Morpholinecarboxylic acid** 79286-79-6, 3-Pyrrolidinamine  
79844-64-7 79852-25-8 80866-91-7 81097-48-5 81661-26-9  
94098-56-3 94651-33-9 95201-93-7 101257-87-8 108408-92-0  
110013-19-9 119692-41-0 128796-39-4 133712-89-7 135217-58-2  
135427-08-6 147701-78-8 180736-67-8 184637-48-7 188816-39-9  
189321-66-2 204339-72-0 276702-20-6 276702-25-1 276703-17-4  
300582-83-6, 2-Morpholinecarboxylic acid 303070-22-6  
361393-33-1 413621-62-2 464913-03-9 473730-78-8 473733-45-8  
473733-46-9 473733-47-0 473733-48-1 473733-49-2 473733-50-5  
473733-51-6 473733-52-7 473733-53-8 473733-54-9 473733-55-0  
473736-96-8 473736-98-0 512190-97-5 608537-49-1 608537-54-8  
608537-74-2 608538-44-9 612541-21-6 654683-32-6 654683-40-6  
654683-69-9 654683-71-3 681509-63-7 681509-64-8 681509-65-9  
681509-67-1 681509-68-2 681509-69-3 681509-70-6 681509-71-7  
681510-00-9 859838-01-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of diaminothiadiazoles as CXC- and CC-chemokine receptor ligands)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 4 OF 4

CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1995:988800 CAPLUS

DOCUMENT NUMBER:

124:76317

TITLE:

Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study

AUTHOR(S) :

Shuaib, Ashfaq; Mahmood, Rana H.; Wishart, Tom; Kanthan, Rani; Murabit, Mohamed A.; Ijaz, Sadiq; Miyashita, Hiro; Howlett, Wendy

CORPORATE SOURCE:

Division of Neurology, Department of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Sask. S7N 0X0, SK, Can.

SOURCE:

Brain Research (1995), 702(1,2), 199-206

CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER:

Elsevier

DOCUMENT TYPE:

Journal

LANGUAGE:

English

ED Entered STN: 19 Dec 1995

AB A sudden surge in the release of glutamate is currently believed to be an important initiating step in neuronal damage due to an ischemic insult. In this experiment, we tested the efficacy of neuroprotection with lamotrigine, a novel antiepileptic drug that blocks voltage gated sodium channels and inhibits the ischemia-induced release of glutamate in the gerbil forebrain model of cerebral ischemia. The medication was administered 30 min before and 30 min after the insult in two groups of animals. Histol. assessment of neuronal damage was evaluated at 7 and 28 days after the ischemic insult. Animals evaluated at 28 days also underwent behavioral testing. Microdialysis was used in the same model to study the response of ischemia-induced glutamate in saline treated controls vs. animals treated with lamotrigine 20 min before the insult. There was highly significant neuronal protection in animals who were treated with lamotrigine either before or after the insult. Protection was seen both at 7 and 28 days after the insult. Behavioral testing also showed significantly better

recovery in both sets of animals in comparison to the saline-treated group. Microdialysis confirmed a significant attenuation of the ischemia-induced glutamate surge when compared to the saline-treated animals. Our morphol., behavioral and microdialysis expts. show that lamotrigine offers significant neuroprotection from the effects of transient forebrain ischemia in gerbils. Neuroprotection with post-ischemic therapy probably depends on preserving the capacity of the sodium/calcium exchanger to reduce intracellular calcium concns. or persistent 'toxicity' of glutamate in the reperfusion period on the already 'primed' injured neurons. These concepts need further study.

CC 1-11 (Pharmacology)  
 IT 84057-84-1, Lamotrigine  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (neuroprotective effects of lamotrigine in global ischemia: histol. and behavioral study)

L44 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1010006 CAPLUS  
 DOCUMENT NUMBER: 144:312050  
 TITLE: A new approach to the synthesis of lamotrigine and other 3,5-diamino-1,2,4-triazine derivatives  
 AUTHOR(S): Ulomskii, E. N.; Shestakova, T. S.; Deev, S. L.;  
 Rusinov, V. L.; Chupakhin, O. N.  
 CORPORATE SOURCE: Ural State Technical University, Yekaterinburg,  
 620002, Russia  
 SOURCE: Russian Chemical Bulletin (2005), 54(3), 726-732  
 CODEN: RCBUEY; ISSN: 1066-5285  
 PUBLISHER: Springer Science+Business Media, Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 ED Entered STN: 19 Sep 2005  
 AB A new in principle method for the synthesis of 6-aryl(hetaryl)-3,5-diamino-1,2,4-triazines by decomposition of pre-synthesized tetrazolo[1,5-b][1,2,4]triazines was developed. The advantages of this method over traditional methods were demonstrated using the synthesis of a modern antiepileptic preparation lamotrigine, as an example. The crystal structure of 6-phenyltetrazolo[1,5-b][1,2,4]triazin-7-amine is presented [monoclinic, space group P21/c, a 10.935(2), b 6.7330(10), c 13.279(3) Å, β 93.20(3)°, V 976.1(3) Å³, Z 4].  
 CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 75  
 IT Bond angle  
 Bond length  
 Crystal structure  
 Hydrogen bond  
 Molecular structure  
 (of tetrazolotriazinamine)  
 IT 879573-90-7P  
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (mol. and crystal structure; preparation of triazinediamines by decomposition of tetrazolotriazines)  
 IT 6719-24-0P 35857-42-2P 38943-76-9P 38943-80-5P 58848-66-1P  
 84057-84-1P, Lamotrigine 191872-72-7P 879573-94-1P  
 879573-95-2P 879573-96-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of triazinediamines by decomposition of tetrazolotriazines)

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:823681 CAPLUS  
 DOCUMENT NUMBER: 143:216704  
 TITLE: Crystalline polymorphs of a CXC-chemokine receptor ligand  
 INVENTOR(S): Hu, Mengwei; Yu, Younong; Dwyer, Michael; Taveras, Arthur G.; Kim-Meade, Agnes; Yin, Jianguo; Fu, Xiaoyong; Mcallister, Timothy; Zhang, Shuyi; Klopfer, Kevin  
 PATENT ASSIGNEE(S): Schering Corporation, USA  
 SOURCE: PCT Int. Appl., 65 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075447	A1	20050818	WO 2005-US3414	20050128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005192345	A1	20050901	US 2005-45772	20050128
PRIORITY APPLN. INFO.:			US 2004-540487P	P 20040130

ED Entered STN: 19 Aug 2005  
 AB The present invention relates to 4 distinct crystalline polymorphs of a monohydrate of 2-hydroxy-N,N-dimethyl-3-[[2-[[1-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide. These 4 polymorphic forms, herein referred to as Forms I, II, III and IV are active as a CXC-chemokine receptor ligands. The invention is further directed to formulations, methods of treatment, and processes of synthesis of these polymorphic forms.  
 IC ICM C07D307-52  
 ICS A61K031-341; A61P029-00; A61P035-00  
 CC 63-6 (Pharmaceuticals)  
 ST cryst polymorph CXC chemokine receptor ligand  
 IT Adenosine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (A2; crystalline polymorphs of CXC-chemokine receptor ligand)  
 IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (CXCR1; crystalline polymorphs of CXC-chemokine receptor ligand)  
 IT Inflammation  
 (Crohn's disease; crystalline polymorphs of CXC-chemokine receptor ligand)  
 IT Intestine, disease  
 (Crohn's; crystalline polymorphs of CXC-chemokine receptor ligand)  
 IT GABA receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(GABAB; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Antihistamines  
(H1; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Antihistamines  
(H3; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Antibodies and Immunoglobulins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(IgE; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Sarcoma  
(Kaposi's; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Ear, disease  
(Meniere's; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Muscarinic antagonists  
(M1; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Muscarinic agonists  
(M2; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Muscarinic antagonists  
(M3; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Tachykinin receptors  
(NK1 antagonists; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Tachykinin receptors  
(NK2 antagonists; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Opioid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ORL1 (opioid receptor-like 1), agonists; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Inflammation  
Pancreas, disease  
(acute pancreatitis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Infection  
(acute viral hepatitis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Respiratory distress syndrome  
(acute; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Respiratory distress syndrome  
(adult; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Hepatitis  
Liver, disease  
(alc.; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Transplant rejection  
(allograft; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Heart, disease  
(angina pectoris; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antibodies to; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Dermatitis  
(atopic; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Bronchi, disease  
(bronchiectasis; **crystalline polymorphs of CXC-chemokine receptor ligand**)

IT Bronchi, disease  
Inflammation  
(bronchiolitis; crystalline polymorphs of CXC-chemokine receptor ligand)  
IT Ischemia  
(cardiac; crystalline polymorphs of CXC-chemokine receptor ligand)  
IT Inflammation  
(carditis, viral; crystalline polymorphs of CXC-chemokine receptor ligand)  
IT Ischemia  
(cerebral; crystalline polymorphs of CXC-chemokine receptor ligand)  
IT Bronchi, disease  
Inflammation  
(chronic bronchitis; crystalline polymorphs of CXC-chemokine receptor ligand)  
IT Lung, disease  
(chronic obstructive pulmonary disease; crystalline polymorphs of CXC-chemokine receptor ligand)  
IT Inflammation  
Pancreas, disease  
(chronic pancreatitis; crystalline polymorphs of CXC-chemokine receptor ligand)  
IT Acne  
Alzheimer's disease  
Angiogenesis  
Angiogenesis inhibitors  
Anticoagulants  
Anticonvulsants  
Antidepressants  
Antirheumatic agents  
Antitumor agents  
Arthritis  
Asthma  
Atherosclerosis  
Autoimmune disease  
Bronchodilators  
Burn  
Celiac disease  
Common cold  
Cough  
Cystic fibrosis  
Decongestants  
Dopamine agonists  
Drug delivery systems  
Emphysema  
Encephalitis  
Expectorants  
Gout  
Hemorrhage  
Hepatitis virus  
Human  
Human herpesvirus  
Human immunodeficiency virus 1  
Hypercapnia  
Immunosuppressants  
Inflammation  
Ischemia  
Leukotriene antagonists  
Lupus erythematosus

Malaria  
Meningitis  
Multiple sclerosis  
Neoplasm  
Osteoarthritis  
Osteoporosis  
Pain  
Parturition  
Platelet aggregation inhibitors  
Polymorphism (*crystal*)  
Pruritus  
Psoriasis  
Rheumatoid arthritis  
Sarcoidosis  
Sepsis  
Strain  
Thrombolytics  
Thrombosis  
    (*crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Interleukin 10  
IT Interleukin 5  
IT Interleukin 8  
    RL: BSU (Biological study, unclassified); BIOL (Biological study)  
    (*crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Alcohols, uses  
    RL: NUU (Other use, unclassified); USES (Uses)  
    (*crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Glucocorticoids  
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
    (*crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Hormones, animal, biological studies  
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
    (*crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Natural products, pharmaceutical  
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
    (*crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Steroids, biological studies  
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
    (*crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Allergy  
    (delayed hypersensitivity; *crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Eye, disease  
    (diabetic retinopathy; *crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Ulcer  
    (duodenal; *crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Intestine, disease  
    (duodenum, ulcer; *crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Breathing (animal)  
    (dyspnea; *crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Esophagus, disease  
    Inflammation  
        (esophagitis; *crystalline polymorphs of CXC-chemokine receptor ligand*)  
IT Lung, disease  
    (fibrosis; *crystalline polymorphs of CXC-chemokine receptor ligand*)

IT Ulcer  
(gastric; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Gingiva, disease  
Inflammation  
(gingivitis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Inflammation  
Kidney, disease  
(glomerulonephritis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Inflammation  
Tongue, disease  
(glossitis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Transplant and Transplantation  
(graft-vs.-host reaction; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Respiratory system, disease  
(hyperresponsiveness; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Hypoxia, animal  
(hypoxemia; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Intestine, disease  
(inflammatory; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Chemokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Reperfusion  
(injury; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Brain, disease  
Heart, disease  
(ischemia; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Leukotriene receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(leukotriene B4, antagonists; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Eye, disease  
(macula, degeneration; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Heart, disease  
Inflammation  
(myocarditis, viral; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Angiogenesis  
(neovascularization, corneal; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Lung, neoplasm  
(non-small-cell carcinoma; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Anti-inflammatory agents  
(nonsteroidal; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Eye, disease  
Inflammation  
(ophthalmitis; **crystalline polymorphs of CXC-chemokine receptor ligand**)

IT Inflammation  
Periodontium, disease  
(periodontitis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Dialysis  
(peritoneal, continuous ambulatory; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Inflammation  
Lung, disease  
(pneumonitis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Myositis  
(polymyositis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Carcinoma  
(pulmonary non-small-cell; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Fibrosis  
Hypertension  
(pulmonary; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Injury  
(reperfusion; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Artery, disease  
(restenosis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Eye, disease  
(retinopathy; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Heart, disease  
(right ventricle, hypertrophy; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Hypertrophy  
(right ventricular; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Shock (circulatory collapse)  
(septic; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Inflammation  
Respiratory system, disease  
(sinusitis, chronic; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Brain, disease  
(stroke; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Shock (circulatory collapse)  
(toxic shock syndrome; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Injury  
(trauma; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Cannabinoid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type CB2; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Tachykinin receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type NK3, antagonists; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Stomach, disease  
(ulcer; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Inflammation

Intestine, disease  
(ulcerative colitis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Blood vessel, disease  
Inflammation  
(vasculitis; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Hepatitis  
(viral, acute; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Breathing (animal)  
(wheezing; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Interleukin 8 receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha$ ; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
( $\beta$ ; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT Adrenoceptor agonists  
( $\beta_2$ -; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT 64-17-5, Ethanol, uses 67-56-1, Methanol, uses 67-64-1, 2-Propanone,  
uses 71-23-8, 1-Propanol, uses 75-09-2, uses  
RL: NUU (Other use, unclassified); USES (Uses)  
(**crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT 862464-58-2P  
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(**crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT 473727-83-2  
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT  
(Reactant or reagent); USES (Uses)  
(**crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT 50-48-6 53-03-2, Prednisone 53-86-1, Indomethacin 59-05-2,  
Methotrexate 72-69-5 298-46-4, Carbamazepin 378-44-9, Betamethasone  
446-86-6 599-79-1, Sulfasalazine 9005-49-6, Heparin, biological  
studies 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1,  
Naproxen 36322-90-4, Piroxicam 60142-96-3, Gabapentin 65271-80-9  
71125-38-7, Meloxicam 75706-12-6, Leflunimide 79217-60-0, Cyclosporin  
84057-84-1, Lamotrigine 105857-23-6, Alteplase 139639-23-9,  
Tissue plasminogen activator 143653-53-6, Abciximab 147245-92-9,  
Glatiramer acetate 148553-50-8, PreGabalain 162011-90-7, Rofecoxib  
169590-42-5, Celecoxib 170277-31-3, Infliximab 181695-72-7, Valdecoxib  
185243-69-0, Etanercept 188627-80-7, Eftifibatide 191588-94-0,  
Tenecteplase 202409-33-4, Etoricoxib 331731-18-1, Adalimumab  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**crystalline polymorphs of CXC-chemokine receptor ligand**)  
IT 9001-84-7, Phospholipase A2 9001-87-0, Phospholipase D 9004-06-2,  
Elastase 9025-82-5, Phosphodiesterase 9036-21-9, Phosphodiesterase 4  
39391-18-9 80619-02-9 141907-41-7 165245-96-5, P38 Kinase  
329900-75-6 329967-85-3, Cyclooxygenase 1  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; **crystalline polymorphs of CXC-chemokine receptor ligand**)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

DOCUMENT NUMBER: 141:282838  
 TITLE: Novel crystalline forms of lamotrigine  
 INVENTOR(S): Parthasaradhi, Reddy Bandi; Rathnakar, Reddy Kura;  
 Raji, Reddy Rapolu; Muralidhara, Reddy Dasari; Subash,  
 Chander Reddy Kesireddy  
 PATENT ASSIGNEE(S): Hetero Drugs Limited, India  
 SOURCE: PCT Int. Appl., 13 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083191	A1	20040930	WO 2003-IN57	20030317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003217437	A1	20041011	AU 2003-217437	20030317
US 2005119265	A1	20050602	US 2003-508099	20030317
EP 1603889	A1	20051214	EP 2003-712623	20030317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			WO 2003-IN57	A 20030317

ED Entered STN: 30 Sep 2004

AB The present invention relates to novel crystalline forms of lamotrigine, to processes for their preparation and pharmaceutical compns. containing them. A process for preparation of crystalline forms of lamotrigine comprises steps of

(i) dissolving lamotrigine in a solvent, (ii) maintaining the solvent at certain temperature for certain time, and (iii) filtering the crystal form solid. For example, 10 g of lamotrigine was added to 100 mL of dioxane, maintained at 50° to 55° for 60 min, cooled to 25° and maintained at this temperature for 2 h. The solid was separated by filtration to give 8.5 g of Form II lamotrigine.

IC ICM C07D253-075

ICS A61K031-53

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 75

ST lamotrigine polymorphism **cryst** form prepn delivery system

IT Drug delivery systems

Polymorphism (**crystal**)

(preparation of stable **crystalline** forms of lamotrigine for delivery systems)

IT Esters, processes

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)

(solvents; preparation of stable **crystalline** forms of lamotrigine for delivery systems)

IT 84057-84-1, Lamotrigine

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP

(Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(preparation of stable crystalline forms of lamotrigine for delivery systems)

IT 67-66-3, Chloroform, processes 68-12-2, Dimethylformamide, processes 79-20-9, Methyl acetate 108-21-4, Isopropyl acetate 109-94-4, Ethyl formate 123-91-1, Dioxane, processes 141-78-6, Ethyl acetate, processes  
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)  
 (preparation of stable crystalline forms of lamotrigine for delivery systems)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:421470 CAPLUS

DOCUMENT NUMBER: 141:7119

TITLE: Preparation of crystalline lamotrigine and its monohydrate

INVENTOR(S): Manjunatha, Sulur G.; Kulkarni, Ashok Krishna; Kishore, Charugundia; Bokka, Ravisankar

PATENT ASSIGNEE(S): Jubilant Organosys Limited, India

SOURCE: Brit. UK Pat. Appl., 25 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2395483	A1	20040526	GB 2003-15608	20030703
WO 2005003104	A2	20050113	WO 2004-IN186	20040628
WO 2005003104	A3	20050922		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-15608 A 20030703

OTHER SOURCE(S): CASREACT 141:7119

ED Entered STN: 26 May 2004

GI



AB The invention relates to crystalline lamotrigine (3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine) (I) monohydrate and anhydrous lamotrigine. An improved process for manufacturing these products comprises reacting 2,3-dichlorobenzoyl cyanide with aminoguanidine bicarbonate in aqueous mineral acid, optionally together with a water miscible organic solvent, at 30-80° to produce the 2-(2,3-dichlorophenyl)-2-(guanidinylimino)acetonitrile (Schiff base) (II). The Schiff base II is further cyclized in aqueous organic solvent, e.g. alc. to produce pure lamotrigine of a pharmaceutically acceptable quality which on further drying at 45-50° under vacuum yields lamotrigine monohydrate, and/or on further drying at 100-110° yields anhydrous lamotrigine. The lamotrigine monohydrate or anhydrous lamotrigine thereby produced may then be brought into association with a pharmaceutically acceptable carrier for administration to a patient in need thereof.

IC ICM C07D253-075  
ICS A61K031-53; A61P025-08

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))  
ST anhyd lamotrigine prepn; cryst lamotrigine monohydrate prepn;  
cyclization dichlorophenylguanidinyliminoacetonitrile; condensation  
dichlorobenzoyl cyanide aminoguanidine

IT Acids, reactions  
RL: RGT (Reagent); RACT (Reactant or reagent)  
(inorg.; preparation of crystalline lamotrigine and its monohydrate by  
condensation of 2,3-dichlorobenzoyl cyanide with aminoguanidine and  
cyclization)

IT Condensation reaction  
Cyclization  
Green chemistry  
(preparation of crystalline lamotrigine and its monohydrate by  
condensation of 2,3-dichlorobenzoyl cyanide with aminoguanidine and  
cyclization)

IT Schiff bases  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of crystalline lamotrigine and its monohydrate by  
condensation of 2,3-dichlorobenzoyl cyanide with aminoguanidine and  
cyclization)

IT Alcohols, uses  
RL: NUU (Other use, unclassified); USES (Uses)  
(solvent; preparation of crystalline lamotrigine and its monohydrate by  
condensation of 2,3-dichlorobenzoyl cyanide with aminoguanidine and  
cyclization)

IT 84057-84-1P, Lamotrigine 375347-20-9P, Lamotrigine  
monohydrate  
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic  
preparation); PREP (Preparation)  
(X-ray diffraction anal.; preparation of

crystalline lamotrigine and its monohydrate by condensation of  
2,3-dichlorobenzoyl cyanide with aminoguanidine and cyclization)

IT 2905-60-4P, 2,3-Dichlorobenzoyl chloride 77668-42-9P,  
2,3-Dichlorobenzoyl cyanide 84689-20-3P, (2,3-  
Dichlorophenyl) (guanidinylimino)acetonitrile  
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic  
preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of crystalline lamotrigine and its monohydrate by  
condensation of 2,3-dichlorobenzoyl cyanide with aminoguanidine and  
cyclization)

IT 50-45-3, 2,3-Dichlorobenzoic acid 544-92-3, Copper cyanide 1068-42-4,  
Aminoguanidine sulfate 1937-19-5, Aminoguanidine hydrochloride  
2582-30-1, Aminoguanidine bicarbonate 10308-82-4, Aminoguanidine nitrate  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of crystalline lamotrigine and its monohydrate by  
condensation of 2,3-dichlorobenzoyl cyanide with aminoguanidine and  
cyclization)

IT 7647-01-0, Hydrochloric acid, reactions 7664-38-2, Phosphoric acid,  
reactions 7664-93-9, Sulfuric acid, reactions 7697-37-2, Nitric acid,  
reactions 10035-10-6, Hydrobromic acid, reactions  
RL: RGT (Reagent); RACT (Reactant or reagent)  
(preparation of crystalline lamotrigine and its monohydrate by  
condensation of 2,3-dichlorobenzoyl cyanide with aminoguanidine and  
cyclization)

IT 64-17-5, Ethanol, uses 67-56-1, Methanol, uses 67-63-0, Isopropyl  
alcohol, uses 67-68-5, Dimethyl sulfoxide, uses 68-12-2,  
Dimethylformamide, uses 71-23-8, n-Propanol, uses 71-36-3, n-Butanol,  
uses 75-05-8, Acetonitrile, uses 75-65-0, tert-Butanol, uses  
111-46-6, Diethylene glycol, uses 123-91-1, 1,4-Dioxane, uses  
RL: NUU (Other use, unclassified); USES (Uses)  
(solvent; preparation of crystalline lamotrigine and its monohydrate by  
condensation of 2,3-dichlorobenzoyl cyanide with aminoguanidine and  
cyclization)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:267313 CAPLUS  
DOCUMENT NUMBER: 140:303705  
TITLE: Two-step process for the synthesis of high-purity  
3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine from  
2,3-dichlorobenzoyl cyanide and aminoguanidine  
dimesylate  
INVENTOR(S): Neu, Jozsef; Gizur, Tibor; Toerley, Jozsef; Csabai,  
Janos; Vegh, Ferenc; Kalvin, Peter; Tarkanyi, Gabor  
PATENT ASSIGNEE(S): Richter Gedeon Vegyeszeti Gyar Rt., Hung.  
SOURCE: PCT Int. Appl., 12 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026845	A1	20040401	WO 2003-HU72	20030918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				

PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2498761 AA 20040401 CA 2003-2498761 20030918  
 AU 2003267676 A1 20040408 AU 2003-267676 20030918  
 EP 1539720 A1 20050615 EP 2003-748368 20030918  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 PRIORITY APPLN. INFO.: HU 2002-3114 A 20020920  
 WO 2003-HU72 W 20030918

OTHER SOURCE(S): CASREACT 140:303705

ED Entered STN: 01 Apr 2004

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB High-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine (I; i.e., lamotrigine) is prepared by the condensation reaction of 2,3-dichlorobenzoyl cyanide (II) with 1-2 mol equivalent of an aminoguanidine salt (e.g., aminoguanidine dimesylate) in 3-6 mol equivalent of methanesulfonic acid, then the obtained adduct (III) is transformed without isolation into the desired product by contacting it with magnesium oxide, followed by crystallization of the product from an appropriate organic solvent (e.g., acetone).  
 IC ICM C07D253-06  
 ICS C07C281-16  
 CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 45  
 IT Crystallization  
 (in the preparation of high-purity lamotrigine)  
 IT 84057-84-1P, Lamotrigine  
 RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)  
 (two-step process for the synthesis of high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine from 2,3-dichlorobenzoyl cyanide and aminoguanidine dimesylate)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2001:499101 CAPLUS  
 DOCUMENT NUMBER: 136:5580  
 TITLE: Hydrogen bonding patterns in 3,5-diamino-6-aryl triazines  
 AUTHOR(S): Kubicki, M.; Codding, P. W.  
 CORPORATE SOURCE: Faculty of Chemistry, Laboratory of Crystallography, Adam Mickiewicz University, Poznan, 60-780, Pol.  
 SOURCE: Journal of Molecular Structure (2001), 570(1-3), 53-60  
 CODEN: JMOB4; ISSN: 0022-2860  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 ED Entered STN: 11 Jul 2001  
 AB The crystal structure of two related 1,2,4-triazine derivs.,

C<sub>9</sub>H<sub>7</sub>N<sub>5</sub>Cl<sub>2</sub>·H<sub>2</sub>O (I) and C<sub>12</sub>H<sub>14</sub>N<sub>5</sub>Cl<sub>2+</sub>·CH<sub>3</sub>SO<sub>3</sub>·H<sub>2</sub>O (II) that have different biol. effects, have been determined. Lamotrigine (Lamictal), I, is a novel anticonvulsant and BWA256C, II, is a class 1 antiarrhythmic drug. The dihedral angles between the least-squares planes of almost exactly planar Ph and triazine rings are 76.42(6) and 76.08(6)°, for compds. I and II, resp. In II, protonation takes place at the iminium nitrogen atom, thus suggesting the importance of resonance through the triazine ring. This resonance is also confirmed by the pattern of bond lengths and angles. Extensive networks of hydrogen bonds, in which all mol. species are involved, rule the crystal packing in both compds. The anal. of hydrogen bond networks in other 3,5-diamino-6-aryl derivs. suggests that there is a strong influence of co-crystallizing solvent mol. on the nature of resulting hydrogen bond topol.

CC 22-3 (Physical Organic Chemistry)

Section cross-reference(s): 1, 28, 75

ST · lamictal hydrogen bonding crystallog mol structure

IT Antiarrhythmics

Anticonvulsants

    Crystal structure

Hydrogen bond

Molecular structure

    (hydrogen bonding patterns in crystal structure of  
    3,5-diamino-6-aryl triazines)

IT 374938-50-8 375347-20-9, Lamotrigine hydrate

RL: PRP (Properties)

    (crystal structure; hydrogen bonding patterns in  
    crystal structure of 3,5-diamino-6-aryl triazines)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER (7 OF 10) CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:338762 CAPLUS

DOCUMENT NUMBER: 134:362292

TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

INVENTOR(S): Farr, Spencer

PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA

SOURCE: PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 1999-165398P	P 19991105	
		US 2000-196571P	P 20000411	

ED Entered STN: 11 May 2001

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

IC ICM C12Q001-68  
ICS G01N033-50

CC 3-4 (Biochemical Genetics)  
Section cross-reference(s): 1, 6, 7, 13, 15

IT Crystallins  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
( $\zeta$ - crystallins; methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 3778-73-2, Iphosphamide 3930-20-9, Sotalol 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline, biological studies 4618-18-2, Lactulose 4697-36-3, Carbenicillin 4759-48-2, Isotretinoin 5051-62-7, Guanabenz 5543-57-7, (s)-Warfarin 5633-20-5, Oxybutynin 5786-21-0, Clozapine 6190-39-2, Dihydroergotamine mesylate 6493-05-6, Pentoxifylline 6621-47-2, Perhexiline 7020-55-5, Clidinium 7235-40-7, Beta carotene 7261-97-4, Dantrolene 7416-34-4, Molindone 7439-93-2, Lithium, biological studies 7447-40-7, Potassium chloride, biological studies 7481-89-2, Zalcitabine 7487-88-9, Magnesium sulfate, biological studies 7648-98-8, Ambenonium 7681-11-0, Potassium iodide, biological studies 7681-93-8, Natamycin 7683-59-2, Isoproterenol 8029-99-0, Paregoric 8049-47-6, Pancreatin 8050-81-5, Simethicone 8063-07-8, Kanamycin 8067-24-1, Ergoloid mesylates 9001-27-8, Blood-coagulation factor VIII 9001-75-6, Pepsin 9004-10-8, Insulin, biological studies 9004-67-5, Methyl cellulose 9005-49-6, Enoxaparin, biological studies 9007-92-5, Glucagon, biological studies 9039-53-6, Urokinase 9046-56-4, Ancrod 10118-90-8, Minocycline 10238-21-8, Glyburide 10262-69-8, Maprotiline 10540-29-1, Tamoxifen 11041-12-6, Cholestyramine 11056-06-7, Bleomycin 11111-12-9, Cephalosporin 12174-11-7, Attapulgite 12244-57-4, Gold sodium thiomalate 12650-69-0, Mupirocin 12794-10-4D, Benzodiazepine, derivs. 13010-47-4, Lomustine 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-28-4, Rimantadine 13647-35-3, Trilostane 14028-44-5, Amoxapine 14124-50-6 14611-51-9, Selegiline 14769-73-4, Levamisole 14838-15-4, Phenylpropanolamine 14882-18-9, Bismuth subsalicylate 15301-69-6, Flavoxate 15307-86-5, Diclofenac 15663-27-1, Cisplatin 15686-71-2, Cephalexin 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 16051-77-7, Isosorbide mononitrate 16068-46-5, Potassium phosphate 16110-51-3, Cromolyn 16590-41-3, Naltrexone 16679-58-6, Desmopressin 17230-88-5, Danazol 17784-12-2, Sulfacytine 18323-44-9, Clindamycin 18559-94-9, Albuterol 18883-66-4, Streptozocin 19216-56-9, Prazosin 19794-93-5,

Trazodone 20537-88-6, Amifostine 20830-75-5, Digoxin 20830-81-3, Daunomycin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22204-53-1, Naproxen 22232-71-9, Mazindol 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probulcol 25322-68-3, Polyethylene glycol 25451-15-4, Felbamate 25614-03-3, Bromocriptine 25812-30-0, Gemfibrozil 26652-09-5, Ritodrine 26787-78-0, Amoxicillin 26807-65-8, Indapamide 26839-75-8, Timolol 27203-92-5, Tramadol 27262-47-1, Levobupivacaine 27686-84-6, Masoprocol 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28782-42-5, Difenoxin 28860-95-9, Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29094-61-9, Glipizide 29110-47-2, Guanfacine 29122-68-7, Atenolol 30516-87-1, Zidovudine 31441-78-8, Mercaptopurine 31677-93-7, Bupropion hydrochloride 31828-71-4, Mexiletine 31883-05-3, Moricizine 32986-56-4, Tobramycin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34089-81-1, Sodium ferric gluconate 35189-28-7, Norgestimate 36322-90-4, Piroxicam 36505-84-7, Buspirone 36791-04-5, Ribavirin 38304-91-5, Minoxidil 40180-04-9, Tienilic acid 40580-59-4, Guanadrel 41575-94-4, Carboplatin 41708-72-9, Tocainide 42399-41-7, Diltiazem 42924-53-8, Nabumetone 49562-28-9, Fenofibrate 50679-08-8, Terfenadine 50925-79-6, Colestipol 50972-17-3, Bacampicillin 51022-71-0, Nabilone 51110-01-1, Somatostatin 51333-22-3, Budesonide 51384-51-1, Metoprolol 51481-61-9, Cimetidine 53179-11-6, Loperamide 53230-10-7, Mefloquine 53608-75-6, Pancrelipase 53714-56-0, Leuprolide 53994-73-3, Cefaclor 54024-22-5, Desogestrel 54063-53-5, Propafenone 54143-56-5, Flecainide acetate 54182-58-0, Sucralfate 54350-48-0, Etretinate 54573-75-0, Doxercalciferol 54910-89-3, Fluoxetine 55142-85-3, Ticlopidine 55268-75-2, Cefuroxime 55985-32-5, Nicardipine 56420-45-2, Epirubicin 58001-44-8 58581-89-8, Azelastine 59122-46-2, Misoprostol 59277-89-3, Acyclovir 59729-33-8, Citalopram 59865-13-3, Cyclosporine A 60142-96-3, Gabapentin 60205-81-4, Ipratropium 61489-71-2, Menotropin 61718-82-9, Fluvoxamine maleate 61869-08-7, Paroxetine 62571-86-2, Captopril 63585-09-1, Foscarnet sodium 63590-64-7, Terazosin 64952-97-2, Latamoxef 65141-46-0, Nicorandil 65277-42-1, Ketoconazole 66085-59-4, Nimodipine 66104-22-1, Pergolide 66357-35-5, Ranitidine 66376-36-1, Alendronate 67227-57-0, Fenoldopam mesylate 68475-42-3, Anagrelide 68844-77-9, Astemizole 69049-73-6, Nedocromil 69123-98-4, Fialuridine 69655-05-6, Didanosine 70359-46-5, Brominide tartrate 70989-04-7, S-Mephenytoin 71320-77-9, Moclobemide 72432-03-2, Miglitol 72509-76-3, Felodipine 72956-09-3, Carvedilol 73590-58-6, Omeprazole 74103-06-3, Ketorolac 74191-85-8, Doxazosin 75330-75-5, Lovastatin 75695-93-1, Isradipine 75706-12-6, Leflunomide 75847-73-3, Enalapril 76470-66-1, Loracarbef 76547-98-3, Lisinopril 76568-02-0, Flosequinan 76584-70-8 76824-35-6, Famotidine 76932-56-4, Nafarelin 76963-41-2, Nizatidine 78110-38-0, Aztreonam 78628-80-5, Terbinafine hydrochloride 79516-68-0, Levocabastine 79617-96-2, Sertraline 79794-75-5, Loratadine 79902-63-9, Simvastatin 80125-14-0, Remoxipride 80474-14-2, Fluticasone propionate 81093-37-0, Pravastatin 81098-60-4, Cisapride 81103-11-9, Clarithromycin 81669-57-0, Anistreplase 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 82626-48-0, Zolpidem 82834-16-0, Perindopril 83366-66-9, Nefazodone 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 83905-01-5, Azithromycin 84057-84-1, Lamotrigine 84449-90-1, Raloxifene 84625-61-6, Itraconazole 85441-61-8, Quinapril 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86541-75-5, Benazepril 87333-19-5, Ramipril 87679-37-6, Trandolapril 88040-23-7, Cefepime 88150-42-9, Amlodipine 89365-50-4, Salmeterol 89778-26-7, Toremifene 90566-53-3, Fluticasone 91714-94-2, Bromfenac  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of determining individual hypersensitivity to a pharmaceutical agent

from gene expression profile)

L44 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2000:12098 CAPLUS  
 DOCUMENT NUMBER: 132:130210  
 TITLE: Structure of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate solvate (lamotrigine isethionate)  
 AUTHOR(S): Potter, Brian; Palmer, Rex A.; Withnall, Robert;  
 Leach, Michael J.; Chowdhry, Babur Z.  
 CORPORATE SOURCE: Department of Crystallography, Birkbeck College,  
 University of London, London, WC1E 7HX, UK  
 SOURCE: Journal of Chemical Crystallography (1999), 29(6),  
 701-706  
 CODEN: JCCYEV; ISSN: 1074-1542  
 PUBLISHER: Kluwer Academic/Plenum Publishers  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 ED Entered STN: 06 Jan 2000  
 AB The crystal and mol. structure of lamotrigine isethionate was determined by direct methods. The compound crystallizes in the tetragonal space group I41/a, with a 19.684(5), c 16.557(5) Å; Z = 16, dc = 1.579; R = 0.0532, Rw = 0.1317 for 2041 reflections. Atomic coordinates are given. The isethionate moiety forms multiple H bonds to the lamotrigine nucleus, three from one isethionate, two from a symmetry related isethionate and a further two from two different symmetry related mols. Protonation of N(2') in the triazine ring, not observed in the native lamotrigine structure is presumably associated with the interaction of the isethionate moiety. Both rings in the lamotrigine moiety are essentially planar, with a dihedral angle of 66.08(7)° compared to 80.70° in native lamotrigine. The connecting bond length C(1)-C(6') 1.493(3) Å also correlates well with values in related compds. (1.480(3) Å) in the native structures.  
 CC 75-8 (Crystallography and Liquid Crystals)  
 Section cross-reference(s): 28  
 ST mol structure lamotrigine isethionate; crystal structure lamotrigine isethionate; hydrogen bond lamotrigine isethionate; protonation lamotrigine isethionate  
 IT Crystal structure  
 Molecular structure  
 (of lamotrigine isethionate)  
 IT 113170-86-8, Lamotrigine isethionate  
 RL: PRP (Properties)  
 (crystal structure of)  
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1996:616102 CAPLUS  
 DOCUMENT NUMBER: 125:256936  
 TITLE: Moisture-Dependent Crystallization of Amorphous Lamotrigine Mesylate  
 AUTHOR(S): Schmitt, E.; Davis, C. W.; Long, S. T.  
 CORPORATE SOURCE: Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA  
 SOURCE: Journal of Pharmaceutical Sciences (1996), 85(11), 1215-1219  
 CODEN: JPMSAE; ISSN: 0022-3549  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

ED Entered STN: 17 Oct 1996  
AB A com. available computer-controlled vacuum moisture balance was used for determining moisture sorption isotherms of freeze-dried and spray-dried lamotrigine mesylate and freeze-dried drug product containing mannitol. The presence or absence of desorption hysteresis and the characteristics of the weight-vs.-time profile as a sample was exposed to a defined relative humidity ramp were sensitive indicators of moisture-induced crystallization. Combination of the moisture sorption data with polarized light microscopy, DSC, and x-ray powder diffraction provided qual. verification of the crystallization with <50 mg of sample. The normalized water loss during crystallization was used to detect as little as 2% amorphous content in phys. mixts. of amorphous and crystalline lamotrigine mesylate. Moisture sorption, water plasticization, and crystallization properties of amorphous forms prepared by spray drying and freeze drying were nearly identical. Cofreeze-drying lamotrigine mesylate with D-mannitol resulted in a mixture of amorphous lamotrigine mesylate with properties similar to those of spray-dried or freeze-dried materials and crystalline D-mannitol. The amount of water needed for crystallization over a time scale observable in the moisture balance was considerably more than the amount needed to lower the glass transition temperature of the sample to the operating temperature of the instrument. This result illustrated the importance of time scale effects in determining critical moisture levels for crystallization from the amorphous state.  
CC 63-5 (Pharmaceuticals)  
ST lamotrigine mesylate crystn moisture  
IT Crystallization  
    Freeze drying  
    Glass temperature and transition  
    Sorption  
        (moisture-dependent crystallization of amorphous lamotrigine mesylate)  
IT Drying  
    (spray, moisture-dependent crystallization of amorphous lamotrigine mesylate)  
IT 181362-54-9  
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
    (moisture-dependent crystallization of amorphous lamotrigine mesylate)  
IT 69-65-8, D-Mannitol  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
    (moisture-dependent crystallization of amorphous lamotrigine mesylate)  
  
L44 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1989:126056 CAPLUS  
DOCUMENT NUMBER: 110:126056  
TITLE: Structure of lamotrigine methanol solvate:  
3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine-methanol, a novel anticonvulsant drug  
AUTHOR(S): James, Robert W.; Lisingarten, John N.; Palmer, Rex A.  
CORPORATE SOURCE: Birkbeck Coll., Univ. London, London, WC1E 7HX, UK  
SOURCE: Acta Crystallographica, Section C: Crystal Structure Communications (1989), C45(1), 129-32  
CODEN: ACSCEE; ISSN: 0108-2701  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
ED Entered STN: 03 Apr 1989  
AB The title compound is monoclinic, space group P21/n, with a 15.456(3), b

11.736(2), c 7.300(3) Å, and  $\beta$  94.417(3) $^\circ$ ; Z = 4 for  $\text{dc} = 1.449$ . The final R = 0.055 for 2444 reflections. Atomic coordinates are given. The Ph and triazine aromatic rings make a dihedral angle of 80.6(9) $^\circ$  with each other. The bond linking the 2 rings is 1.480(3) Å. The structure is stabilized by a network of H bonds involving amino and ring N atoms, one of the Cl atoms, and the MeOH of crystallization

CC 75-8 (Crystallography and Liquid Crystals)

Section cross-reference(s): 1, 28

IT Crystal structure

Molecular structure

(of diamino(dichlorophenyl)triazine-methanol solvate)

IT 119441-74-6

RL: PRP (Properties)

(crystal structure of)

=> d ibib l48 1-2

L48 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:875073 CAPLUS  
 DOCUMENT NUMBER: 139:354488  
 TITLE: Pharmaceutical composition containing lamotrigine  
 particles of defined morphology  
 INVENTOR(S): Aronhime, Judith; Samburski, Guy  
 PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva  
 Pharmaceuticals USA, Inc.  
 SOURCE: PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090693	A2	20031106	WO 2003-US13002	20030423
WO 2003090693	A3	20040108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483103	AA	20031106	CA 2003-2483103	20030423
AU 2003234240	A1	20031110	AU 2003-234240	20030423
EP 1496864	A2	20050119	EP 2003-728552	20030423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005238724	A1	20051027	US 2004-511987	20041021
PRIORITY APPLN. INFO.:			US 2002-374923P	P 20020423
			WO 2003-US13002	W 20030423

L48 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:676002 CAPLUS  
 DOCUMENT NUMBER: 137:222039  
 TITLE: New crystal forms of lamotrigine and processes for  
 their preparations  
 INVENTOR(S): Garti, Nissim; Berkovich, Yana; Dolitzky, Ben-Zion;  
 Aronhime, Judith; Singer, Claude; Lieberman,  
 Anita; Gershon, Neomi  
 PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva  
 Pharmaceuticals USA, Inc.  
 SOURCE: PCT Int. Appl., 65 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002068398	A1	20020906	WO 2002-US6160	20020227
WO 2002068398	C2	20021121		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2439468	AA	20020906	CA 2002-2439468	20020227
US 2003018030	A1	20030123	US 2002-86157	20020227
US 6861426	B2	20050301		
EP 1390355	A2	20040225	EP 2002-706471	20020227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004526714	T2	20040902	JP 2002-567912	20020227
US 2005171107	A1	20050804	US 2005-45355	20050131
PRIORITY APPLN. INFO.:			US 2001-271688P	P 20010227
			US 2002-86157	A1 20020227
			WO 2002-US6160	W 20020227
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=> log hold  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
3.86	8.87

SESSION WILL BE HELD FOR 60 MINUTES  
 STN INTERNATIONAL SESSION SUSPENDED AT 08:13:14 ON 17 JUL 2006

**THIS PAGE BLANK (USPTO)**